Crystal form of acid salt of sulfoximine compound, preparation method therefor, and use thereof

Abstract

The present invention relates to a crystal form of a sulfoximine compound, a preparation method therefor, and a use thereof. Specifically, disclosed are a crystal form of a compound as shown in a formula (I), a preparation method therefor, and a use thereof. The crystal form has excellent stability, and can be widely applied to the preparation of drugs for preventing and / or treating diseases related to increased FGFR2 activity and expression level. The crystal form is preferably a hydrochloride crystal form I of the compound represented by formula I, and the X-ray powder diffraction pattern of the hydrochloride crystal form I has a 2θ angle selected from the following group: 6.68 + / -0.2 degrees, 13.34 + / -0.2 degrees, and 21.42 + / -0.2 degrees.

Description

Technical Field The present invention relates to the field of medicinal development, specifically to a crystal form of an acid salt of a sulfoximine compound, preparation method therefor, and a use thereof. Background Fibroblast growth factor receptors (FGFRs) are receptors for fibroblast growth factor (FGF) signaling, and its family consists of four members (FGFR1, FGFR2, FGFR3, and FGFR4). Each FGFR is a glycoprotein composed of an extracellular immunoglobulin (Ig)-like domain, a hydrophobic transmembrane region, and an intracellular domain that includes a tyrosine kinase domain. Binding of FGF ligands induces receptor dimerization and conformational changes in the intracellular domain, leading to intermolecular phosphorylation in the kinase domain and the intracellular tail. Phosphorylated residues serve as docking sites for adaptor proteins, which facilitate downstream signaling cascades, resulting in cellular behaviors including proliferation, survival, differentiation, migration, and angiogenesis. Abnormal FGFR signaling is implicated in various cancer types, including hepatocellular carcinoma, intrahepatic cholangiocarcinoma, bladder cancer, endometrial cancer, breast cancer, and lung cancer, and contributes to disease progression through overexpression, point mutations, and / or chromosomal translocations. As research progresses, pan-FGFR1-3 inhibitors have demonstrated clinical responses in various FGFR-altered cancers, however, they also exhibit target-limited toxicities, leading to adverse side effects such as hyperphosphatemia and tissue mineralization, as the regulation of phosphate reabsorption is mediated by FGFR1 and FGFR3. Some studies have reported FGFR2 translocations in 14% of intrahepatic cholangiocarcinomas; FGFR2 mutations occur in 12-14% of endometrial cancers and 5% of squamous non-small cell lung cancers; FGFR2 is amplified in 12-14% of gastric cancers and 4% of breast cancers. FGFR2 contributes to the development of acquired resistance to human epidermal growth factor receptor 2 (HER2)-targeted therapy by indirectly overactivating FGFR2 in tumor-associated fibroblasts. Therefore, given the unmet clinical needs, the development of FGFR2-selective inhibitors for treatment holds significant value and promising prospects. Summary of the Invention The objective of the present invention is to develop pharmaceutically acceptable salt forms and crystal forms of a sulfoximine FGFR inhibitor compound, and a preparation method therefor. In one aspect of the present invention, provided is a compound of formula (I), (I) in an amorphous form or a crystal form or a solvate thereof; wherein m is 1, 2, 3, 4, 5, 6, 7, 8, or 9; n is 0, 0.5, 1, 1.5, 2, 2.5, or 3; and X is selected from the group consisting of: hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid or phosphoric acid, formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid, hippuric acid, glycolic acid, or glutaric acid. In another preferred embodiment, the structure of the compound of Formula I-1 is as follows: the present invention provides a crystal form A of the compound of Formula I-1, the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 9 angles: 11.59±0.2°, 12.00±0.2°, 14.16±0.2°, 15.50±0.2°, 16.74±0.2°, 18.38±0.2°, 18.81±0.2°, 21.32 ± 0.2°, 21.80 ± 0.2 °, 23.01  ± 0.2°, 24.37 ± 0.2°, 26.50 ± 0.2°, 28.90 ± 0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the crystal form A of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 9 angles: 8.44±0.2°, 11.59±0.2°, 12.00±0.2°, 12.34±0.2°, 14.16 ± 0.2°, 15.50 ± 0.2°, 16.50 ± 0.2°, 16.74 ± 0.2°, 18.38 ± 0.2°, 18.81 ± 0.2°, 19.79 ± 0.2°, 20.44±0.2°, 21.32±0.2°, 21.53±0.2°, 21.80±0.2°, 22.24±0.2°, 23.01±0.2°, 24.37±0.2°, 25.43±0.2°, 26.50±0.2°, 27.13±0.2°, 27.74±0.2°, 28.90±0.2°, 29.72±0.2°, 29.93±0.2°, 30.83±0.2°, 31.56±0.2°, 32.47±0.2°, 33.64±0.2°, 34.12±0.2°, 35.03±0.2°, 36.17±0.2°. In some embodiments of the present invention, the XRPD pattern of the crystal form A of the compound of Formula I-1 is shown in Figure 1. Table 1 XRPD analysis data for the crystal form A of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak#1 8.443401 10.46377 465.3955 776.6761 0.02581691 0.100 Peak#2 11.59481 7.625884 1981.868 2352.141 0.1099402 0.100 Peak#3 12.00092 7.368722 2054.35 2439.293 0.113961 0.100 Peak#4 12.33819 7.168041 863.7459 1256.884 0.04791462 0.100 Peak#5 14.16416 6.247813 16,581.67 17,117.91 0.9198356 0.100 Peak#6 15.49514 5.714016 11,020.04 11,669.23 0.6113151 0.100 Peak#7 16.50191 5.367605 3768.419 4467.886 0.2090457 0.121 Peak#8 16.74475 5.290301 15,225.11 15,931.87 0.8445831 0.100 Peak#9 18.3777 4.823748 3973.455 4712.12 0.2204197 0.133 Peak#10 18.81417 4.712814 4317.971 5066.824 0.239531 0.100 Peak#11 19.79016 4.482541 3621.8 4405.136 0.2009123 0.100 Peak#12 20.44199 4.341054 784.3597 1607.157 0.04351082 0.100 Peak#13 21.32422 4.163405 6370.541 7270.211 0.3533933 0.102 Peak#14 21.52857 4.124347 4452.761 5370.366 0.2470082 0.102 Peak#15 21.79978 4.073646 10,626.56 11,565.94 0.5894879 0.100 Peak#16 22.24138 3.99375 2008.293 2978.074 0.1114061 0.100 Peak#17 23.00732 3.862497 18,026.77 19,034.55 1 0.100 Peak#18 24.37473 3.648822 13,513.07 14,542.2 0.749611 0.132 Peak#19 25.43489 3.499086 2514.506 3519.17 0.1394873 0.151 Peak#20 26.50102 3.360687 3923.504 4867.41 0.2176488 0.104 Peak#21 27.13202 3.283944 634.6851 1535.413 0.03520792 0.100 Peak#22 27.73726 3.213646 1539.967 2427.688 0.08542667 0.100 Peak#23 28.89928 3.087016 3747.38 4612.75 0.2078786 0.110 Peak#24 29.72192 3.00342 798.2333 1621.757 0.04428044 0.228 Peak#25 29.92524 2.983475 708.6496 1518.506 0.03931096 0.228 Peak#26 30.83398 2.897586 1476.005 2267.967 0.08187852 0.106 Peak#27 31.55616 2.832901 1184.099 1972.253 0.06568556 0.127 Peak#28 32.46742 2.75544 834.8455 1614.822 0.04631143 0.123 Peak#29 33.63531 2.662387 408.7598 1182.296 0.02267515 0.176 Peak#30 34.12203 2.625516 495.4477 1258.51 0.02748399 0.109 Peak#31 35.03429 2.559211 678.4774 1427.322 0.03763721 0.196 Peak#32 36.17301 2.481217 667.2708 1389.91 0.03701555 0.124 In some embodiments of the present invention, the differential scanning calorimetry (DSC) curve of the crystal form A of the compound of Formula I-1 has the onsets of the endothermic peaks at 26.10°C ± 2°C and 223.34°C ± 2°C. In some embodiments of the present invention, the crystal form A of the compound of Formula I-1 has a DSC pattern as shown in Figure 2. In some embodiments of the present invention, the thermogravimetric analysis (TGA) curve of crystal form A of the compound of Formula I-1 has three small weight loss steps at 24.00°C ± 2°C, 110.00°C ± 2°C, and 200.00°C ± 2°C, and decomposition begins above 250.00°C ± 2°C. In some embodiments of the present invention, the TGA pattern of the crystal form A of the compound of Formula I-1 is as shown in Figure 3. The present invention also provides a method for preparing the crystal form A of the compound of Formula I-1, which includes adding the compound of Formula I-1 to acetonitrile, an alcoholic solvent, an ester solvent, an ether solvent, or a mixed solvent of an alcoholic solvent and water, and then performing recrystallization or slurrying to obtain it, wherein the alcoholic solvent is selected from methanol, ethanol, isopropanol, etc., the ester solvent is selected from ethyl acetate, isopropyl acetate, methyl formate, ethyl formate, isopropyl formate, etc., the ether solvent is selected from methyl tert-butyl ether, tetrahydrofuran, ethylene glycol dimethyl ether, etc, and the mixed solvent of an alcoholic solvent and water is selected from a mixture of methanol and water, a mixture of ethanol and water, or a mixture of isopropanol and water, and in the mixed solvent of an alcoholic solvent and water, the volume ratio of the alcoholic solvent to water is selected from 1:0.1 to 1.5. The present invention also provides the maleate crystal form A of the compound of 10 15 Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 29 angles: 5.82±0.2°, 9.86±0.2°, 11.29±0.2°, 12.72 ± 0.2°, 13.04 ± 0.2°, 15.17 ± 0.2°, 17.88  ± 0.2°, 18.11  ± 0.2 °, 22.28 ± 0.2°, 23.02 ± 0.2°, 24.42  ± 0.2°, 25.34 ± 0.2°, 26.77 ± 0.2°. In some embodiments of the present invention, the maleate crystal form A of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 9 angles in its X-ray powder diffraction pattern: 8.44±0.2°, 11.59 ±0.2°, 12.00 ±0.2°, 12.34±0.2°, 14.16 ± 0.2°, 15.50 ± 0.2°, 16.50 ± 0.2°, 16.74 ± 0.2°, 18.38 ± 0.2°, 18.81  ± 0.2°, 19.79 ± 0.2°, 20.44±0.2°, 21.32±0.2°, 21.53±0.2°, 21.80±0.2°, 22.24±0.2°, 23.01±0.2°, 24.37 ±0.2°, 25.43±0.2°, 26.50±0.2°, 27.13±0.2°, 27.74±0.2°, 28.90±0.2°, 29.72±0.2°, 29.93 ±0.2°, 30.83±0.2°, 31.56±0.2°, 32.47±0.2°, 33.64±0.2°, 34.12 ±0.2°, 35.03±0.2° , 36.17 ± 0.2°. In some embodiments of the present invention, the XRPD pattern of the maleate crystal form A of the compound of Formula I-1 is shown in Figure 4. Table 2 XRPD analysis data for the maleate crystal form A of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak#1 5.816485 15.18233 49.66369 65.44668 0.2465863 0.100 Peak#2 9.859919 8.96345 73.92227 91.99165 0.3670331 0.101 Peak#3 11.06471 7.990012 33.00455 54.12584 0.1638716 0.142 Peak#4 11.29159 7.829976 71.99976 93.48729 0.3574875 0.129 Peak#5 11.64355 7.594069 28.69745 50.38568 0.1424863 0.133 Peak#6 11.90079 7.430491 53.98288 75.53851 0.2680315 0.100 Peak#7 12.72461 6.951217 49.88066 70.707 0.2476635 0.148 Peak#8 13.0453 6.781051 55.81887 75.97722 0.2771474 0.168 Peak#9 15.16811 5.836466 162.1551 178.0625 0.8051198 0.100 Peak#10 15.66005 5.65421 60.71101 77.37029 0.3014376 0.100 Peak#11 16.36081 5.413575 29.68445 47.71005 0.1473869 0.132 Peak#12 17.70085 5.006646 96.75628 119.5969 0.4804066 0.122 Peak#13 17.87988 4.956915 66.58391 89.8793 0.3305972 0.217 Peak#14 18.1084 4.894873 88.23072 111.9404 0.4380763 0.215 Peak#15 18.35028 4.830894 79.95369 103.8986 0.3969797 0.220 Peak#16 18.61376 4.763102 50.00529 73.96861 0.2482823 0.100 Peak#17 19.40942 4.569603 61.80075 86.36585 0.3068482 0.100 Peak#18 20.15778 4.401615 61.40547 87.72269 0.3048856 0.134 Peak#19 20.38478 4.353108 57.58932 84.15148 0.285938 0.162 Peak#20 20.68509 4.290583 29.13599 55.74016 0.1446637 0.222 Peak#21 21.32064 4.164098 69.45016 95.71144 0.3448285 0.100 Peak#22 21.6195 4.107205 29.40524 56.03273 0.1460006 0.150 Peak#23 22.28023 3.986875 117.0337 144.4462 0.5810865 0.100 Peak#24 22.70711 3.912881 56.87783 84.4616 0.2824053 0.102 Peak#25 23.02009 3.860384 201.405 228.6998 1 0.100 Peak#26 24.42011 3.642144 192.9104 220.1278 0.9578236 0.110 Peak#27 24.99754 3.559304 38.4386 65.54317 0.1908523 0.100 Peak#28 25.33689 3.512397 60.09032 86.57373 0.2983557 0.100 Peak#29 26.24092 3.393405 39.44109 63.79497 0.1958298 0.164 Peak#30 26.77359 3.327089 56.9196 80.2638 0.2826127 0.100 Peak#31 29.85257 2.990573 36.64283 61.98938 0.1819361 0.268 Peak#32 34.08594 2.628213 27.72369 53.10707 0.1376515 0.100 The present invention also provides a method for preparing crystal form A of the compound of formula I-1, comprising adding the compound of formula I-1 and maleic acid to acetonitrile and dichloromethane, and then performing recrystallization or slurrying to obtain it, wherein the ratio of the compound of Formula I-1 to maleic acid is selected from 0.8 to 1.2. The present invention also provides monomaleate crystal form B of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 9 angles: 7.98±0.2°, 8.29 ± 0.2°, 11.61 ± 0.2°, 13.21 ± 0.2° , 13.99 ± 0.2 °, 15.25 ± 0.2 °, 15.95 ± 0.2°, 16.57 ± 0.2°, 17.38 ± 0.2°, 18.06 ± 0.2°, 20.39 ± 0.2° , 21.25 ± 0.2°, 21.61 ± 0.2°, 22.17 ± 0.2°, 23.54±0.2°, 24.70±0.2°, 25.91±0.2°, 27.24±0.2°, 29.47±0.2°, 29.71±0.2°, 32.64±0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the monomaleate crystal form B of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 9 angles: 7.98±0.2°, 8.29±0.2°, 10.27±0.2°, 11.61±0.2°, 13.21± 0.2°, 13.99±0.2°, 14.52±0.2°, 15.25±0.2°, 15.95±0.2°, 16.57±0.2°, 16.89±0.2°, 17.38± 0.2°, 18.06±0.2°, 20.39±0.2°, 20.61±0.2°, 21.25±0.2°, 21.61±0.2°, 22.17±0.2°, 23.31± 0.2°, 23.54 ± 0.2°, 23.98 ± 0.2°, 24.70 ± 0.2°, 24.93 ± 0.2°, 25.32 ± 0.2°, 25.91 ± 0.2°, 26.55±0.2°,  27.24±0.2°,  28.23±0.2°,  28.54±0.2°,  29.00±0.2°,  29.47±0.2°,  29.71±0.2°, 32.64±0.2°, 35.12±0.2°. In some embodiments of the present invention, the XRPD pattern of the monomaleate crystal form B of the compound of Formula I-1 is shown in Figure 5. Table 3 X-ray diffraction data for the monomaleate crystal form B of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak#1 7.981822 11.06781 1723.857 1994.387 0.1169017 0.149 Peak#2 8.291428 10.65522 1137.191 1412.092 0.07711747 0.164 Peak#3 10.26916 8.607141 529.8829 820.8134 0.03593348 0.100 Peak#4 11.61435 7.613101 2756.817 3085.549 0.1869509 0.100 Peak#5 13.21075 6.696494 2119.543 2516.378 0.1437347 0.100 Peak#6 13.98848 6.325882 11811.49 12269.85 0.8009846 0.100 Peak#7 14.5199 6.095533 1061.446 1551.665 0.0719809 0.100 Peak#8 15.25275 5.804268 6038.434 6581.751 0.4094904 0.100 Peak#9 15.94566 5.553574 11989.22 12576.86 0.8130369 0.100 Peak#10 16.57134 5.34527 14746.21 15361.82 1 0.100 Peak#11 16.89114 5.244782 1575.195 2200.658 0.1068203 0.100 Peak#12 17.37723 5.099149 13942.37 14577.09 0.9454884 0.100 Peak#13 18.05592 4.908983 13096.95 13733.03 0.888157 0.100 Peak#14 20.39062 4.351873 14023.45 14713.4 0.9509865 0.100 Peak#15 20.61231 4.305566 5244.903 5947.155 0.355678 0.100 Peak#16 21.24602 4.178554 7214.775 7944.283 0.4892629 0.100 Peak#17 21.60538 4.109857 7723.3 8463.026 0.523748 0.175 Peak#18 22.17168 4.006149 3996.755 4744.93 0.271036 0.100 Peak#19 23.30505 3.813822 2970.041 3761.162 0.2014104 0.178 Peak#20 23.53755 3.776674 6206.884 7010.807 0.4209137 0.108 Peak#21 23.98418 3.707347 1311.471 2135.541 0.08893615 0.100 Peak#22 24.70086 3.601379 9470.771 10314.98 0.642251 0.100 Peak#23 24.92502 3.569496 3107.844 3955.256 0.2107554 0.100 Peak#24 25.31763 3.515025 1042.744 1892.22 0.07071263 0.167 Peak#25 25.91234 3.435686 10856.43 11700.45 0.736218 0.100 Peak#26 26.54931 3.354684 685.3824 1512.089 0.04647854 0.205 Peak#27 27.2363 3.271608 3106.794 3914.549 0.2106842 0.100 Peak#28 28.22876 3.1588 2131.622 2937.217 0.1445538 0.224 Peak#29 28.53832 3.125235 2016.763 2825.172 0.1367648 0.240 Peak#30 28.99892 3.076636 1532.671 2340.075 0.1039366 0.100 Peak#31 29.46878 3.028641 2286.111 3086.088 0.1550303 0.168 Peak#32 29.7058 3.005013 3049.359 3843.141 0.2067892 0.153 Peak#33 32.63929 2.741322 4630.014 5344.848 0.3139799 0.100 Peak#34 35.11711 2.553365 1318.593 1961.014 0.08941906 0.213 In some embodiments of the present invention, the monomaleate crystal form B of the compound of Formula I-1 has the onset of the endothermic peak at 213.92°C ± 2°C in its differential scanning calorimetry (DSC) curve. In some embodiments of the present invention, the monomaleate crystal form B of the 5 compound of Formula I-1 has a DSC pattern as shown in Figure 6. In some embodiments of the present invention, the monomaleate crystal form B of the compound of Formula I-1 has two weight loss steps at 24.00°C ± 2°C and 180.00°C ± 2°C in its thermogravimetric analysis (TGA) curve, and decomposition begins above 250.00°C ± 2°C. 10       In some embodiments of the present invention, the TGA pattern of the monomaleate crystal form B of the compound of Formula I-1 is shown in Figure 7. The present invention also provides a method for preparing the monomaleate crystal form B of the compound of Formula I-1, comprising adding the compound of Formula I-1 and maleic acid to tetrahydrofuran, and then performing recrystallization or slurrying to obtain it, wherein the ratio of the compound of Formula I-1 to maleic acid is selected from 0.8 to 1.2. The present invention also provides the fumarate crystal form A of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at 5 the following 29 angles: 5.11 ±0.2°, 10.20±0.2°, 14.23±0.2°, 17.03±0.2°, 18.79 ± 0.2°, 28.85 ± 0.2 °, and 29.46 ± 0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the fumarate crystal form A of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 9 angles: 5. 11±0.2°, 7.26±0.2°, 10.20±0.2°, 10.51±0.2°, 14.23 ± 10   0.2°, 14.47 ± 0.2°, 14.93 ± 0.2°, 16.17 ± 0.2°, 17.03 ± 0.2°, 17.90 ± 0.2 °, 18.79 ± 0.2°, 19.44±0.2°, 20.19±0.2°, 20.80±0.2°, 22.48±0.2°, 23.07±0.2°, 23.74±0.2°, 24.07± 0.2°, 27.06 ±0.2°, 27.85±0.2°, 28.30±0.2°, 28.85 ±0.2°, 29.46±0.2°, 38.24±0.2°. In some embodiments of the present invention, the X-ray powder diffraction (XRPD) pattern of the fumarate crystal form A of the compound of Formula I-1 is shown in Figure 8. 15 Table 4 XRPD analysis data for the fumarate crystal form A of the compound of Formula I- 1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak#1 5.106943 17.29001 66.02386 80.74232 0.6328462 0.100 Peak#2 7.257269 12.17109 15.48998 32.61639 0.1484732 0.123 Peak#3 10.20005 8.665302 44.82843 61.36366 0.4296856 0.171 Peak#4 10.50647 8.413257 25.31782 41.40717 0.2426742 0.100 Peak#5 14.22988 6.219109 94.52111 109.7326 0.9059956 0.138 Peak#6 14.46519 6.118463 44.95081 60.22918 0.4308586 0.153 Peak#7 14.93302 5.927817 26.26917 41.2175 0.251793 0.100 Peak#8 16.16592 5.478399 35.9365 51.60095 0.3444554 0.117 Peak#9 17.02807 5.202913 44.72762 61.55038 0.4287193 0.100 Peak#10 17.90158 4.950956 21.9525 40.30973 0.2104172 0.178 Peak#11 18.78968 4.718902 49.85003 67.55918 0.4778182 0.107 Peak#12 19.44071 4.562319 28.59071 45.95156 0.2740452 0.100 Peak#13 20.19247 4.394129 33.90914 52.76979 0.325023 0.149 Peak#14 20.79758 4.267629 33.02869 51.93834 0.3165837 0.201 Peak#15 22.48454 3.951108 11.28123 28.946 0.1081319 0.169 Peak#16 23.06632 3.852751 12.43236 31.23554 0.1191656 0.167 Peak#17 23.73916 3.745054 18.25035 37.17823 0.1749317 0.152 Peak#18 24.07149 3.694097 20.07611 38.59465 0.1924318 0.207 Peak#19 27.06206 3.292275 40.86212 66.92372 0.3916681 0.119 Peak#20 27.84687 3.201246 20.41484 49.1985 0.1956785 0.160 Peak#21 28.29739 3.151295 22.67108 52.42942 0.2173048 0.199 Peak#22 28.84687 3.092505 104.3285 134.4994 1 0.101 Peak#23 29.46212 3.02931 23.97766 53.60007 0.2298286 0.138 Peak#24 38.24442 2.351456 16.4544 35.48725 0.1577173 0.165 The present invention also provides a method for preparing the fumarate crystal form A of the compound of Formula I-1, comprising adding the compound of Formula I-1 and fumaric acid to acetonitrile and dichloromethane, and then performing recrystallization or slurrying to obtain it, wherein the ratio of the compound of Formula I-1 to fumaric acid is selected from 0.8 to 1.2. The present invention also provides the hemifumarate crystal form B of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 9 angles: 5.12 ± 0.2°, 10.20 ±0.2°, 10.53 ± 0.2°, 14.24 ±0.2°, 16.99 ± 0.2°, 18.81  ± 0.2°, 19.45  ± 0.2°, 20.22  ± 0.2°, 20.43 ± 0.2°, 20.84 ± 0.2°, 27.04 ± 0.2°, 27.904±0.2°, 28.254±0.2° , 28.754±0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the hemifumarate crystal form B of the compound of formula I-1 has characteristic diffraction peaks at the following 2 9 angles: 5.12± 0.2°, 7.27 ±0.2°, 7.48±0.2°, 8.77 ± 0.2°, 9.18 ± 0.2°, 9.74 ± 0.2°, 10.20 ± 0.2°, 10.53  ± 0.2°, 14.24 ± 0.2°, 14.96 ± 0.2°, 16.09±0.2°, 16.99±0.2°, 17.61±0.2° , 17.95±0.2°, 18.81±0.2°, 19.45±0.2°, 20.22±0.2°, 20.43±0.2°, 20.84±0.2°, 22.51±0.2°, 23.11±0.2°, 23.76±0.2°, 24.19±0.2°, 25.24±0.2°, 27.04±0.2°, 27.90±0.2°, 28.25±0.2°, 28.75±0.2°, 29.73±0.2°, 30.14±0.2°, 30.77±0.2°, 31.28±0.2°, 33.95±0.2°, 34.52±0.2°, 37.07±0.2°, 38.26±0.2°. In some embodiments of the present invention, the XRPD pattern of the hemifumarate crystal form B of the compound of Formula I-1 is shown in Figure 9. Table 5 XRPD analysis data for the hemifumarate crystal form B of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak#1 5.12113 17.24215 4647.751 4910.723 0.8420983 0.100 Peak#2 7.273411 12.14412 623.8793 910.8909 0.113037 0.142 Peak#3 7.477666 11.81285 412.141 704.9915 0.07467337 0.142 Peak#4 8.774699 10.06943 198.996 518.1956 0.03605491 0.129 Peak#5 9.180456 9.62527 368.1948 696.2799 0.06671103 0.133 Peak#6 9.736835 9.076479 448.8479 784.1718 0.08132408 0.128 Peak#7 10.19865 8.666491 2325.105 2662.089 0.421272 0.188 Peak#8 10.53449 8.390942 2150.306 2486.023 0.3896012 0.100 Peak#9 14.24094 6.214301 5519.25 6023.346 1 0.100 Peak#10 14.9559 5.918799 899.1369 1478.035 0.1629093 0.106 Peak#11 16.09258 5.503201 1338.067 2023.104 0.2424364 0.154 Peak#12 16.99405 5.213253 2242.453 3003.123 0.4062966 0.122 Peak#13 17.60838 5.03273 547.075 1350.681 0.09912127 0.100 Peak#14 17.95021 4.937653 762.8884 1587.368 0.1382232 0.100 Peak#15 18.80551 4.714965 2077.941 2945.17 0.3764898 0.133 Peak#16 19.45143 4.55983 1987.91 2878.464 0.3601776 0.100 Peak#17 20.2158 4.389112 1462.113 2370.312 0.2649115 0.315 Peak#18 20.42854 4.343882 1577.348 2488.53 0.2857904 0.310 Peak#19 20.84079 4.258877 1320.896 2235.486 0.2393253 0.176 Peak#20 22.50678 3.947253 631.9739 1528.338 0.1145036 0.100 Peak#21 23.11194 3.84525 710.6365 1587.676 0.128756 0.189 Peak#22 23.75574 3.742477 1328.016 2177.066 0.2406154 0.100 Peak#23 24.18724 3.676679 635.7908 1461.799 0.1151951 0.100 Peak#24 25.23851 3.525865 378.4447 1133.886 0.06856815 0.100 Peak#25 27.04291 3.294563 1310.952 2070.533 0.2375235 0.253 Peak#26 27.90105 3.195153 1727.994 2515.479 0.313085 0.100 Peak#27 28.25099 3.156364 1116.084 1911.047 0.2022166 0.100 Peak#28 28.74762 3.102957 1000.29 1801.975 0.1812366 0.100 Peak#29 29.73267 3.002359 710.9998 1512.519 0.1288218 0.100 Peak#30 30.14065 2.962642 604.3896 1400.594 0.1095058 0.211 Peak#31 30.76595 2.903837 492.9324 1275.009 0.08931148 0.161 Peak#32 31.27625 2.857613 378.292 1143.485 0.06854048 0.140 Peak#33 33.94976 2.638443 415.4766 1098.577 0.07527773 0.125 Peak#34 34.52381 2.595875 324.9706 1017.928 0.05887949 0.115 Peak#35 37.06812 2.423331 331.5999 994.89 0.06008062 0.178 Peak#36 38.25865 2.350615 330.8221 950.937 0.05993968 0.142 In some embodiments of the present invention, the hemifumarate crystal form B of the compound of Formula I-1 has the onsets of the endothermic peaks at 21.34°C ± 2°C, 172.21°C ± 2°C, and 234.34°C ± 2°C in its differential scanning calorimetry (DSC) curve. In some embodiments of the present invention, the hemifumarate crystal form B of the compound of Formula I-1 has a DSC pattern as shown in Figure 10. In some embodiments of the present invention, the hemifumarate crystal form B of the compound of Formula I-1 has three weight loss steps at 31.90°C ± 2°C, 90.00°C ± 2°C, and 190.00°C ± 2°C in its thermogravimetric analysis (TGA) curve, and decomposition begins above 270.00°C ± 2°C. In some embodiments of the present invention, the TGA pattern of the hemifumarate crystal form B of the compound of Formula I-1 is shown in Figure 11. The present invention also provides a method for preparing the hemifumarate crystal form B of the compound of Formula I-1, comprising adding the compound of Formula I-1 and fumaric acid to tetrahydrofuran, and then performing recrystallization or slurrying to obtain it, wherein the ratio of the compound of Formula I-1 to fumaric acid is selected from 1.6 to 2.4. The present invention also provides the monoglycolate crystal form A of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 9  angles: 6.37 ± 0.2°, 10.37 ± 0.2°, 12.69 ± 0.2°, 13.55 ± 0.2°, 14.06 ± 0.2°, 18.22 ± 0.2°, 18.47 ± 0.2°, 21.25 ± 0.2°, 22.83 ± 0.2°, 23.49 ± 0.2°, 26.41  ± 0.2°, 30.96 ± 0.2°. In some embodiments of the present invention, the monoglycolate crystal form A of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 0 angles: 6.37 ± 0.2°, 10.37 ± 0.2°, 11.09±0.2°, 11.70±0.2°, 12.69 ± 0.2°, 13.55 ± 0.2 °, 14.06 ± 0.2°, 15.97 ± 0.2°, 17.34 ± 0.2°, 18.22 ± 0.2°, 18.47±0.2°,  19.09±0.2°,  20.41±0.2°,  20.71±0.2°,  21.25±0.2°,  22.06±0.2°,  22.43±0.2°, 22.83±0.2°,  23.49±0.2°,  24.09±0.2°,  24.79±0.2°,  25.21±0.2°,  26.41±0.2°,  27.23±0.2°, 5   28.00±0.2°, 29.59±0.2°, 30.44±0.2°, 30.96±0.2°, 38.67±0.2°. In some embodiments of the present invention, the XRPD pattern of the monoglycolate crystal form A of the compound of Formula I-1 is shown in Figure 12. Table 6 XRPD analysis data for the monoglycolate crystal form A of the compound of Formula I-1 Name Angle dValue Net Intensity Gross Intensity Rel. Intensity FWHM Peak#1 6.367303 13.87013 2029.288 2272.519 0.07434029 0.100 Peak#2 10.37207 8.521972 6470.729 6785.768 0.2370466 0.100 Peak#3 11.09208 7.970361 1010.483 1340.449 0.0370177 0.100 Peak#4 11.70461 7.55459 1500.982 1841.876 0.05498648 0.100 Peak#5 12.69449 6.967646 3589.622 3976.064 0.131501 0.100 Peak#6 13.55449 6.527435 10232.45 10650.02 0.3748523 0.100 Peak#7 14.05714 6.29514 10135.51 10557.75 0.3713008 0.100 Peak#8 15.97294 5.544148 3536.131 4003.394 0.1295415 0.100 Peak#9 17.33713 5.110852 2288.859 2836.97 0.0838493 0.100 Peak#10 18.21904 4.865397 27297.29 27912.26 1 0.100 Peak#11 18.46709 4.800599 12375.91 13004.16 0.453375 0.138 Peak#12 19.08811 4.645792 4405.293 5056.107 0.1613821 0.100 Peak#13 20.40513 4.348813 1117.151 1859.68 0.04092536 0.179 Peak#14 20.71391 4.284677 1886.923 2660.549 0.06912491 0.165 Peak#15 21.2549 4.176828 9592.014 10411.04 0.3513907 0.100 Peak#16 22.05512 4.027056 1278.383 2158.564 0.04683188 0.127 Peak#17 22.43277 3.960109 1131.067 2042.437 0.04143513 0.131 Peak#18 22.83447 3.891343 14043.22 14981.57 0.5144547 0.100 Peak#19 23.48801 3.784526 9793.021 10761.67 0.3587543 0.157 Peak#20 24.09406 3.690687 3140.149 4121.826 0.1150352 0.108 Peak#21 24.78808 3.588905 6995.654 7974.427 0.2562765 0.100 Peak#22 25.21228 3.529473 3274.032 4241.681 0.1199398 0.108 Peak#23 26.41114 3.37192 15344.24 16294.99 0.5621157 0.100 Peak#24 27.22701 3.272703 1465.29 2397.752 0.05367895 0.114 Peak#25 27.99766 3.184346 3541.794 4432.819 0.1297489 0.100 Peak#26 29.59053 3.016456 1490.567 2310.24 0.05460494 0.100 Peak#27 30.43898 2.934282 1485.749 2333.618 0.05442845 0.100 Peak#28 30.96021 2.886059 7547.225 8398.33 0.2764826 0.100 Peak#29 38.66922 2.326597 1355.032 1979.99 0.04963982 0.100 In some embodiments of the present invention, the monoglycolate crystal form A of the compound of Formula I-1 has the onsets of the endothermic peaks at 109.66°C ± 2°C and 198.83°C ± 2°C in its differential scanning calorimetry (DSC) curve. In some embodiments of the present invention, the monoglycolate crystal form A of the compound of Formula I-1 has a DSC pattern as shown in Figure 13. In some embodiments of the present invention, the monoglycolate crystal form A of the compound of Formula I-1 has three weight loss steps at 33.00°C ± 2°C, 100.00°C ± 2°C, and 165.00°C ± 2°C in its thermogravimetric analysis (TGA) curve, and decomposition begins above 200.00°C ± 2°C. In some embodiments of the present invention, the TGA pattern of the monoglycolate crystal form A of the compound of Formula I-1 is shown in Figure 14. The present invention also provides a method for preparing the monoglycolate crystal form A of the compound of Formula I-1, comprising adding the compound of Formula I-1 and glycolic acid to acetonitrile, and then performing recrystallization or slurrying to obtain it, wherein the ratio of the compound of Formula I-1 to glycolic acid is selected from 0.8 to 1.2. The present invention also provides the glycolate crystal form B of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 9  angles: 5.95±0.2°, 12.20 ± 0.2°, 13.87 ± 0.2°, 15.79 ± 0.2°, 15.97 ± 0.2°, 16.44 ± 0.2°, 16.63 ± 0.2°, 16.79 ± 0.2°, 17.30 ± 0.2°, 19.49 ± 0.2°, 23.50 ± 0.2°, 26.68 ± 0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the glycolate crystal form B of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 9 angles: 5.95± 0.2°, 11.06±0.2°, 12.20 ±0.2°, 13.87± 0.2°, 15.01 ±0.2°, 15.79±0.2°, 15.97±0.2°, 16.44±0.2°, 16.63±0.2°, 16.79±0.2°, 17.30±0.2°, 17.90 ±0.2°, 18.33±0.2°, 18.91±0.2°, 19.49±0.2°, 21.59±0.2°, 22.18±0.2°, 22.80±0.2°, 23.16 ±0.2°, 23.50±0.2°, 23.93±0.2°, 24.49±0.2° , 25.13±0.2°, 26.68±0.2°, 27.95±0.2°, 30.49 ±0.2°, 31.62±0.2°, 32.27±0.2°. In some embodiments of the present invention, the XRPD pattern of the glycolate crystal form B of the compound of Formula I-1 is shown in Figure 15. Table 7 XRPD analysis data for the glycolate crystal form B of the compound of Formula I- 1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak#1 5.94826 14.84628 47.21226 62.80721 0.2820042 0.100 Peak#2 11.05959 7.993703 27.85228 46.52969 0.1663649 0.100 Peak#3 12.19964 7.249135 42.98131 61.03759 0.2567323 0.100 Peak#4 13.8704 6.379468 111.6527 128.6609 0.6669146 0.100 Peak#5 15.01254 5.896596 26.83811 41.78902 0.1603071 0.100 Peak#6 15.78903 5.60831 44.40633 61.01559 0.2652441 0.100 Peak#7 15.97478 5.543516 34.20984 51.4254 0.2043393 0.100 Peak#8 16.43714 5.388608 14.20148 32.83326 0.08482705 0.166 Peak#9 16.6293 5.326771 22.48186 41.62296 0.1342867 0.166 Peak#10 16.79174 5.275602 31.88576 51.36475 0.1904573 0.100 Peak#11 17.30051 5.12159 142.7281 162.7214 0.8525316 0.100 Peak#12 17.89638 4.952384 43.38684 63.59336 0.2591546 0.100 Peak#13 18.32724 4.836915 84.93102 104.8279 0.5073028 0.100 Peak#14 18.91279 4.688461 18.65536 37.72074 0.1114306 0.100 Peak#15 19.48954 4.550999 167.4168 186.2042 1 0.100 Peak#16 21.58975 4.112796 17.46467 35.08154 0.1043185 0.100 Peak#17 22.18036 4.0046 52.74449 72.09505 0.3150489 0.100 Peak#18 22.80481 3.896337 60.85134 82.53977 0.363472 0.173 Peak#19 23.15596 3.83804 45.15902 67.61517 0.26974 0.125 Peak#20 23.49665 3.783154 107.6953 130.5205 0.6432761 0.100 Peak#21 23.92768 3.715973 15.04318 37.80346 0.08985461 0.191 Peak#22 24.49098 3.631765 17.92286 39.70282 0.1070553 0.161 Peak#23 25.12531 3.541494 38.13791 58.55093 0.2278021 0.119 Peak#24 26.67703 3.338912 82.84576 102.2695 0.4948473 0.100 Peak#25 27.94708 3.189994 33.99763 54.5564 0.2030717 0.107 Peak#26 30.48514 2.929944 31.34254 53.22852 0.1872126 0.100 Peak#27 31.62302 2.827063 15.2675 32.42916 0.09119453 0.100 Peak#28 32.26844 2.771976 22.99334 38.4986 0.1373419 0.192 The present invention also provides a method for preparing the glycolate crystal form B of the compound of Fomular I-1, comprising adding the compound of Formula I-1 and glycolic acid to tetrahydrofuran and dichloromethane, and then performing recrystallization or slurrying to obtain it, wherein the ratio of the compound of Formula I-1 to glycolic acid is selected from 0.8 to 1.2. The present invention also provides the mono-L-malate crystal form A of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 9 angles: 6.01 ±0.2°, 15.15 ±0.2°, 17.27 ±0.2°, 17.99±0.2°, 18.58 ± 0.2°, 22.58 ± 0.2 °, 24.00 ± 0.2°, 24.50 ± 0.2°, 25.00 ± 0.2°, 29.40 ± 0.2°, 30.53 ± 0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the mono-L-malate crystal form A of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 9 angles: 6.01 ±0.2°, 10.06±0.2°, 11.04±0.2°, 11.98± 0.2°, 12.66 ± 0.2° , 12.86 ± 0.2°, 13.39 ± 0.2° , 15.15 ± 0.2°, 15.62 ± 0.2°, 16.46 ± 0.2°, 17.27 ± 0.2°, 17.99±0.2°, 18.58±0.2°, 19.53±0.2°, 19.77±0.2°, 20.25±0.2°, 21.01 ±0.2°, 21.57±0.2°, 22.04±0.2°, 22.58±0.2°, 23.67±0.2°, 24.00±0.2°, 24.50±0.2°, 25.00 ±0.2°, 27.34±0.2°, 28.54±0.2°, 28.91±0.2°, 29.40±0.2°, 29.89±0.2°, 30.53 ±0.2°, 31.33 ±0.2°, 33.67±0.2°, 36.16±0.2°. In some embodiments of the present invention, the XRPD pattern of the mono-L-malate crystal form A of the compound of Formula I-1 is shown in Figure 16. Table 8. XRPD analysis data for the mono-L-malate crystal form A of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak#1 6.005817 14.70413 3458.47 3698.186 0.1756963 0.100 Peak#2 10.05991 8.785703 1235.219 1524.838 0.06275127 0.100 Peak#3 11.04048 8.007493 1010.378 1324.343 0.05132898 0.100 Peak#4 11.98007 7.381497 1546.43 1893.062 0.07856131 0.100 Peak#5 12.65977 6.986674 1564.73 1932.612 0.07949098 0.141 Peak#6 12.86478 6.875793 1744.169 2115.445 0.0886068 0.133 Peak#7 13.39037 6.607066 1748.559 2122.191 0.08882982 0.100 Peak#8 15.15275 5.842348 6447.348 6874.498 0.3275365 0.100 Peak#9 15.61757 5.669495 415.1237 858.8148 0.021089 0.100 Peak#10 16.46146 5.3807 1753.405 2260.688 0.08907603 0.100 Peak#11 17.27465 5.129198 9650.521 10,238.98 0.4902632 0.100 Peak#12 17.99119 4.926498 11,219.57 11,861.34 0.5699735 0.109 Peak#13 18.57705 4.772433 10,433.66 11,106.38 0.5300483 0.108 Peak#14 19.52605 4.542572 1184.517 1891.812 0.06017552 0.222 Peak#15 19.77436 4.486085 3155.73 3872.169 0.1603165 0.130 Peak#16 20.24735 4.382343 3376.988 4105.192 0.1715568 0.121 Peak#17 21.0078 4.225396 2453.564 3206.388 0.1246453 0.100 Peak#18 21.5734 4.115878 3826.304 4620.834 0.1943829 0.100 Peak#19 22.04117 4.029573 2859.582 3680.584 0.1452717 0.100 Peak#20 22.58438 3.933865 15,035.12 15,877.77 0.7638101 0.100 Peak#21 23.67221 3.755494 3964.6 4821.112 0.2014086 0.100 Peak#22 24.00331 3.704436 19,684.37 20,537.32 1 0.100 Peak#23 24.50464 3.629771 6524.69 7365.307 0.3314656 0.100 Peak#24 24.99671 3.559421 4225.784 5046.185 0.2146772 0.104 Peak#25 27.33987 3.259448 1009.065 1702.707 0.05126226 0.100 Peak#26 28.53714 3.125362 2079.627 2806.331 0.1056487 0.100 Peak#27 28.90615 3.086298 1564.794 2296.025 0.07949425 0.100 Peak#28 29.4012 3.035449 2180.341 2910.555 0.1107651 0.142 Peak#29 29.89372 2.986549 849.0558 1570.18 0.04313351 0.153 Peak#30 30.52674 2.926045 1898.222 2595.839 0.09643298 0.163 Peak#31 31.33463 2.852422 933.9003 1606.439 0.04744376 0.120 Peak#32 33.66905 2.659796 1560.925 2238.357 0.07929768 0.183 Peak#33 36.16417 2.481803 1357.96 2054.411 0.06898671 0.100 In some embodiments of the present invention, the mono-L-malate crystal form A of the compound of Formula I-1 has the onset of endothermic peak at 204.74°C ± 2°C in its differential scanning calorimetry (DSC) curve. In some embodiments of the present invention, the DSC pattern of the mono-L-malate 5 crystal form A of the compound of Formula I-1 is shown in Figure 17. In some embodiments of the present invention, the mono-L-malate crystal form A of the compound of Formula I-1 has two weight loss steps at 33.00°C ± 2°C and 185.00°C ± 2°C in its thermogravimetric analysis (TGA) curve, and decomposition begins above 250.00°C ± 2°C. In some embodiments of the present invention, the TGA pattern of mono-L-malate crystal form A of the compound of Formula I-1 is shown in Figure 18. The present invention also provides a method for preparing the mono-L-malate crystal form A of the compound of Formula I-1, comprising adding the compound of Formula I-1 and L-malic acid to acetonitrile, tetrahydrofuran, and dichloromethane, and then performing recrystallization or slurrying to obtain it, wherein the ratio of the compound of Formula I-1 to L-malic acid is selected from 0.8 to 1.2. The present invention also provides the monosuccinate crystal form A of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 9 angles: 6.15±0.2°, 12.26 ± 0.2°, 17.59 ± 0.2°, 18.40 ± 0.2°, 18.89 ± 0.2°, 19.11 ± 0.2°, 19.73 ± 0.2°, 20.90 ± 0.2°, 23.12±0.2°, 23.83±0.2°, 24.09±0.2°, 24.35±0.2°, 24.62±0.2°, 24.93±0.2°, 25.17±0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the monosuccinate crystal form A of the compound of formula I-1 has characteristic diffraction peaks at the following 2 9 angles: 6.15 ±0.2°, 9.64±0.2°, 9.95±0.2°, 11.19± 0.2°, 12.26 ± 0.2 °, 12.70 ± 0.2 °, 13.30 ± 0.2°, 14.95 ± 0.2°, 15.25 ± 0.2°, 16.18 ± 0.2°, 17.59 ± 0.2°, 18.40±0.2°, 18.89±0.2°, 19.11±0.2°, 19.73±0.2°, 20.28±0.2°, 20.90±0.2°, 21.27±0.2°, 21.64±0.2°, 22.12±0.2°, 23.12±0.2°, 23.83±0.2°, 24.09±0.2°, 24.35±0.2°, 24.62±0.2°, 24.93±0.2°, 25.17±0.2°, 26.05 ± 0.2°, 27.00±0.2°, 28.27±0.2°, 28.72±0.2°, 30.12±0.2°, 31.20±0.2°, 33.57±0.2°, 34.13±0.2°, 34.58±0.2°, 35.60±0.2°, 38.23±0.2°. In some embodiments of the present invention, the XRPD pattern of the monosuccinate crystal form A of the compound of Formula I-1 is shown in Figure 19. Table 9: XRPD analysis data for the monosuccinate crystal form A of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 6.150476 14.35861 1079.754 1326.613 0.07385032 0.100 Peak #2 9.639017 9.168368 507.5315 837.8813 0.03471289 0.100 Peak #3 9.947687 8.884562 756.1947 1093.582 0.05172034 0.193 Peak #4 11.19269 7.898941 418.548 786.0864 0.02862681 0.104 Peak #5 12.26293 7.211865 5643.144 6055.72 0.3859659 0.100 Peak #6 12.69721 6.966156 1808.497 2238.503 0.1236932 0.183 Peak #7 13.30472 6.649406 441.7258 886.793 0.03021207 0.170 Peak #8 14.94649 5.922504 2066.371 2623.71 0.1413305 0.100 Peak #9 15.25239 5.804404 2862.093 3448.346 0.1957544 0.100 Peak #10 16.17555 5.475159 3974.573 4631.365 0.271843 0.100 Peak #11 17.58521 5.039309 9714.239 10,581.19 0.6644106 0.178 Peak #12 18.40139 4.817592 12,708.81 13,696.54 0.8692256 0.109 Peak #13 18.8852 4.69525 3,885.743 4935.811 0.2657675 0.275 Peak #14 19.10943 4.640657 3969.688 5046.307 0.271509 0.284 Peak #15 19.73177 4.495673 5384.054 6526.596 0.3682452 0.100 Peak #16 20.28191 4.374954 2270.541 3461.857 0.1552948 0.126 Peak #17 20.90259 4.246425 3615.605 4851.244 0.2472912 0.100 Peak #18 21.27065 4.173772 3046.671 4303.229 0.2083787 0.102 Peak #19 21.63627 4.10406 1379.22 2652.606 0.0943325 0.100 Peak #20 22.1207 4.015265 1392.721 2682.337 0.0952559 0.100 Peak #21 23.11513 3.844727 6964.299 8265.567 0.476327 0.234 Peak #22 23.83111 3.730811 7252.805 8544.42 0.4960595 0.101 Peak #23 24.0942 3.690666 12,167.04 13,451.31 0.832171 0.100 Peak #24 24.35121 3.652293 10,144.41 11,419.54 0.6938321 0.100 Peak #25 24.61575 3.613639 14,620.84 15,884.53 1 0.130 Peak #26 24.93286 3.568392 5294.415 6541.669 0.3621143 0.100 Peak #27 25.16802 3.535581 5032.057 6265.21 0.3441702 0.100 Peak #28 26.0534 3.417403 778.8174 1944.266 0.05326763 0.100 Peak #29 27.00305 3.299335 1246.342 2313.507 0.08524425 0.216 Peak #30 28.26834 3.154467 725.8612 1800.543 0.04964567 0.228 Peak #31 28.7181 3.106079 1720.941 2828.181 0.1177047 0.111 Peak #32 30.12463 2.964181 1318.532 2489.126 0.09018173 0.343 Peak #33 31.20475 2.863997 646.1497 1825.823 0.04419375 0.353 Peak #34 33.56967 2.667443 732.0571 1829.258 0.05006944 0.187 Peak #35 34.12764 2.625098 1220.828 2279.93 0.08349918 0.114 Peak #36 34.58483 2.591435 594.5156 1615.563 0.04066221 0.137 Peak #37 35.60008 2.519824 551.2985 1542.296 0.03770636 0.154 Peak #38 38.23304 2.352131 558.504 1479.673 0.03819918 0.162 In some embodiments of the present invention, the monosuccinate crystal form A of the compound of Formula I-1 has the onsets of the endothermic peaks at 72.75°C ± 2°C, 146.41°C ± 2°C, and 175.72°C ± 2°C in its differential scanning calorimetry (DSC) curve. In some embodiments of the present invention, the DSC pattern of the monosuccinate 5 crystal form A of the compound of Formula I-1 is shown in Figure 20. In some embodiments of the present invention, the monosuccinate crystal form A of the compound of Formula I-1 has three weight loss steps at 33.00°C ± 2°C, 90.00°C ± 2°C, and 160.00°C ± 2°C in its thermogravimetric analysis (TGA) curve, and decomposition begins above 260.00°C ± 2°C. 10       In some embodiments of the present invention, the TGA pattern of the monosuccinate crystal form A of the compound of Formula I-1 is shown in Figure 21. The present invention also provides a method for preparing the monosuccinate crystal form A of the compound of Formula I-1, comprising adding the compound of Formula I-1 and succinic acid to acetonitrile, tetrahydrofuran, dichloromethane, and then performing 15 recrystallization or slurrying to obtain it, wherein the ratio of the compound of Formula I-1 to succinic acid is selected from 0.8 to 1.2. The present invention also provides the sulfate crystal form A of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 9 angles: 6.74±0.2°, 9.56±0.2°, 12.89±0.2°, 13.78 ± 0.2°, 14.97 ± 0.2 °, 15.70 ± 0.2 °, 18.68 ± 0.2 °, 19.87  ± 0.2 °, 20.21  ± 0.2 °, 21.54 ± 0.2°, 21.76±0.2°, 22.58±0.2°, 23.75±0.2°, 24.11±0.2°, 24.50±0.2°, 25.25±0.2°, 25.86±0.2°, 27.73±0.2°, 5   28.41±0.2°, 29.70±0.2°, 30.21±0.2°, 30.99±0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the sulfate crystal form A of the compound of formula I-1 has characteristic diffraction peaks at the following 2 9 angles: 6. 74±0.2°, 9.56±0.2°, 12.89 ± 0.2°, 13.78 ± 0.2 ° , 14.68 ± 0.2°, 14.97 ± 0.2°, 15.49 ± 0.2 °, 15.70 ± 0.2 °, 16.41 ± 0.2°, 16.90±0.2°, 18.47 10    ±0.2°, 18.68±0.2°, 18.86±0.2°, 19.33±0.2°, 19.87±0.2°, 20.21±0.2°, 20.70±0.2°, 21.54 ±0.2°, 21.76±0.2°, 22.25±0.2°, 22.58±0.2°, 23.75±0.2°, 24.11±0.2°, 24.50±0.2°, 25.25 ±0.2°, 25.86±0.2°, 26.10±0.2°, 26.71±0.2°, 26.96±0.2°, 27.73±0.2°, 28.41±0.2°, 28.90 ±0.2°, 29.70±0.2°, 30.21±0.2°, 30.99±0.2°. In some embodiments of the present invention, the XRPD pattern of sulfate crystal form 15 A of the compound of Formula I-1 is shown in Figure 22. Table 10 XRPD analysis data for the sulfate crystal form A of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 6.744119 13.09598 35.65135 52.09074 0.07305558 0.100 Peak #2 9.561178 9.242833 46.10621 65.47356 0.09447933 0.100 Peak #3 12.8933 6.860647 63.02497 82.15709 0.1291487 0.100 Peak #4 13.78205 6.420164 125.4007 141.7527 0.256967 0.100 Peak #5 14.67751 6.03043 43.68357 60.03772 0.08951494 0.120 Peak #6 14.9725 5.912276 162.9075 180.921 0.3338248 0.100 Peak #7 15.48903 5.716255 33.8544 53.65991 0.06937333 0.137 Peak #8 15.70464 5.638256 75.82063 95.95579 0.1553692 0.107 Peak #9 16.40931 5.397684 27.52728 46.81891 0.056408 0.122 Peak #10 16.89674 5.243056 26.01051 42.90306 0.05329987 0.137 Peak #11 18.46692 4.800645 66.26648 87.1077 0.1357911 0.100 Peak #12 18.68092 4.74613 150.3831 172.4377 0.3081601 0.100 Peak #13 18.85655 4.702318 68.76389 91.63316 0.1409087 0.100 Peak #14 19.32761 4.58876 43.94986 68.19607 0.09006061 0.100 Peak #15 19.86924 4.464878 73.86705 99.83997 0.1513659 0.100 Peak #16 20.2137 4.389563 488.0031 514.8398 1 0.100 Peak #17 20.70499 4.286504 63.89549 90.87065 0.1309325 0.100 Peak #18 21.54397 4.121434 97.47784 125.4785 0.1997484 0.159 Peak #19 21.76018 4.080969 98.40488 127.1933 0.2016481 0.180 Peak #20 22.24623 3.992892 67.09114 96.74156 0.137481 0.122 Peak #21 22.57571 3.935357 161.0002 190.5227 0.3299163 0.100 Peak #22 23.74843 3.743612 56.21038 83.58575 0.1151845 0.100 Peak #23 24.11135 3.68808 61.4445 89.07555 0.1259101 0.193 Peak #24 24.4972 3.630857 66.60504 93.7385 0.1364849 0.117 Peak #25 25.25065 3.524197 48.23406 75.23211 0.09883966 0.100 Peak #26 25.8563 3.443004 47.72845 74.68002 0.09780359 0.197 Peak #27 26.09526 3.412015 76.15202 102.5496 0.1560482 0.133 Peak #28 26.70874 3.33502 23.33187 50.96179 0.04781092 0.168 Peak #29 26.96348 3.304087 15.27831 43.83334 0.03130781 0.168 Peak #30 27.73352 3.214072 36.22639 65.48412 0.07423393 0.100 Peak #31 28.40891 3.139177 73.84084 101.121 0.1513122 0.100 Peak #32 28.90162 3.086772 32.87369 60.11243 0.06736368 0.171 Peak #33 29.6984 3.005745 44.70893 73.78767 0.09161608 0.101 Peak #34 30.20773 2.956216 44.79463 73.28409 0.09179169 0.100 Peak #35 30.98633 2.883686 44.91674 71.77048 0.09204191 0.100 The present invention also provides a method for preparing the sulfate crystal form A of the compound of Formula I-1, comprising adding the compound of Formula I-1 and sulfuric acid to acetonitrile, and then performing recrystallization or slurrying to obtain it, wherein the ratio of the compound of Formula I-1 to sulfuric acid is selected from 0.8 to 1.2. The present invention also provides the L-tartarate crystral form A of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 9 angles: 5.53±0.2°, 8.90±0.2°, 9.35±0.2°, 11.05±0.2°, 12.54 ± 0.2 °, 12.90 ± 0.2 °, 14.35 ± 0.2 °, 14.64 ± 0.2 °, 16.95 ± 0.2°, 18.70±0.2°, 19.45±0.2°, 19.74±0.2°, 20.38±0.2°, 20.79±0.2°, 21.45±0.2°, 21.94±0.2°, 22.88±0.2°, 23.80±0.2°, 25.01±0.2°, 25.77±0.2°, 27.33±0.2°, 27.80±0.2°, 28.65±0.2°, 29.41±0.2°, 30.00±0.2°, 31.09±0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the L-tartarate crystal form A of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 9 angles: 5.53 ±0.2°, 8.90±0.2°, 9.35 ±0.2°, 11.05± 0.2°, 12.54 ± 0.2°, 12.90 ± 0.2°, 14.35 ± 0.2°, 14.64 ± 0.2°, 16.95 ± 0.2°, 18.70 ± 0.2°, 19.45 ± 0.2°, 19.74±0.2°,  20.38±0.2°,  20.79±0.2°,  21.45±0.2°,  21.94±0.2°,  22.88±0.2°,  23.80±0.2°, 25.01±0.2°,  25.77±0.2°,  27.33±0.2°,  27.80±0.2°,  28.65±0.2°,  29.41±0.2°,  30.00±0.2°, 31.09±0.2°. In some embodiments of the present invention, the XRPD pattern of the L-tartrate crystal form A of the compound of Formula I-1 is shown in Figure 23. Table 11 XRPD analysis data for the L-tartrate crystal form A of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 5.532435 15.96118 109.1809 126.6481 0.7936769 0.100 Peak #2 8.902002 9.925714 17.76301 34.91975 0.129126 0.100 Peak #3 9.347501 9.453633 20.67122 38.23275 0.1502669 0.107 Peak #4 11.05106 7.999851 40.37062 57.19987 0.2934692 0.100 Peak #5 12.53919 7.053588 73.71306 91.06278 0.5358478 0.100 Peak #6 12.8953 6.859589 31.62126 49.20035 0.2298668 0.106 Peak #7 14.3487 6.167873 24.90215 41.21078 0.1810231 0.181 Peak #8 14.63806 6.046594 38.96151 55.6525 0.2832258 0.169 Peak #9 16.94772 5.227398 113.6682 132.2339 0.8262969 0.100 Peak #10 18.69887 4.741615 16.89806 36.56548 0.1228383 0.100 Peak #11 19.44714 4.560826 31.79594 53.59855 0.2311366 0.134 Peak #12 19.74014 4.493786 40.01748 62.17728 0.290902 0.139 Peak #13 20.37972 4.354178 102.8208 125.9592 0.7474431 0.112 Peak #14 20.79081 4.269002 137.5634 161.0057 1 0.100 Peak #15 21.45161 4.138969 104.2521 127.0696 0.7578474 0.100 Peak #16 21.942 4.047562 66.40536 87.87263 0.4827255 0.118 Peak #17 22.88227 3.883322 13.39118 34.40554 0.09734552 0.175 Peak #18 23.79606 3.736227 26.73411 47.92166 0.1943403 0.100 Peak #19 25.01189 3.557295 31.7189 53.23115 0.2305766 0.117 Peak #20 25.77077 3.454237 53.50304 75.36505 0.3889337 0.121 Peak #21 27.33488 3.260032 22.88951 45.80283 0.1663924 0.213 Peak #22 27.80017 3.206517 29.94634 54.00067 0.2176912 0.141 Peak #23 28.65149 3.113149 48.81897 74.25991 0.3548834 0.140 Peak #24 29.40593 3.034971 65.22767 90.68871 0.4741644 0.100 Peak #25 30.00085 2.976129 29.92109 54.13644 0.2175076 0.149 Peak #26 31.09079 2.874235 31.22145 54.13402 0.2269605 0.100 The present invention also provides a method for preparing the L-tartarate crystal form A of the compound of Formula I-1, comprising adding the compound of Formula I-1 and L-tartaric acid to acetonitrile, and then performing recrystallization or slurrying to obtain it, wherein the ratio of the compound of Formula I-1 to L-tartaric acid is selected from 0.8 to 1.2. 5       The present invention also provides the hippurate crystal form A of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 0 angles: 6.17 ± 0.2°, 6.52 ± 0.2°, 12.30 ± 0.2°, 14.18 ± 0.2°, 15.62 ± 0.2°, 16.06 ± 0.2°, 16.78± 0.2°, 17.64± 0.2°, 18.78±0.2°, 20.42±0.2°, 21.15±0.2°, 21.29±0.2°, 21.79±0.2°, 24.42±0.2°, 26.45±0.2°. 10        In some embodiments of the present invention, the X-ray powder diffraction pattern of the hippurate crystal form A of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 0 angles: 6.17±0.2°, 6.52±0.2°, 8.77±0.2°, 10.74± 0.2°, 11.16± 0.2°, 12.30±0.2°, 14.18±0.2°, 14.70±0.2°, 15.62±0.2°, 16.06±0.2°, 16.78±0.2°, 17.64±0.2°, 18.78±0.2°,  20.42±0.2°,  21.15±0.2°,  21.29±0.2°,  21.79±0.2°,  23.03±0.2°,  24.05±0.2°, 15   24.42±0.2°, 25.32±0.2°, 26.45±0.2°, 26.87±0.2°, 28.85±0.2°. In some embodiments of the present invention, the XRPD pattern of the hippurate crystal form A of the compound of Formula I-1 is shown in Figure 24. Table 12 XRPD analysis data for the hippurate crystal form A of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 6.165727 14.32313 46.84962 63.97629 0.3607576 0.100 Peak #2 6.518609 13.54852 37.30031 54.89573 0.2872247 0.183 Peak #3 8.770015 10.07479 10.25155 31.52564 0.07894034 0.100 Peak #4 10.73528 8.23445 17.72863 43.06414 0.1365163 0.199 Peak #5 11.15514 7.925448 11.28448 37.4897 0.08689421 0.131 Peak #6 12.30332 7.188276 107.018 134.0704 0.8240739 0.100 Peak #7 14.18347 6.239351 32.73286 58.3698 0.2520539 0.100 Peak #8 14.69591 6.022922 13.75151 40.19582 0.1058912 0.226 Peak #9 15.6192 5.668907 24.5425 53.66223 0.1889853 0.216 Peak #10 16.064 5.512926 40.11842 71.12805 0.3089251 0.160 Peak #11 16.78293 5.278353 30.71124 63.47039 0.2364867 0.100 Peak #12 17.64042 5.02366 38.97564 76.05798 0.3001254 0.146 Peak #13 18.78433 4.720233 129.8645 172.2274 1 0.106 Peak #14 20.41602 4.346517 36.85044 83.07684 0.2837606 0.194 Peak #15 21.14778 4.197742 32.82731 78.65607 0.2527812 0.181 Peak #16 21.29136 4.169756 29.05938 74.61411 0.2237668 0.155 Peak #17 21.79278 4.074936 27.59339 71.68633 0.2124783 0.186 Peak #18 23.02744 3.859168 22.89831 60.05222 0.1763246 0.100 Peak #19 24.05033 3.697299 16.04067 52.94743 0.1235185 0.171 Peak #20 24.42373 3.641612 21.46288 58.33859 0.1652713 0.230 Peak #21 25.32431 3.514113 21.20499 56.21917 0.1632854 0.182 Peak #22 26.44801 3.367302 20.40374 50.96436 0.1571156 0.203 Peak #23 26.8689 3.315503 12.99294 41.55479 0.1000499 0.117 Peak #24 28.85276 3.091887 14.44897 46.59393 0.1112619 0.138 10 15 The present invention also provides a method for preparing the hippurate crystal form A of compound of Formula I-1, comprising adding the compound of Formula I-1 and hippuric acid to tetrahydrofuran, and then performing recrystallization or slurrying to obtain it, wherein the ratio of compound of Formula I-1 to hippuric acid is selected from 0.8 to 1.2. The present invention also provides the glutarate crystal form A of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 9 angles: 11.82±0.2°, 12.75±0.2°, 13.19±0.2°, 14.87±0.2°, 15.10±0.2°, 17.10±0.2°, 17.82±0.2°, 18.35±0.2°, 19.75±0.2°, 20.14±0.2°, 20.70±0.2°, 22.23±0.2°, 23.20±0.2°, 24.26 ±0.2°, 24.47±0.2°, 29.92±0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the glutarate crystal form A of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 9 angles: 9.86±0.2°, 10.97±0.2°, 11.82±0.2°, 12.29±0.2°, 12.75 ± 0.2°, 13.19 ± 0.2°, 14.87 ± 0.2°, 15.10 ± 0.2°, 15.37 ± 0.2°, 16.33 ± 0.2°, 17.10 ± 0.2°, 17.82±0.2°, 18.35±0.2°, 19.17±0.2°, 19.75±0.2°, 20.14±0.2°, 20.70±0.2°, 21.14±0.2°, 22.23±0.2°, 23.20±0.2°, 24.26±0.2°, 24.47±0.2°, 24.86±0.2°, 25.28±0.2°, 29.92±0.2°. In some embodiments of the present invention, the XRPD pattern of the glutarate crystal form A of the compound of Formula I-1 is shown in Figure 25. Table 13 XRPD analysis data for the glutarate crystal form A of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 9.863811 8.959923 12.85162 32.81104 0.08830153 0.172 Peak #2 10.98613 8.046987 10.89521 32.04998 0.07485931 0.116 Peak #3 11.82328 7.479033 49.71856 70.34775 0.3416087 0.100 Peak #4 12.28926 7.196469 17.15315 37.49989 0.1178567 0.218 Peak #5 12.74523 6.94002 19.68536 39.10459 0.1352551 0.100 Peak #6 13.18652 6.708745 33.55265 51.90237 0.2305351 0.100 Peak #7 14.8743 5.951086 39.69448 53.88385 0.2727347 0.129 Peak #8 15.09693 5.863826 34.88612 49.31273 0.2396972 0.216 Peak #9 15.37447 5.758588 31.72464 46.23314 0.2179752 0.115 Peak #10 16.33454 5.422222 16.56744 32.81384 0.1138324 0.100 Peak #11 17.103 5.180287 40.75071 60.68394 0.2799919 0.100 Peak #12 17.81628 4.974467 117.4363 139.108 0.8068871 0.142 Peak #13 18.34729 4.831675 68.64827 90.59112 0.4716718 0.100 Peak #14 19.17292 4.625432 24.33756 46.22366 0.1672196 0.100 Peak #15 19.7465 4.492352 38.56743 60.27261 0.2649909 0.156 Peak #16 20.14022 4.405412 21.05011 42.03999 0.1446321 0.236 Peak #17 20.69634 4.288275 50.58425 69.74656 0.3475567 0.100 Peak #18 21.13538 4.200177 21.00321 38.04622 0.1443098 0.128 Peak #19 22.23299 3.99524 31.02705 52.27459 0.2131821 0.116 Peak #20 23.19805 3.83117 145.5424 170.8203 1 0.110 Peak #21 24.25913 3.665946 52.19791 78.5784 0.3586439 0.282 Peak #22 24.47135 3.634633 118.7159 144.8973 0.8156791 0.263 Peak #23 24.86463 3.578029 53.22074 78.66595 0.3656716 0.103 Peak #24 25.28382 3.519649 25.77899 49.91108 0.1771235 0.100 Peak #25 29.92096 2.983892 13.18526 36.99868 0.09059394 0.107 10 The present invention also provides a method for preparing the glutarate crystal form A of the compound of Formula I-1, comprising adding the compound of Formula I-1 and glutaric acid to acetonitrile and dichloromethane, and then performing recrystallization or slurrying to obtain it, wherein the ratio of the compound of Formula I-1 to glutaric acid is selected from 0.8 to 1.2. The present invention also provides the p-toluenesulfonate crystal form A of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 0 angles: 7.08±0.2°, 10.23±0.2°, 13.36±0.2°, 14.16± 0.2°, 17.77 ± 0.2°, 18.10 ± 0.2°, 18.90 ± 0.2 °, 19.12  ± 0.2°, 20.11 ± 0.2°, 20.53 ± 0.2°, 20.91 ± 0.2°, 24.41±0.2°, 25.51±0.2°, 28.28±0.2°, 29.95±0.2°, 30.98±0.2°, 35.22±0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the p-toluenesulfonate crystal form A of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 9 angles: 7.08 ±0.2°, 8.00 ±0.2°, 9.39 ±0.2°, 10.23 ± 0.2°, 13.36 ± 0.2°, 14.16 ± 0.2°, 14.81  ± 0.2°, 15.77 ± 0.2°, 16.21  ± 0.2°, 17.77 ± 0.2°, 18.10 ± 0.2°, 18.90±0.2°, 19.12±0.2°, 20.11±0.2°, 20.53±0.2°, 20.91±0.2°, 21.29 ±0.2°, 22.49±0.2°, 23.11±0.2°, 24.41±0.2°, 25.51±0.2°, 26.77±0.2°, 28.28±0.2°, 28.81 5    ±0.2°, 29.22±0.2°, 29.95±0.2°, 30.98±0.2°, 35.22±0.2°. In some embodiments of the present invention, the X-ray powder diffraction (XRPD) pattern of the p-toluenesulfonate crystal form A of the compound of Formula I-1 is shown in Figure 26. Table 14 XRPD analysis data for the p-toluenesulfonate crystal form A of the compound of 10                                        Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 7.079945 12.47553 85.42383 101.1101 0.2852689 0.100 Peak #2 7.997392 11.0463 13.96909 31.70288 0.04664912 0.102 Peak #3 9.390173 9.410768 23.25926 45.09923 0.07767321 0.100 Peak #4 10.22862 8.641167 147.574 170.6116 0.4928164 0.100 Peak #5 13.36138 6.621338 128.1409 150.1271 0.4279206 0.106 Peak #6 14.15906 6.250054 101.5931 123.0315 0.3392653 0.100 Peak #7 14.81465 5.974915 18.95654 40.14683 0.06330448 0.100 Peak #8 15.77269 5.614086 40.74862 62.03128 0.1360781 0.148 Peak #9 16.20564 5.46506 21.01715 41.812 0.07018578 0.100 Peak #10 17.76859 4.98771 130.6191 157.9745 0.4361964 0.159 Peak #11 18.10162 4.896693 89.64201 119.1474 0.2993553 0.175 Peak #12 18.89753 4.692213 123.9464 156.6549 0.4139133 0.146 Peak #13 19.11654 4.638949 299.4503 332.5616 1 0.100 Peak #14 20.11447 4.410995 277.3101 311.3669 0.9260639 0.100 Peak #15 20.52951 4.322745 236.2305 269.9984 0.7888807 0.164 Peak #16 20.90733 4.245474 119.2478 152.1095 0.3982224 0.239 Peak #17 21.2862 4.170756 69.93179 101.2655 0.2335339 0.129 Peak #18 22.49223 3.949774 43.0219 68.77164 0.1436696 0.100 Peak #19 23.11408 3.844899 30.92543 55.90915 0.103274 0.101 Peak #20 24.4086 3.643835 70.81258 94.66067 0.2364753 0.125 Peak #21 25.51375 3.488449 44.21862 66.18475 0.147666 0.100 Peak #22 26.77312 3.327147 28.30337 54.19617 0.09451779 0.228 Peak #23 28.28136 3.153044 122.5069 156.2957 0.409106 0.100 Peak #24 28.80565 3.096838 18.56351 52.80252 0.06199198 0.183 Peak #25 29.21899 3.053962 27.92734 61.68496 0.09326204 0.145 Peak #26 29.94764 2.981295 30.47235 61.59036 0.101761 0.100 Peak #27 30.98179 2.884098 24.56855 53.25895 0.0820455 0.117 Peak #28 35.21519 2.546478 18.38519 46.0497 0.06139646 0.100 The present invention also provides a method for preparing the p-toluenesulfonate crystal form A of the compound of Formula I-1, comprising adding the compound of Formula I-1 and p-toluenesulfonic acid to acetonitrile, and then performing recrystallization or slurrying to obtain it, wherein the ratio of the compound of Formula I-1 to p-toluenesulfonic acid is selected from 0.8 to 1.2. The present invention also provides the p-toluenesulfonate crystal form B of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 9 angles: 8.27 ± 0.2°, 13.69 ± 0.2°, 13.95 ± 0.2°, 16.15 ± 0.2°, 17.72 ± 0.2°, 19.52 ± 0.2°, 21.05 ± 0.2°, 22.45 ± 0.2°, 23.91  ± 0.2°, 25.40 ± 0.2°, 27.33 ± 0.2°, 29.25 ± 0. °. In some embodiments of the present invention, the X-ray powder diffraction pattern of the p-toluenesulfonate crystal form B of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 9 angles: 8.27 ±0.2°, 12.59±0.2°, 13.69± 0.2°, 13.95± 0.2°, 14.63 ±  0.2 °, 16.15  ±  0.2°, 17.72  ±  0.2 °, 18.68 ± 0.2 °, 19.52 ± 0.2°, 20.75 ± 0.2°, 21.05 ± 0.2°, 21.92±0.2°, 22.45±0.2°, 23.23±0.2°, 23.91±0.2°, 25.40±0.2°, 27.33±0.2°, 29.25±0.2°. In some embodiments of the present invention, the XRPD pattern of the p-toluenesulfonate crystal form B of the compound of Formula I-1 is shown in Figure 27. Table 15 XRPD analysis data for the p-toluenesulfonate crystal form B of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 8.269233 10.68376 66.65063 82.69354 0.205002 0.100 Peak #2 12.58982 7.025336 25.67633 42.4886 0.07897448 0.113 Peak #3 13.68799 6.464071 66.10264 84.78497 0.2033165 0.100 Peak #4 13.95157 6.342537 205.2721 224.0923 0.6313697 0.100 Peak #5 14.63412 6.048212 56.90355 74.64372 0.1750222 0.100 Peak #6 16.14528 5.485354 75.07107 90.46928 0.2309013 0.100 Peak #7 17.7228 5.000495 52.54952 70.41904 0.1616302 0.161 Peak #8 18.68129 4.746037 24.92735 44.40676 0.0766708 0.106 Peak #9 19.51727 4.544596 325.1219 346.1157 1 0.100 Peak #10 20.74879 4.277555 39.79155 64.27892 0.1223896 0.131 Peak #11 21.04592 4.217828 131.2454 156.5197 0.4036806 0.142 Peak #12 21.91903 4.051752 33.07592 58.38848 0.1017339 0.100 Peak #13 22.4462 3.95777 89.58733 113.2832 0.27555 0.104 Peak #14 23.22516 3.82676 15.41252 37.83067 0.04740537 0.159 Peak #15 23.9116 3.718435 104.2562 125.6726 0.3206681 0.176 Peak #16 25.40249 3.503475 177.7236 200.8911 0.5466368 0.100 Peak #17 27.3258 3.261095 60.00591 86.0919 0.1845644 0.141 Peak #18 29.24715 3.051085 41.28314 68.31211 0.1269774 0.100 The present invention also provides a method for preparing the p-toluenesulfonate crystal form B of the compound of Formula I-1, comprising adding the compound of Formula I-1 and p-toluenesulfonic acid to tetrahydrofuran, and then performing recrystallization or slurrying to obtain it, wherein the ratio of the compound of Formula I-1 to p-toluenesulfonic acid is selected from the 0.8 to 1.2. 5        The present invention also provides the methanesulfonate crystal form A of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 9 angles: 6.70 ± 0.2°, 9.10 ± 0.2°, 9.81 ± 0.2°, 10.16 ± 0.2°, 13.34 ± 0.2°, 13.87 ± 0.2°, 14.27 ± 0.2°, 15.37 ± 0.2°, 17.21 ± 0.2°, 19.57 ± 0.2°, 21.16 ± 0.2°, 22.09 ± 0.2°, 23.86 ± 0.2°, 24.30 ± 0.2°, 24.99 ± 0.2° , 27.18 ± 0.2°. 10       In some embodiments of the present invention, the X-ray powder diffraction pattern of the methanesulfonate crystal form A of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 9 angles: 6.70 ±0.2°, 9. 10±0.2°, 9.81±0.2°, 10.16± 0.2°, 13.34±0.2°, 13.87±0.2°, 14.27±0.2°, 15.37±0.2°, 15.79±0.2°, 17.21±0.2°, 18.75±0.2°, 19.57±0.2°, 21.16±0.2°, 22.09±0.2°, 23.31±0.2°, 23.86±0.2°, 24.30±0.2°, 24.99±0.2°, 15   27.18±0.2°, 28.04±0.2°, 28.83±0.2°. In some embodiments of the present invention, the XRPD pattern of methanesulfonate crystal form A of the compound of Formula I-1 is shown in Figure 28. Table 16 XRPD analysis data for the methanesulfonate crystal form A of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 6.697615 13.18681 29.2205 44.84843 0.1374156 0.100 Peak #2 9.102916 9.707085 21.63046 38.52872 0.1017218 0.100 Peak #3 9.807705 9.011051 21.38057 39.66219 0.1005466 0.143 Peak #4 10.16039 8.699037 29.45585 47.7616 0.1385223 0.161 Peak #5 13.34429 6.629781 27.07287 46.42973 0.1273159 0.100 Peak #6 13.87172 6.378866 29.43882 48.18745 0.1384423 0.100 Peak #7 14.27292 6.20045 66.19603 83.79364 0.3113008 0.100 Peak #8 15.36627 5.761644 37.38631 53.25999 0.175817 0.100 Peak #9 15.78599 5.609385 17.09895 33.88383 0.0804114 0.134 Peak #10 17.21072 5.148107 48.49517 67.62392 0.2280588 0.100 Peak #11 18.75375 4.727863 28.35833 51.94065 0.133361 0.100 Peak #12 19.57472 4.531386 212.6433 239.0555 1 0.110 Peak #13 21.16175 4.195003 37.02691 62.74215 0.1741268 0.160 Peak #14 22.09032 4.020719 46.08796 67.99896 0.2167384 0.100 Peak #15 23.31411 3.81236 19.21252 40.88506 0.09035092 0.173 Peak #16 23.85573 3.727016 34.5036 58.00617 0.1622605 0.100 Peak #17 24.30463 3.659186 33.63316 57.83051 0.158167 0.190 Peak #18 24.98785 3.560663 65.20639 89.03184 0.3066468 0.106 Peak #19 27.18207 3.278012 31.54118 56.58994 0.148329 0.104 Peak #20 28.04009 3.179624 18.07375 44.88169 0.08499562 0.164 Peak #21 28.8345 3.093804 24.47278 50.48177 0.1150884 0.249 The present invention also provides a method for preparing methanesulfonate crystal form A of the compound of Formula I-1, comprising adding the compound of Formula I-1 and methanesulfonic acid to tetrahydrofuran, and then performing recrystallization or slurrying to obtain it, wherein the ratio of the compound of Formula I-1 to methanesulfonic acid is selected from 0.8 to 1.2. The present invention also provides the hydrochloride crystal form C1 of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 0 angles: 7.47±0.2°, 7.73±0.2°, 12.25±0.2°, 13.18±0.2°, 13.51 ± 0.2 °, 14.96 ± 0.2°, 15.46 ± 0.2°, 17.31 ± 0.2° , 18.56 ± 0.2°, 19.34 ± 0.2°, 19.57 ± 0.2°, 19.78±0.2°, 20.01±0.2°, 20.41±0.2°, 20.76±0.2°, 24.36±0.2°, 25.63±0.2°, 26.47±0.2°, 27.51±0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the hydrochloride crystal form C1 of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 0 angles: 7.47±0.2°, 7.73±0.2°, 9.63±0.2°, 11.46±0.2°, 12.25 ± 0.2°, 13.18 ± 0.2°, 13.51 ± 0.2°, 14.96 ± 0.2°, 15.46 ± 0.2°, 16.79 ± 0.2°, 17.04 ± 0.2°, 17.31±0.2°,  17.72±0.2°,  18.56±0.2°,  19.34±0.2°,  19.57±0.2°,  19.78±0.2°,  20.01±0.2°, 20.41±0.2°,  20.76±0.2°,  22.60±0.2°,  23.09±0.2°,  23.80±0.2°,  24.36±0.2°,  25.63±0.2°, 26.47±0.2°, 27.51±0.2°, 29.09±0.2°, 30.76±0.2°, 31.99±0.2°, 36.24±0.2°. In some embodiments of the present invention, the X-ray diffraction (XRPD) pattern of the hydrochloride crystal form C1 of the compound of Formula I-1 is shown in Figure 29. Table 17 XRPD analysis data for the hydrochloride crystal form C1 of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 7.469565 11.82564 170.3781 233.8982 0.3741632 0.165 Peak # 2 7.727614 11.43132 288.2178 351.6654 0.6329481 0.135 Peak # 3 9.625598 9.181119 30.23456 95.12409 0.06639738 0.154 Peak # 4 11.46039 7.715022 35.40674 99.13931 0.07775588 0.100 Peak # 5 12.25008 7.219398 187.329 254.1297 0.4113886 0.100 Peak # 6 13.18162 6.711229 176.609 244.8173 0.3878468 0.165 Peak # 7 13.50989 6.548882 101.0302 168.6256 0.22187 0.120 Peak # 8 14.96371 5.915727 130.4177 199.7892 0.2864071 0.106 Peak # 9 15.46443 5.725291 145.8036 215.9147 0.3201957 0.100 Peak #10 16.79406 5.27488 51.23669 120.018 0.1125197 0.134 Peak #11 17.03815 5.199857 68.14204 136.5628 0.1496451 0.220 Peak # 12 17.31437 5.117519 68.7573 136.3839 0.1509962 0.143 Peak# 13 17.72217 5.000671 20.89011 88.21156 0.04587625 0.100 Peak # 14 18.56032 4.776697 158.9897 234.8893 0.3491534 0.100 Peak # 15 19.33619 4.586743 193.7012 275.9999 0.4253825 0.106 Peak # 16 19.57052 4.532349 243.5362 327.1351 0.5348239 0.151 Peak # 17 19.78009 4.4848 455.3577 539.8668 1 0.100 Peak# 18 20.01093 4.433581 150.447 235.6875 0.330393 0.100 Peak #19 20.41269 4.347219 117.9435 203.7759 0.2590128 0.250 Peak # 20 20.7621 4.274841 143.6874 229.3326 0.3155484 0.146 Peak#21 22.59736 3.931636 57.59861 153.2617 0.1264909 0.179 Peak # 22 23.0917 3.848574 47.79654 145.3939 0.1049648 0.222 Peak # 23 23.80311 3.735136 47.23293 145.9101 0.1037271 0.250 Peak # 24 24.35631 3.65154 118.0796 215.7209 0.2593118 0.170 Peak # 25 25.63398 3.472358 54.12675 146.5311 0.1188664 0.100 Peak # 26 26.4743 3.364018 165.1317 261.6809 0.3626417 0.106 Peak # 27 27.51233 3.239408 144.2079 250.5756 0.3166913 0.122 Peak # 28 29.09444 3.066751 56.66905 168.875 0.1244495 0.150 Peak # 29 30.76101 2.904293 47.74388 156.956 0.1048492 0.218 Peak # 30 31.99164 2.795325 54.65399 155.6174 0.1200243 0.100 Peak # 31 36.23993 2.476788 45.47268 131.7606 0.09986144 0.111 In some embodiments of the present invention, the hydrochloride crystal form C1 of the compound of Formula I-1 has the onsets of the endothermic peaks at 39.76°C ± 2°C and 153.80°C ± 2°C in its differential scanning calorimetry (DSC) curve, and decomposition begins above 214.75°C ± 2°C. In some embodiments of the present invention, the DSC pattern of the hydrochloride crystal form C1 of the compound of Formula I-1 is shown in Figure 30. In some embodiments of the present invention, the hydrochloride crystal form C1 of the compound of Formula I-1 has three weight loss steps at 26.03°C ± 2°C, 100.00°C ± 2°C, and 150.00°C ± 2°C in its thermogravimetric analysis (TGA) curve. In some embodiments of the present invention, the TGA pattern of the hydrochloride crystal form C1 of the compound of Formula I-1 is shown in Figure 31. The present invention also provides a method for preparing the hydrochloride crystal form C1 of the compound of Formula I-1, comprising adding the compound of Formula I-1 and hydrochloric acid to ethyl acetate, and then performing recrystallization or slurrying to obtain it, wherein the ratio of the compound of Formula I-1 to hydrochloric acid is selected from 0.8 to 1.2, the hydrochloride crystal form C1 of the compound of Formula I-1 is an ethyl acetate solvate and hydrate crystal form, with an ethyl acetate content of 0.62 equivalents and a water content of 3.0 equivalents. The present invention also provides the hydrochloride crystal form C2 of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 9 angles: 7.56±0.2°, 7.79±0.2°, 12.32 ± 0.2°, 13.21 ± 0.2°, 13.63 ± 0.2°, 15.10 ± 0.2°, 15.56 ± 0.2°, 18.58 ± 0.2°, 19.36 ± 0.2°, 19.66±0.2°, 19.82±0.2°, 20.91±0.2°, 24.35±0.2°, 26.56±0.2°, 30.74±0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the hydrochloride crystal form C2 of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 9 angles: 7.56±0.2°, 7.79±0.2°, 9.65±0.2°, 11.48±0.2°, 12.32 ± 0.2°, 13.21 ± 0.2°, 13.63 ± 0.2°, 15.10 ± 0.2°, 15.56 ± 0.2°, 16.86±0.2°, 17.16±0.2°, 17.41±0.2°,  17.77±0.2°,  18.58±0.2°,  19.36±0.2°,  19.66±0.2°,  19.82±0.2°,  20.32±0.2°, 20.91±0.2°,  22.71±0.2°,  23.21±0.2°,  23.80±0.2°,  24.35±0.2°,  25.71±0.2°,  26.56±0.2°, 27.53±0.2°,  27.80±0.2°,  28.20±0.2°,  29.15±0.2°,  30.74±0.2°,  32.06±0.2°,  36.30±0.2°, 38.22±0.2°. In some embodiments of the present invention, the X-ray diffraction (XRPD) pattern of the hydrochloride crystal form C2 of the compound of Formula I-1 is shown in Figure 32. Table 18 XRPD analysis data for the hydrochloride crystal form C2 of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 7.561379 11.68225 594.0467 654.5096 0.4930706 0.153 Peak # 2 7.785987 11.34575 665.0544 725.5987 0.5520085 0.143 Peak # 3 9.653943 9.154226 64.07269 124.0171 0.05318161 0.100 Peak # 4 11.47599 7.704572 59.76658 119.5923 0.04960746 0.100 Peak # 5 12.32226 7.177275 486.3391 550.8688 0.4036712 0.100 Peak # 6 13.20849 6.697635 382.8189 452.7995 0.3177474 0.100 Peak # 7 13.63449 6.489313 383.4615 454.04 0.3182808 0.102 Peak # 8 15.10227 5.861764 417.983 490.954 0.3469343 0.110 Peak # 9 15.55625 5.691705 359.4082 431.791 0.298316 0.100 Peak # 10 16.8609 5.254121 157.987 227.7439 0.1311324 0.100 Peak # 11 17.16267 5.162411 180.6607 252.0321 0.149952 0.249 Peak # 12 17.41028 5.089545 224.9247 297.1292 0.186692 0.132 Peak # 13 17.77288 4.986517 60.75385 133.3784 0.0504269 0.100 Peak # 14 18.58392 4.770684 327.1711 410.2261 0.2715586 0.102 Peak # 15 19.35654 4.581967 330.6791 422.6897 0.2744703 0.152 Peak # 16 19.66373 4.511075 642.4008 736.7739 0.5332054 0.141 Peak # 17 19.82029 4.475794 1204.79 1300.107 1 0.141 Peak # 18 20.31755 4.36736 218.6828 315.8102 0.1815111 0.229 Peak # 19 20.91171 4.244595 405.4756 502.4253 0.3365528 0.110 Peak # 20 22.71078 3.912256 178.8163 287.4753 0.1484211 0.150 Peak # 21 23.21358 3.828644 150.452 262.2883 0.1248782 0.283 Peak # 22 23.79538 3.736332 153.2322 266.4649 0.1271858 0.169 Peak # 23 24.35296 3.652033 290.4572 402.7315 0.2410853 0.185 Peak # 24 25.71424 3.461702 106.9341 225.8246 0.08875742 0.149 Peak # 25 26.56012 3.353343 433.4701 562.3314 0.3597888 0.100 Peak # 26 27.52862 3.237527 341.6432 479.7618 0.2835706 0.127 Peak # 27 27.8036 3.206129 133.144 272.6549 0.1105122 0.236 Peak # 28 28.20096 3.161851 78.81534 219.3735 0.0654183 0.108 Peak #29 29.15277 3.060749 104.427 242.8467 0.08667652 0.174 Peak # 30 30.74315 2.90594 210.473 344.75 0.1746968 0.189 Peak# 31 32.06215 2.789339 87.68976 212.1315 0.07278425 0.163 Peak # 32 36.29795 2.472962 112.9378 222.361 0.0937406 0.138 Peak # 33 38.21926 2.352947 80.73588 192.5904 0.06701239 0.238 In some embodiments of the present invention, the hydrochloride crystal form C2 of the compound of Formula I-1 has the onsets of the endothermic peaks at 33.27°C ± 2°C and 155.72°C ± 2°C in its differential scanning calorimetry (DSC) curve, and decomposition of the sample begins above 212.45°C ± 2°C. In some embodiments of the present invention, the DSC pattern of the hydrochloride crystal form C2 of the compound of Formula I-1 is shown in Figure 33. In some embodiments of the present invention, the hydrochloride crystal form C2 of the compound of Formula I-1 has three weight loss steps at 28.19°C ± 2°C, 115.00°C ± 2°C, and 150.00°C ± 2°C in its thermogravimetric analysis (TGA) curve. In some embodiments of the present invention, the TGA pattern of the hydrochloride crystal form C2 of the compound of Formula I-1 is shown in Figure 34. The present invention also provides a method for preparing the hydrochloride crystal form C2 of the compound of Formula I-1, comprising adding the compound of Formula I-1 and hydrochloric acid to 2-methyl-tetrahydrofuran, and then performing recrystallization or slurrying to obtain it, wherein the ratio of the compound of Formula I-1 to hydrochloric acid is selected from 0.8 to 1.2, and the hydrochloride crystal form C2 of the compound of Formula I-1 is a 2-methyl tetrahydrofuran solvate and hydrate crystal form, with a 2-methyl tetrahydrofuran content of 0.21 equivalents and a water content of 2.8 equivalents. The present invention also provides the hydrochloride crystal form D of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 9 angles: 6.60±0.2°, 7.79±0.2°, 9.84±0.2°, 13.31 ± 0.2°, 15.23 ± 0.2°, 15.93 ± 0.2 °, 20.09 ± 0.2°, 20.41 ± 0.2°, 21.23 ± 0.2°, 21.80 ± 0.2 °. In some embodiments of the present invention, the X-ray powder diffraction pattern of the hydrochloride crystal form D of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 9 angles: 6.60±0.2°, 7.26±0.2°, 7.79±0.2°, 8.48±0.2°, 9.84±0.2°, 11.18±0.2°,  13.31±0.2°,  13.89±0.2°,  14.64±0.2°,  14.98±0.2°,  15.23±0.2°,  15.93±0.2°, 16.27±0.2°,  17.04±0.2°,  18.21±0.2°,  19.33±0.2°,  20.09±0.2°,  20.41±0.2°,  21.23±0.2°, 21.80±0.2°, 23.49±0.2°, 24.79±0.2°, 28.43±0.2°. In some embodiments of the present invention, the XRPD pattern of the hydrochloride crystal form D of the compound of Formula I-1 is shown in Figure 35. Table 19 XRPD analysis data for the hydrochloride crystal form D of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 6.601512 13.37856 164.5807 360.2378 0.1722114 0.100 Peak # 2 7.256653 12.17213 58.27498 262.8102 0.06097686 0.111 Peak # 3 7.786158 11.3455 216.3087 427.6613 0.2263378 0.100 Peak # 4 8.479876 10.41884 94.11929 310.7975 0.09848309 0.100 Peak # 5 9.837548 8.983783 292.5006 516.1531 0.3060622 0.100 Peak # 6 11.17929 7.90838 73.00758 297.2161 0.07639254 0.277 Peak # 7 13.30976 6.6469 222.7104 477.5637 0.2330362 0.166 Peak # 8 13.88618 6.372257 72.43765 337.7217 0.07579618 0.133 Peak # 9 14.63502 6.047843 144.9248 428.148 0.1516442 0.108 Peak # 10 14.98003 5.90932 217.5238 511.2758 0.2276092 0.380 Peak # 11 15.22908 5.813237 300.9823 601.7073 0.3149371 0.185 Peak # 12 15.92681 5.560104 334.7283 652.176 0.3502478 0.198 Peak # 13 16.26554 5.445069 139.724 463.7961 0.1462023 0.356 Peak # 14 17.03894 5.199618 77.78125 421.2977 0.08138753 0.183 Peak #15 18.21142 4.867415 117.7768 497.4332 0.1232375 0.100 Peak # 16 19.32967 4.588276 229.9395 646.4288 0.2406005 0.100 Peak # 17 20.08674 4.41702 708.8257 1144.215 0.74169 0.100 Peak # 18 20.40698 4.348422 955.69 1397.604 1 0.156 Peak # 19 21.2275 4.182158 313.6636 768.3183 0.3282064 0.236 Peak # 20 21.80498 4.072686 320.5857 780.7736 0.3354495 0.287 Peak #21 23.48703 3.784683 59.54105 519.681 0.06230164 0.125 Peak # 22 24.78517 3.589319 87.48044 546.9264 0.09153642 0.283 Peak # 23 28.43383 3.136483 65.95297 507.909 0.06901085 0.100 In some embodiments of the present invention, the hydrochloride crystal form D of the compound of Formula I-1 has the onsets of the endothermic peaks at 55.20°C ± 2°C and 164.37°C ± 2°C in its differential scanning calorimetry (DSC) curve, and decomposition of the sample begins above 211.35°C ± 2°C. In some embodiments of the present invention, the DSC pattern of the hydrochloride crystal form D of the compound of Formula I-1 is shown in Figure 36. In some embodiments of the present invention, the hydrochloride crystal form D of the compound of Formula I-1 has two weight loss steps at 36.24°C ± 2°C and 110.00°C ± 2°C in its thermogravimetric analysis (TGA) curve. In some embodiments of the present invention, the TGA pattern of the hydrochloride crystal form D of the compound of Formula I-1 is shown in Figure 37. The present invention also provides a method for preparing the hydrochloride crystal form D of the compound of Formula I-1, comprising adding the compound of Formula I-1 and hydrochloric acid to butanone, and then performing recrystallization or slurrying to obtain it, wherein the ratio of the compound of Formula I-1 to hydrochloric acid is selected from 0.8 to 1.2, and the hydrochloride crystal form D of the compound of Formula I-1 is an anhydrous crystal form. The present invention also provides the hydrochloride crystal form E1 of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 9 angles: 6.15±0.2°, 7.66 ± 0.2 °, 7.90 ± 0.2 °, 13.06 ± 0.2 °, 14.06 ± 0.2 °, 16.25 ± 0.2 °, 18.37 ± 0.2 °, 19.01 ± 0.2°, 19.75 ± 0.2 °, 20.19 ± 0.2 ° , 21.81 ± 0.2 ° , 23.56 ± 0.2 °, 24.95 ± 0.2 ° , 25.18 ± 0.2 °, 25.63 ± 0.2°, 26.71±0.2°, 27.10±0.2°, 27.91±0.2°, 29.81±0.2°, 32.93±0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the hydrochloride crystal form E1 of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 9 angles: 6. 15±0.2°, 7.66 ± 0.2°, 7.90 ± 0.2°, 8.41 ± 0.2°, 9.49 ± 0.2°, 9.91 ± 0.2°, 10.88 ± 0.2°, 11.42 ± 0.2°, 13.06±0.2°, 13.66±0.2°, 14.06±0.2°, 14.69±0.2°,  15.32±0.2°,  15.52±0.2°,  15.88±0.2°,  16.25±0.2°,  16.81±0.2°,  17.35±0.2°, 18.37±0.2°,  19.01±0.2°,  19.75±0.2°,  20.19±0.2°,  21.15±0.2°,  21.51±0.2°,  21.81±0.2°, 22.50±0.2°,  22.87±0.2°,  23.56±0.2°,  24.95±0.2°,  25.18±0.2°,  25.63±0.2°,  26.71±0.2°, 27.10±0.2°,  27.91±0.2°,  28.47±0.2°,  29.30±0.2°,  29.81±0.2°,  30.12±0.2°,  32.93±0.2°, 34.96±0.2°. In some embodiments of the present invention, the X-ray diffraction (XRPD) pattern of the hydrochloride crystal form E1 of the compound of Formula I-1 is shown in Figure 38. Table 20 XRPD analysis data for the hydrochloride crystal form E1 of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 6.145037 14.37131 302.5578 499.1663 0.2048961 0.100 Peak # 2 7.657481 11.53586 704.3558 925.7552 0.476999 0.166 Peak # 3 7.895144 11.18912 1359.082 1582.423 0.9203882 0.122 Peak #4 8.406717 10.50935 126.4409 351.9904 0.08562741 0.100 Peak # 5 9.487387 9.314556 269.7384 513.6247 0.1826704 0.100 Peak # 6 9.912072 8.916405 216.5638 468.4002 0.1466598 0.100 Peak # 7 10.87609 8.128153 501.5989 764.5867 0.3396893 0.100 Peak # 8 11.42041 7.741942 388.9748 654.0305 0.2634188 0.103 Peak # 9 13.0554 6.775825 780.8158 1077.419 0.5287787 0.100 Peak#10 13.66123 6.476674 386.5541 712.326 0.2617795 0.100 Peak # 11 14.05527 6.295974 1337.484 1680.198 0.9057618 0.166 Peak# 12 14.69153 6.024707 287.5207 654.2143 0.1947128 0.174 Peak# 13 15.32495 5.777086 541.0035 927.4278 0.3663747 0.141 Peak # 14 15.51518 5.706679 615.061 1006.604 0.4165273 0.127 Peak #15 15.88049 5.576216 593.2246 993.5515 0.4017395 0.100 Peak # 16 16.24859 5.45071 1265.391 1673.182 0.8569396 0.100 Peak # 17 16.80916 5.270176 302.3594 718.8266 0.2047618 0.124 Peak#18 17.3498 5.10715 190.8611 612.6349 0.1292536 0.104 Peak#19 18.37336 4.824878 1145.505 1605.355 0.7757506 0.100 Peak # 20 19.00938 4.664856 933.6566 1421.984 0.6322845 0.121 Peak#21 19.75294 4.490902 1276.167 1792.503 0.8642372 0.143 Peak # 22 20.1886 4.394964 1476.64 2006.738 1 0.108 Peak # 23 21.1496 4.197384 506.0891 1059.635 0.3427301 0.132 Peak # 24 21.51016 4.127835 703.582 1263.474 0.4764749 0.100 Peak # 25 21.80766 4.07219 1196.181 1760.296 0.8100696 0.205 Peak # 26 22.49543 3.949219 424.1585 994.5509 0.2872457 0.245 Peak # 27 22.87291 3.884891 627.939 1199.706 0.4252485 0.100 Peak # 28 23.56058 3.773034 1049.806 1620.304 0.7109421 0.109 Peak # 29 24.94623 3.566509 489.7659 1058.782 0.3316759 0.205 Peak # 30 25.18339 3.533457 337.6172 908.0272 0.2286388 0.210 Peak# 31 25.63268 3.472533 183.0638 754.5255 0.1239732 0.135 Peak # 32 26.70567 3.335397 778.4288 1371.446 0.5271622 0.163 Peak # 33 27.10295 3.2874 496.8693 1098.879 0.3364864 0.226 Peak # 34 27.90941 3.194215 564.1411 1179.394 0.3820437 0.137 Peak # 35 28.46869 3.132721 384.4941 1004.999 0.2603845 0.167 Peak# 36 29.30478 3.045216 189.4714 811.8213 0.1283125 0.284 Peak # 37 29.81338 2.994414 368.8845 988.831 0.2498134 0.244 Peak# 38 30.11576 2.965034 245.5084 862.7616 0.1662615 0.309 Peak# 39 32.93307 2.717536 268.7507 882.8731 0.1820015 0.168 Peak # 40 34.95511 2.564826 179.9061 751.8131 0.1218347 0.133 In some embodiments of the present invention, the hydrochloride crystal form E1 of the compound of Formula I-1 has the onsets of the endothermic peaks at 13.36°C ± 2°C and 174.06°C ± 2°C in its differential scanning calorimetry (DSC) curve, and decomposition of the sample begins at 211.29°C ± 2°C. In some embodiments of the present invention, the DSC pattern of the hydrochloride crystal form E1 of the compound of Formula I-1 is shown in Figure 39. In some embodiments of the present invention, the hydrochloride crystal form E1 of the compound of Formula I-1 has three weight loss steps at 25.81 °C ± 2°C, 120.00°C ± 2°C, and 160.00°C ± 2°C in its thermogravimetric analysis (TGA) curve. In some embodiments of the present invention, the TGA pattern of the hydrochloride crystal form E1 of the compound of Formula I-1 is shown in Figure 40. The present invention also provides a method for preparing the hydrochloride crystal form E1 of the compound of Formula I-1, comprising adding the compound of Formula I-1 and hydrochloric acid to ethanol, and then performing recrystallization or slurrying to obtain it, wherein the ratio of the compound of Formula I-1 to hydrochloric acid is selected from 0.8 to 1.2, and the hydrochloride crystal form E1 of the compound of Formula I-1 is a hydrate crystal form with a water content of 1.7 equivalents. The present invention also provides the hydrochloride crystal form E2 of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 9 angles: 7.88±0.2°, 10.90±0.2°, 13.10±0.2°, 14.14±0.2°, 16.30±0.2°, 19.01±0.2°,  19.75±0.2°,  21.54±0.2°,  21.84±0.2°,  23.63±0.2°,  24.96±0.2°,  26.78±0.2°, 29.91±0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the hydrochloride crystal form E2 of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 9 angles: 7.88±0.2°, 9.51±0.2°, 10.90±0.2°, 11.49 ± 0.2°, 13.10 ± 0.2°, 13.64 ± 0.2 ° , 14.14 ± 0.2°, 14.76 ± 0.2°, 15.39 ± 0.2°, 15.75 ± 0.2°, 16.30±0.2°, 16.93±0.2°,  19.01±0.2°,  19.75±0.2°,  20.69±0.2°,  21.54±0.2°,  21.84±0.2°,  22.19±0.2°, 22.57±0.2°,  23.01±0.2°,  23.63±0.2°,  24.96±0.2°,  25.90±0.2°,  26.32±0.2°,  26.78±0.2°, 27.19±0.2°,  27.48±0.2°,  27.94±0.2°,  28.68±0.2°,  29.07±0.2°,  29.50±0.2°,  29.91±0.2°, 31.74±0.2°, 32.96±0.2°, 33.66±0.2°. In some embodiments of the present invention, the X-ray diffraction (XRPD) pattern of the hydrochloride crystal form E2 of the compound of Formula I-1 is shown in Figure 41. Table 21 XRPD analysis data for the hydrochloride crystal form E2 of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 7.884071 11.20481 540.4462 605.2851 0.7774932 0.100 Peak # 2 9.512653 9.289872 103.279 168.8765 0.1485786 0.100 Peak # 3 10.89717 8.112479 210.551 276.9264 0.3029015 0.100 Peak # 4 11.48909 7.695814 43.11554 110.4364 0.0620266 0.100 Peak # 5 13.10177 6.75195 192.5077 264.6825 0.2769442 0.100 Peak # 6 13.63865 6.487342 77.58062 155.1348 0.1116085 0.100 Peak # 7 14.13521 6.260545 695.1138 775.9518 1 0.100 Peak # 8 14.76314 5.995642 28.98997 111.9226 0.04170537 0.133 Peak # 9 15.39103 5.752432 33.00134 117.8404 0.04747616 0.121 Peak# 10 15.74691 5.623217 62.01804 146.7878 0.08921998 0.100 Peak # 11 16.30386 5.432357 432.7301 515.7111 0.6225314 0.100 Peak # 12 16.92825 5.233366 61.63427 140.1845 0.08866789 0.100 Peak# 13 19.01114 4.664429 210.1703 287.2018 0.3023539 0.115 Peak# 14 19.75051 4.49145 445.9855 532.7929 0.6416007 0.109 Peak # 15 20.69488 4.288574 111.2609 205.316 0.1600614 0.100 Peak# 16 21.54478 4.12128 168.5169 267.2058 0.2424307 0.360 Peak # 17 21.84486 4.06534 251.1638 351.1669 0.3613276 0.271 Peak# 18 22.19098 4.002708 154.7814 255.5625 0.2226706 0.100 Peak# 19 22.57326 3.935779 98.63 199.3557 0.1418904 0.148 Peak # 20 23.01374 3.861435 105.6459 205.1103 0.1519836 0.100 Peak#21 23.62687 3.762597 325.2303 420.8155 0.4678806 0.106 Peak # 22 24.95749 3.564925 196.3293 294.1708 0.282442 0.100 Peak # 23 25.89573 3.437852 40.57758 148.8828 0.05837544 0.163 Peak # 24 26.32397 3.382887 50.33425 163.4267 0.07241153 0.100 Peak # 25 26.7799 3.326319 265.6382 383.6885 0.3821507 0.118 Peak # 26 27.19104 3.276951 182.0309 303.3774 0.261872 0.349 Peak # 27 27.47843 3.243327 83.98383 206.9736 0.1208203 0.100 Peak # 28 27.9352 3.191324 112.1196 236.6009 0.1612967 0.196 Peak # 29 28.68201 3.109905 100.0596 224.0822 0.1439471 0.191 Peak # 30 29.06967 3.069308 59.76442 182.13 0.0859779 0.187 Peak# 31 29.50209 3.025297 98.35264 217.703 0.1414914 0.100 Peak # 32 29.90704 2.98525 144.627 260.0349 0.2080623 0.120 Peak # 33 31.74403 2.816562 90.48898 199.877 0.1301787 0.130 Peak # 34 32.95559 2.71573 84.64176 195.0735 0.1217668 0.157 Peak # 35 33.65558 2.66083 72.07199 181.9605 0.1036837 0.165 In some embodiments of the present invention, the hydrochloride crystal form E2 of the compound of Formula I-1 has the onsets of the endothermic peaks at 14.99°C ± 2°C and 174.19°C ± 2°C in its differential scanning calorimetry (DSC) curve, and decomposition of the sample begins at 213.17°C ± 2°C. In some embodiments of the present invention, the DSC pattern of the hydrochloride crystal form E2 of the compound of Formula I-1 is shown in Figure 42. In some embodiments of the present invention, the hydrochloride crystal form E2 of the compound of Formula I-1 has three weight loss steps at 33.18°C ± 2°C, 90.00°C ± 2°C, and 140.00°C ± 2°C in its thermogravimetric analysis (TGA) curve. In some embodiments of the present invention, the TGA pattern of the hydrochloride crystal form E2 of the compound of Formula I-1 is shown in Figure 43. The present invention also provides a method for preparing the hydrochloride crystal form E2 of the compound of Formula I-1, comprising drying the hydrochloride crystal form F of the compound of Formula I-1 under vacuum at 25°C, 50°C, or 100°C, wherein the ratio of the compound of Formula I-1 to hydrochloric acid is selected from 0.8 to 1.2, and the hydrochloride crystal form E2 of the compound of Formula I-1 is a hydrate crystal form with a water content of 1.8 equivalents. The present invention also provides the hydrochloride crystal form F of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 0 angles: 7.65 ± 0.2°, 11.47 ± 0.2 °, 13.93 ± 0.2°, 14.80 ± 0.2°, 15.25 ± 0.2 °, 19.84 ± 0.2 °, 20.09 ± 0.2°, 21.51 ± 0.2 °, 23.22 ± 0.2 °, 25.06 ± 0.2 °, 26.68 ± 0.2 ° , 28.87 ± 0.2 °, 32.45 ± 0.2°, 33.59 ± 0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the hydrochloride crystal form F of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 0 angles: 6.85±0.2°, 7.65±0.2°, 10.21±0.2°, 10.70±0.2°, 11.47±0.2°, 13.93±0.2°,  14.80±0.2°,  15.25±0.2°,  16.60±0.2°,  16.88±0.2°,  17.84±0.2°,  19.00±0.2°, 19.16±0.2°,  19.84±0.2°,  20.09±0.2°,  20.34±0.2°,  21.51±0.2°,  22.35±0.2°,  23.22±0.2°, 23.86±0.2°,  25.06±0.2°,  25.31±0.2°,  25.63±0.2°,  26.68±0.2°,  28.10±0.2°,  28.87±0.2°, 30.53±0.2°, 32.45±0.2°, 33.59±0.2°. In some embodiments of the present invention, the X-ray powder diffraction (XRPD) pattern of the hydrochloride crystal form F of the compound of Formula I-1 is shown in Figure 44. Table 22 XRPD analysis data for the hydrochloride crystal form F of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 6.848274 12.89704 50.41388 108.1367 0.09768955 0.100 Peak # 2 7.651177 11.54535 516.0621 576.032 1 0.100 Peak # 3 10.20579 8.660445 49.75304 111.4053 0.096409 0.100 Peak # 4 10.70466 8.257937 69.10229 130.8267 0.133903 0.100 Peak #5 11.47234 7.707018 361.2969 420.3412 0.7001035 0.100 Peak # 6 13.93093 6.351884 397.6063 461.8362 0.7704621 0.100 Peak # 7 14.80051 5.98059 260.9636 327.9683 0.5056826 0.100 Peak # 8 15.25096 5.804945 153.9308 220.6624 0.2982796 0.108 Peak # 9 16.60372 5.334918 34.92417 97.03252 0.06767435 0.155 Peak #10 16.88418 5.246928 60.09497 120.1826 0.1164491 0.183 Peak #11 17.83583 4.969059 73.02078 128.1677 0.1414961 0.100 Peak#12 19.00091 4.666917 115.9687 180.328 0.2247185 0.128 Peak # 13 19.16145 4.628178 78.67841 145.1145 0.1524592 0.128 Peak # 14 19.83859 4.471706 220.5375 294.1044 0.4273469 0.172 Peak # 15 20.08921 4.416483 227.1443 302.6826 0.440149 0.184 Peak # 16 20.34485 4.361562 44.52192 121.6991 0.0862724 0.197 Peak # 17 21.51468 4.126979 342.1507 422.0398 0.6630028 0.116 Peak # 18 22.35365 3.973946 135.1561 215.3622 0.2618989 0.110 Peak # 19 23.22226 3.827231 214.9216 298.199 0.4164645 0.154 Peak # 20 23.85788 3.726686 87.52694 170.3065 0.1696054 0.210 Peak # 21 25.06488 3.549895 214.0289 298.1458 0.4147348 0.168 Peak # 22 25.30611 3.516599 90.23993 175.521 0.1748625 0.178 Peak # 23 25.63199 3.472623 125.4472 211.7709 0.2430855 0.106 Peak # 24 26.68101 3.338423 102.6051 191.2798 0.1988232 0.141 Peak # 25 28.09525 3.173506 86.42886 182.8679 0.1674776 0.175 Peak # 26 28.86665 3.090432 110.8668 209.6979 0.2148323 0.144 Peak # 27 30.53301 2.925459 35.61448 133.7473 0.069012 0.100 Peak # 28 32.44866 2.756991 82.21487 181.7001 0.159312 0.123 Peak # 29 33.58943 2.665919 45.26086 135.2353 0.08770428 0.196 In some embodiments of the present invention, the hydrochloride crystal form F of the compound of Formula I-1 has the onsets of the endothermic peaks at 36.03°C ± 2°C and 172.45°C ± 2°C in its differential scanning calorimetry (DSC) curve, and decomposition of the sample begins at 212.66°C ± 2°C. In some embodiments of the present invention, the DSC pattern of the hydrochloride crystal form F of the compound of Formula I-1 is shown in Figure 45. In some embodiments of the present invention, the hydrochloride crystal form F of the compound of Formula I-1 has three weight loss steps at 33.35°C ± 2°C, 100.00°C ± 2°C, and 150.00°C ± 2°C in its thermogravimetric analysis (TGA) curve. In some embodiments of the present invention, the TGA pattern of the hydrochloride crystal form F of the compound of Formula I-1 is shown in Figure 46. The present invention also provides a method for preparing the hydrochloride crystal form F of the compound of Formula I-1, comprising adding the compound of Formula I-1 and hydrochloric acid to ethanol, acetone, ethyl acetate, acetonitrile, tetrahydrofuran, or a mixed solvent of methyl isobutyl ketone / trifluoroethanol, and then performing recrystallization at 50°C or slurrying to obtain it, the ratio of the compound of Formula I-1 to hydrochloric acid is selected from 0.8 to 1.2, the hydrochloride crystal form F of the compound of Formula I-1 is a hydrate crystal form with a water content of 2.0 equivalents. The present invention also provides the hydrochloride crystal form G of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 0 angles: 5.83±0.2°, 9.97±0.2°, 13.26±0.2°, 14.17±0.2°, 15.52±0.2°, 16.77±0.2°,  18.37±0.2°,  20.27±0.2°,  20.48±0.2°,  21.35±0.2°,  21.82±0.2°,  22.65±0.2°, 23.04±0.2°, 24.43±0.2°, 26.24±0.2°, 26.54±0.2°, 28.94±0.2°, 30.18±0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the hydrochloride crystal form G of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 0 angles: 5.83±0.2°, 7.18±0.2°, 9.97±0.2°, 11.63±0.2°, 12.00±0.2°, 12.35±0.2°, 13.26±0.2°, 13.58±0.2°, 14.17±0.2°, 14.60±0.2°, 15.52±0.2°, 16.77±0.2°, 17.64±0.2°, 18.37±0.2°, 18.81±0.2°, 19.14±0.2°, 19.80±0.2°, 20.27±0.2°, 20.48±0.2°, 21.35±0.2°, 21.82±0.2°, 22.65±0.2°, 23.04±0.2°, 23.35±0.2°, 24.43±0.2°, 25.47±0.2°, 26.24±0.2°, 26.54±0.2°, 26.84±0.2°, 27.92±0.2°, 28.94±0.2°, 29.31±0.2°, 30.18±0.2°. 5       In some embodiments of the present invention, the X-ray powder diffraction (XRPD) pattern of the hydrochloride crystal form G of the compound of Formula I-1 is shown in Figure 47. Table 23 XRPD analysis data for the hydrochloride crystal form G of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 5.828182 15.15189 579.1664 753.4305 0.6023378 0.100 Peak # 2 7.17844 12.30457 172.8027 365.0822 0.1797163 0.100 Peak # 3 9.974504 8.860736 346.1045 556.5733 0.3599515 0.100 Peak # 4 11.62806 7.604156 506.9125 722.6564 0.5271932 0.100 Peak # 5 11.99626 7.371572 122.0042 338.9887 0.1268854 0.100 Peak # 6 12.34862 7.162008 128.8925 346.0245 0.1340493 0.171 Peak # 7 13.25774 6.672863 324.0526 556.4399 0.3370174 0.153 Peak # 8 13.58265 6.513966 171.4265 412.3184 0.178285 0.100 Peak # 9 14.16958 6.245436 598.4322 852.499 0.6223745 0.111 Peak # 10 14.59519 6.064257 283.763 545.6206 0.2951159 0.100 Peak # 11 15.51762 5.705785 961.5308 1251.04 1 0.100 Peak # 12 16.7697 5.282487 931.9397 1272.279 0.969225 0.205 Peak # 13 17.63585 5.024953 178.8619 547.5662 0.1860179 0.140 Peak # 14 18.37159 4.825339 771.5197 1159.492 0.8023869 0.116 Peak # 15 18.80623 4.714787 372.962 770.2344 0.3878836 0.100 Peak # 16 19.1386 4.633651 288.6279 691.9684 0.3001754 0.100 Peak # 17 19.80226 4.479828 214.2406 626.9946 0.222812 0.100 Peak # 18 20.26602 4.378349 301.9755 719.1638 0.314057 0.247 Peak # 19 20.48124 4.332824 436.0151 854.6628 0.4534594 0.221 Peak # 20 21.35452 4.157567 768.4391 1191.466 0.7991831 0.193 Peak # 21 21.8184 4.07021 387.7249 811.9121 0.4032371 0.121 Peak # 22 22.64517 3.923443 357.5557 779.4445 0.371861 0.137 Peak # 23 23.04393 3.856443 885.9234 1304.702 0.9213678 0.100 Peak # 24 23.34855 3.806815 376.3249 791.8521 0.391381 0.259 Peak # 25 24.42592 3.641291 722.9464 1152.347 0.7518703 0.191 Peak # 26 25.47185 3.494093 192.4108 637.1698 0.2001088 0.250 Peak # 27 26.2382 3.393751 388.4084 838.7321 0.4039479 0.112 Peak # 28 26.53974 3.355873 427.7524 878.9491 0.444866 0.256 Peak #29 26.83974 3.319039 219.5827 670.9071 0.2283678 0.233 Peak # 30 27.92213 3.192788 126.4753 572.1395 0.1315354 0.191 Peak # 31 28.94164 3.082595 395.4236 826.9805 0.4112438 0.119 Peak # 32 29.31307 3.044374 215.0207 639.3233 0.2236233 0.100 Peak # 33 30.18123 2.958751 262.0633 665.0064 0.272548 0.174 In some embodiments of the present invention, the hydrochloride crystal form G of the compound of Formula I-1 has the onsets of the endothermic peaks at 59.42°C ± 2°C, 151.02°C ± 2°C, and 166.01°C ± 2°C in its differential scanning calorimetry (DSC) curve. In some embodiments of the present invention, the DSC pattern of the hydrochloride crystal form G of the compound of Formula I-1 is shown in Figure 48. In some embodiments of the present invention, the hydrochloride crystal form G of the compound of Formula I-1 has three weight loss steps at 26.28°C ± 2°C, 120.00°C ± 2°C, and 150.00°C ± 2°C in its thermogravimetric analysis (TGA) curve. In some embodiments of the present invention, the TGA pattern of the hydrochloride crystal form G of the compound of Formula I-1 is shown in Figure 49. The present invention also provides a method for preparing the hydrochloride crystal form G of the compound of Formula I-1, comprising adding the compound of Formula I-1 and hydrochloric acid to water, and then performing suspension recrystallization at 25°C, 50°C, or under heating-cooling cycles or slurrying to obtain it, wherein the ratio of the compound of Formula I-1 to hydrochloric acid is selected from 0.8 to 1.2, the hydrochloride crystal form G of the compound of Formula I-1 is a hydrate crystal form with a water content of 3.0 equivalents. The present invention also provides the hydrochloride crystal form H of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 0 angles: 5.83±0.2°, 7.16±0.2°, 10.02±0.2°, 11.64±0.2°, 13.23 ± 0.2 °, 14.58 ± 0.2°, 16.67 ± 0.2°, 18.40 ± 0.2°, 18.62 ± 0.2°, 20.23 ± 0.2°, 20.54 ± 0.2°, 21.40±0.2°, 22.62±0.2°,  22.78±0.2°,  23.36±0.2°,  24.73±0.2°,  26.23±0.2°,  26.57±0.2°,  26.91±0.2°, 29.30±0.2°, 30.21±0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the hydrochloride crystal form H of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 0 angles: 5.83±0.2°, 7.16±0.2°, 10.02±0.2°, 11.64±0.2°, 12.35 ± 0.2°, 13.23 ± 0.2°, 13.59 ± 0.2°, 14.58 ± 0.2°, 15.51 ± 0.2°, 15.97 ± 0.2°, 16.67±0.2°, 17.63±0.2°, 18.40±0.2°,  18.62±0.2°,  19.11±0.2°,  20.23±0.2°,  20.54±0.2°,  21.40±0.2°,  22.07±0.2°, 22.62±0.2°,  22.78±0.2°,  23.36±0.2°,  24.73±0.2°,  24.98±0.2°,  26.23±0.2°,  26.57±0.2°, 26.91±0.2°,  27.88±0.2°,  29.01±0.2°,  29.30±0.2°,  29.61±0.2°,  30.21±0.2°,  31.21±0.2°, 32.12±0.2°, 34.66±0.2°. In some embodiments of the present invention, the X-ray powder diffraction (XRPD) pattern of the hydrochloride crystal form H of the compound of Formula I-1 is shown in Figure 50. Table 24 XRPD analysis data for the hydrochloride crystal form H of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 5.830629 15.14553 1285.098 1470.157 1 0.100 Peak # 2 7.162398 12.3321 377.9528 573.1634 0.2941044 0.100 Peak # 3 10.01798 8.822379 706.8278 901.1703 0.5500187 0.100 Peak # 4 11.6369 7.598398 793.7754 997.5475 0.6176772 0.100 Peak #5 12.34503 7.164086 105.4623 314.7852 0.0820656 0.100 Peak # 6 13.23145 6.686064 823.9066 1041.888 0.6411238 0.100 Peak # 7 13.59459 6.508269 401.2484 621.5343 0.3122319 0.100 Peak # 8 14.57996 6.070556 742.7775 974.6781 0.5779932 0.100 Peak # 9 15.50704 5.709655 380.8936 631.5181 0.2963928 0.100 Peak# 10 15.97407 5.543761 171.5876 429.1406 0.133521 0.155 Peak # 11 16.6685 5.31433 1043.568 1307.615 0.8120532 0.105 Peak #12 17.62552 5.027874 219.7633 491.7105 0.171009 0.216 Peak#13 18.40211 4.817406 1027.482 1307.842 0.7995363 0.141 Peak #14 18.61999 4.761522 548.1824 829.8808 0.4265687 0.141 Peak #15 19.11054 4.640391 363.7106 646.7841 0.2830218 0.183 Peak#16 20.23249 4.385529 650.7493 943.71 0.5063812 0.111 Peak#17 20.54409 4.31971 816.0809 1113.529 0.6350342 0.201 Peak#18 21.40318 4.148226 761.1138 1066.179 0.5922615 0.170 Peak#19 22.07037 4.024309 60.53448 366.7205 0.04710497 0.100 Peak # 20 22.62083 3.927608 474.4857 778.4302 0.3692215 0.202 Peak#21 22.77518 3.90134 428.924 731.7242 0.3337676 0.202 Peak # 22 23.35825 3.805256 580.0465 876.5105 0.4513638 0.100 Peak # 23 24.73165 3.596966 435.214 762.8337 0.3386622 0.164 Peak # 24 24.97894 3.561912 239.3857 574.4449 0.1862782 0.170 Peak # 25 26.23346 3.394353 689.8587 1053.781 0.5368143 0.200 Peak # 26 26.56802 3.352364 373.9151 743.0274 0.2909624 0.141 Peak # 27 26.91138 3.310365 474.4957 847.8385 0.3692293 0.233 Peak # 28 27.87534 3.198041 319.8667 699.1384 0.2489046 0.100 Peak #29 29.00736 3.075759 319.4596 694.5037 0.2485878 0.100 Peak # 30 29.30335 3.045362 580.9927 952.9413 0.4521 0.139 Peak# 31 29.61104 3.014414 311.5282 679.3771 0.242416 0.100 Peak # 32 30.20776 2.956213 486.7111 844.0698 0.3787347 0.169 Peak # 33 31.21426 2.863146 132.2233 464.1539 0.1028897 0.149 Peak # 34 32.11699 2.784701 156.8051 469.2422 0.122018 0.137 Peak # 35 34.65822 2.586115 156.4141 451.3805 0.1217138 0.157 In some embodiments of the present invention, the hydrochloride crystal form H of the compound of Formula I-1 has the onsets of the endothermic peaks at 51.49°C ± 2°C and 153.61°C ± 2°C in its differential scanning calorimetry (DSC) curve, and decomposition of the sample begins at 211.73°C ± 2°C. In some embodiments of the present invention, the DSC pattern of the hydrochloride crystal form H of the compound of Formula I-1 is shown in Figure 51. In some embodiments of the present invention, the hydrochloride crystal form H of the compound of Formula I-1 has three weight loss steps at 26.12°C ± 2°C, 110.00°C ± 2°C, and 150.00°C ± 2°C in its thermogravimetric analysis (TGA) curve. In some embodiments of the present invention, the TGA pattern of the hydrochloride crystal form H of the compound of Formula I-1 is shown in Figure 52. The present invention also provides a method for preparing the hydrochloride crystal form H of the compound of Formula I-1, comprising adding the compound of Formula I-1 and hydrochloric acid to a methanol / water mixed solvent, and then performing suspension recrystallization at 25°C or 50°C or slurrying to obtain it, wherein the ratio of the compound of Formula I-1 to hydrochloric acid is selected from 0.8 to 1.2, the hydrochloride crystal form H of the compound of Formula I-1 is a hydrate crystal form, with a water content of 3.9 equivalents. The present invention also provides the hydrochloride crystal form I of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 9 angles: 6.68±0.2°, 12.31±0.2°, 12.54 ± 0.2°, 13.34 ± 0.2°, 14.05 ± 0.2°, 14.96 ± 0.2°, 17.92 ± 0.2 °, 19.03 ± 0.2°, 19.74 ± 0.2°, 19.99 ± 0.2°, 20.96 ± 0.2°, 21.42 ± 0.2°, 21.62 ± 0.2°, 26.81±0.2°, 27.21±0.2°, 27.60±0.2°, 27.78±0.2°, 30.07±0.2°, 31.00±0.2°, 34.83±0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the hydrochloride crystal form I of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 9 angles: 6.68±0.2°, 9.50±0.2°, 12.31±0.2°, 12.54 ± 0.2°, 13.34 ± 0.2°, 14.05 ± 0.2°, 14.96 ± 0.2°, 15.38 ± 0.2°, 17.18 ± 0.2°, 17.92±0.2°, 19.03±0.2°, 19.74±0.2°, 19.99±0.2°,  20.96±0.2°,  21.42±0.2°,  21.62±0.2°,  21.99±0.2°,  22.98±0.2°,  23.52±0.2°, 23.80±0.2°,  24.38±0.2°,  25.92±0.2°,  26.81±0.2°,  27.21±0.2°,  27.60±0.2°,  27.78±0.2°, 28.26±0.2°, 28.74±0.2°, 30.07±0.2°, 31.00±0.2°, 32.69±0.2°, 34.02±0.2°, 34.83±0.2°. In some embodiments of the present invention, the X-ray diffraction (XRPD) pattern of the hydrochloride crystal form I of the compound of Formula I-1 is shown in Figure 53. Table 25 XRPD analysis data for the hydrochloride crystal form I of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 6.683047 13.21552 6066.766 6257.472 1 0.100 Peak # 2 9.502496 9.29978 589.4446 779.7198 0.09715961 0.100 Peak # 3 12.30501 7.187298 1473.677 1683.435 0.2429098 0.123 Peak # 4 12.54249 7.05174 1045.291 1257.185 0.1722979 0.127 Peak # 5 13.34207 6.630879 3563.501 3783.915 0.5873806 0.100 Peak # 6 14.04679 6.299753 1592.864 1818.627 0.2625557 0.100 Peak # 7 14.95737 5.918223 1689.783 1912.131 0.2785311 0.100 Peak # 8 15.37841 5.757124 366.1042 582.8315 0.06034585 0.100 Peak # 9 17.17957 5.157372 679.5376 900.721 0.1120099 0.100 Peak #10 17.91742 4.946615 2463.704 2704.65 0.4060984 0.100 Peak #11 19.02736 4.66049 1726.037 1982.815 0.2845069 0.100 Peak #12 19.74237 4.493283 1203.647 1471.858 0.1984002 0.192 Peak#13 19.98544 4.43918 1433.109 1702.924 0.2362228 0.173 Peak#14 20.96464 4.233996 1457.9 1735.907 0.2403092 0.100 Peak #15 21.42234 4.144559 5250.236 5529.593 0.8654093 0.100 Peak#16 21.61991 4.107128 1554.836 1833.5 0.2562874 0.100 Peak#17 21.98783 4.039227 591.0263 866.3695 0.09742032 0.100 Peak #18 22.98335 3.866472 515.3694 786.2349 0.0849496 0.100 Peak# 19 23.52402 3.778814 255.2394 529.0739 0.04207174 0.166 Peak # 20 23.80309 3.735139 274.9154 548.0394 0.04531498 0.232 Peak # 21 24.38212 3.647733 666.5188 933.2823 0.1098639 0.116 Peak # 22 25.92394 3.434175 635.7052 928.6979 0.1047848 0.117 Peak # 23 26.81065 3.322574 1095.841 1412.559 0.1806302 0.100 Peak # 24 27.2072 3.275041 877.7557 1200.082 0.1446826 0.117 Peak # 25 27.60325 3.228944 689.9982 1014.847 0.1137341 0.134 Peak # 26 27.77863 3.208954 1194.642 1519.628 0.1969159 0.134 Peak # 27 28.25596 3.155821 372.9469 695.2362 0.06147375 0.100 Peak # 28 28.7368 3.1041 304.8406 620.1004 0.05024763 0.100 Peak #29 30.06931 2.969508 807.1132 1116.959 0.1330384 0.171 Peak # 30 30.99668 2.882746 682.3029 984.0446 0.1124657 0.100 Peak # 31 32.68733 2.737403 496.4317 815.9324 0.08182806 0.100 Peak # 32 34.01857 2.633264 468.1613 783.8876 0.07716818 0.178 Peak # 33 34.83157 2.57364 645.0126 947.0595 0.106319 0.108 In some embodiments of the present invention, the hydrochloride crystal form I of the compound of Formula I-1 has the onsets of the endothermic peaks at 18.15°C ± 2°C and 194.49°C ± 2°C in its differential scanning calorimetry (DSC) curve, and decomposition of the sample begins at 215.51°C ± 2°C 5       In some embodiments of the present invention, the DSC pattern of the hydrochloride crystal form I of the compound of Formula I-1 is shown in Figure 54. In some embodiments of the present invention, the hydrochloride crystal form I of the compound of Formula I-1 has three weight loss steps at 28.31 °C ± 2°C, 70.00°C ± 2°C, and 173.00°C ± 2°C in its thermogravimetric analysis (TGA) curve. 10       In some embodiments of the present invention, the TGA pattern of the hydrochloride crystal form I of the compound of Formula I-1 is shown in Figure 55. The present invention also provides a method for preparing the hydrochloride crystal form I of the compound of Formula I-1, comprising adding the compound of Formula I-1 and hydrochloric acid to methanol or a methanol / tert-butyl methyl ether mixed solvent, and then 15 performing suspension recrystallization in a tert-butyl methyl ether or slurrying to obtain it, the ratio of the compound of Formula I-1 to hydrochloric acid is selected from 0.8 to 1.2, and the hydrochloride crystal form I of the compound of Formula I-1 is an anhydrous crystal form. The present invention also provides the hydrochloride crystal form J1 of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 0 angles: 6.80 ± 0.2°, 11.69 ± 0.2°, 14.87 ± 0.2°, 15.98 ± 0.2°, 18.05±0.2°, 19.49±0.2°,  20.41±0.2°,  21.55±0.2°,  21.70±0.2°,  22.06±0.2°,  23.69±0.2°,  24.92±0.2°, 25.13±0.2°, 29.07±0.2°, 30.16±0.2°. 5        In some embodiments of the present invention, the X-ray powder diffraction pattern of the hydrochloride crystal form J1 of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 0 angles: 6.80±0.2°, 7.82±0.2°, 7.95±0.2°, 10.08±0.2°, 11.69 ± 0.2°, 12.30 ± 0.2°, 12.60 ± 0.2°, 13.60 ± 0.2°, 14.87 ± 0.2°, 15.98 ± 0.2°, 16.25 ± 0.2°, 18.05±0.2°,  18.60±0.2°,  18.79±0.2°,  19.49±0.2°,  20.41±0.2°,  20.82±0.2°,  21.55±0.2°, 10   21.70±0.2°,  22.06±0.2°,  22.88±0.2°, 23.69±0.2°,  24.92±0.2°,  25.13±0.2°, 26.19±0.2°, 26.57±0.2°, 29.07±0.2°, 30.16±0.2°, 31.85±0.2°, 32.80±0.2°. In some embodiments of the present invention, the X-ray diffraction (XRPD) pattern of the hydrochloride crystal form J1 of the compound of Formula I-1 is shown in Figure 56. Table 26 XRPD analysis data for the hydrochloride crystal form J1 of the compound of 15                                        Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 6.795494 12.99709 1045.542 1237.377 0.3823281 0.100 Peak # 2 7.822898 11.2923 230.3243 429.0735 0.0842237 0.101 Peak # 3 7.947547 11.11546 173.3303 372.1519 0.06338246 0.101 Peak # 4 10.08289 8.765732 113.045 325.6056 0.04133766 0.100 Peak # 5 11.69263 7.562305 581.4788 792.2735 0.212632 0.100 Peak # 6 12.29569 7.192721 271.5138 485.7134 0.09928567 0.160 Peak # 7 12.5974 7.021128 160.1172 374.2798 0.05855079 0.186 Peak # 8 13.6026 6.504458 195.112 411.141 0.07134749 0.100 Peak # 9 14.87382 5.951278 2734.673 2980.22 1 0.100 Peak #10 15.97916 5.542004 742.0891 1013.763 0.271363 0.100 Peak #11 16.25086 5.449955 156.1842 432.9994 0.05711259 0.129 Peak#12 18.05202 4.910034 797.7896 1127.659 0.2917313 0.100 Peak#13 18.59785 4.767141 489.3123 835.8884 0.178929 0.213 Peak #14 18.7898 4.718873 408.4137 759.966 0.1493465 0.213 Peak #15 19.4894 4.55103 554.901 920.6138 0.2029131 0.100 Peak#16 20.41075 4.347628 1084.362 1459.224 0.3965236 0.100 Peak#17 20.81767 4.263556 308.0087 683.4725 0.1126309 0.100 Peak # 18 21.55439 4.119464 785.2869 1156.483 0.2871594 0.270 Peak # 19 21.69789 4.092543 917.0377 1286.597 0.3353373 0.270 Peak # 20 22.05619 4.026863 513.4854 877.8127 0.1877685 0.100 Peak #21 22.87765 3.884097 242.5795 597.0117 0.08870515 0.100 Peak # 22 23.6933 3.752199 965.4345 1321.158 0.3530348 0.100 Peak # 23 24.92196 3.569928 433.7296 789.9819 0.1586039 0.223 Peak # 24 25.13496 3.540156 587.4705 941.8578 0.214823 0.149 Peak # 25 26.18639 3.400348 228.3669 583.2324 0.08350793 0.100 Peak # 26 26.56552 3.352674 207.2965 567.4351 0.07580306 0.127 Peak # 27 29.07455 3.068804 275.8094 631.2031 0.1008565 0.100 Peak # 28 30.16433 2.96037 409.7868 740.9128 0.1498486 0.100 Peak #29 31.851 2.807346 160.3939 484.1836 0.05865197 0.206 Peak # 30 32.79772 2.728441 190.6454 520.0348 0.06971417 0.182 In some embodiments of the present invention, the hydrochloride crystal form J1 of the compound of Formula I-1 has the onsets of the endothermic peaks at 70.82°C ± 2°C and 165.48°C ± 2°C in its differential scanning calorimetry (DSC) curve, and decomposition of the sample begins at 212.96°C ± 2°C. In some embodiments of the present invention, the DSC pattern of the hydrochloride crystal form J1 of the compound of Formula I-1 is shown in Figure 57. In some embodiments of the present invention, the hydrochloride crystal form J1 of the compound of Formula I-1 has two weight loss steps at 33.94°C ± 2°C and 110.00°C ± 2°C in its thermogravimetric analysis (TGA) curve. In some embodiments of the present invention, the TGA pattern of the hydrochloride crystal form J1 of the compound of Formula I-1 is shown in Figure 58. The present invention also provides a method for preparing the hydrochloride crystal form J1 of the compound of Formula I-1, comprising adding the compound of Formula I-1 and hydrochloric acid to 2-methyl-tetrahydrofuran, and then performing suspension recrystallization at 50°C or under heating-cooling cycles or slurrying to obtain it, the ratio of the compound of Formula I-1 to hydrochloric acid is selected from 0.8 to 1.2, the hydrochloride crystal form J1 of the compound of Formula I-1 is a solvate of 2-methyl tetrahydrofuran and water, with a 2-methyl tetrahydrofuran content of 0.75 equivalents and a water content of 0.98 equivalents. The present invention also provides the hydrochloride crystal form J2 of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 9 angles: 6.78±0.2°, 11.59±0.2°, 12.24 ± 0.2°, 13.56 ± 0.2°, 14.69 ± 0.2°, 17.45 ± 0.2°, 18.12 ± 0.2°, 18.89 ± 0.2°, 19.51 ± 0.2°, 21.28±0.2°, 21.46±0.2°, 22.23±0.2°, 24.09±0.2°, 24.86±0.2°, 24.99±0.2°, 29.00±0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the hydrochloride crystal form J2 of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 9 angles: 6.78±0.2°, 7.96±0.2°, 8.31±0.2°, 11.59±0.2°, 12.24 ± 0.2°, 13.56 ± 0.2°, 14.69 ± 0.2 °, 16.44 ± 0.2°, 16.63 ± 0.2°, 17.45 ± 0.2°, 18.12 ± 0.2°, 18.89±0.2°,  19.51±0.2°,  20.12±0.2°,  20.35±0.2°,  20.49±0.2°,  21.28±0.2°,  21.46±0.2°, 22.23±0.2°,  22.75±0.2°,  23.27±0.2°,  24.09±0.2°,  24.86±0.2°,  24.99±0.2°,  25.37±0.2°, 25.65±0.2°,  26.54±0.2°,  27.62±0.2°,  28.61±0.2°,  29.00±0.2°,  30.43±0.2°,  32.10±0.2°, 33.01±0.2°, 36.96±0.2°. In some embodiments of the present invention, the X-ray diffraction (XRPD) pattern of the hydrochloride crystal form J2 of the compound of Formula I-1 is shown in Figure 59. Table 27 XRPD analysis data for the hydrochloride crystal form J2 of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 6.780673 13.02546 486.214 549.5581 0.2816536 0.100 Peak # 2 7.958976 11.09953 123.6075 188.0724 0.07160323 0.161 Peak # 3 8.310797 10.63043 73.68546 139.4296 0.04268445 0.107 Peak # 4 11.59174 7.627896 375.3433 450.2339 0.2174286 0.100 Peak # 5 12.23828 7.226334 153.1708 226.7464 0.08872864 0.100 Peak # 6 13.55637 6.526536 180.8496 254.4021 0.1047624 0.100 Peak # 7 14.68543 6.027195 1726.283 1805.761 1 0.100 Peak # 8 16.4355 5.389143 215.2298 299.1415 0.1246781 0.184 Peak # 9 16.62825 5.327103 129.1316 213.7627 0.07480326 0.184 Peak # 10 17.44625 5.079131 220.9248 310.6566 0.1279771 0.103 Peak # 11 18.1169 4.892595 133.8183 226.216 0.07751816 0.100 Peak# 12 18.88617 4.695011 516.7839 612.7637 0.2993622 0.100 Peak # 13 19.5106 4.546134 397.7841 496.3569 0.2304281 0.100 Peak # 14 20.11981 4.409835 184.1742 286.9377 0.1066883 0.320 Peak # 15 20.34798 4.360898 241.6843 346.9122 0.1400027 0.238 Peak# 16 20.48667 4.331687 265.6085 372.0766 0.1538615 0.238 Peak# 17 21.28307 4.171363 432.1003 541.9163 0.2503067 0.121 Peak# 18 21.45671 4.137996 276.4566 386.148 0.1601456 0.121 Peak# 19 22.22805 3.996116 497.313 614.4642 0.2880831 0.100 Peak # 20 22.75281 3.905124 142.7566 265.5026 0.08269595 0.156 Peak#21 23.27106 3.819316 113.8295 241.2689 0.06593904 0.171 Peak # 22 24.09327 3.690806 385.4814 518.8451 0.2233013 0.130 Peak # 23 24.85536 3.579343 212.2231 344.9595 0.1229364 0.175 Peak # 24 24.98804 3.560637 267.8217 399.8474 0.1551436 0.175 Peak # 25 25.3711 3.507738 162.8907 291.8631 0.09435921 0.226 Peak # 26 25.64969 3.470267 130.3427 256.16 0.07550482 0.219 Peak # 27 26.53912 3.355949 103.8878 220.8986 0.06018002 0.100 Peak # 28 27.62185 3.226811 76.33185 194 0.04421745 0.256 Peak #29 28.60708 3.11788 106.999 228.0308 0.06198227 0.100 Peak # 30 29.00274 3.07624 319.7704 443.9528 0.1852363 0.100 Peak # 31 30.42807 2.935309 124.64 247.0201 0.07220139 0.100 Peak # 32 32.10201 2.785966 131.7526 254.2239 0.07632156 0.113 Peak # 33 33.0099 2.711386 81.86591 203.6693 0.04742322 0.136 Peak # 34 36.95634 2.430403 74.8323 193.9958 0.04334879 0.176 In some embodiments of the present invention, the hydrochloride crystal form J2 of the compound of Formula I-1 has the onsets of the endothermic peaks at 77.60°C ± 2°C and 163.47°C ± 2°C in its differential scanning calorimetry (DSC) curve, and decomposition of the sample begins at 211.78°C ± 2°C. 5       In some embodiments of the present invention, the DSC pattern of the hydrochloride crystal form J2 of the compound of Formula I-1 is shown in Figure 60. In some embodiments of the present invention, the hydrochloride crystal form J2 of the compound of Formula I-1 has two weight loss steps at 28.73°C ± 2°C and 120.00°C ± 2°C in its thermogravimetric analysis (TGA) curve. In some embodiments of the present invention, the TGA pattern of the hydrochloride crystal form J2 of the compound of Formula I-1 is shown in Figure 61. The present invention also provides a method for preparing the hydrochloride crystal form J2 of the compound of Formula I-1, comprising heating the hydrochloride crystal form J1 of the compound of Formula I-1 to 110°C to obtain it, wherein the ratio of the compound of Formula I-1 to hydrochloric acid is selected from 0.8 to 1.2, the hydrochloride crystal form J2 of the compound of Formula I-1 is a solvate of 2-methyl-tetrahydrofuran and water, with a 2-methyl-tetrahydrofuran content of 0.39 equivalents and a water content of 0.94 equivalents. The present invention also provides the hydrochloride crystal form K of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 0 angles: 6.79 ± 0.2°, 11.61 ± 0.2°, 14.93 ± 0.2°, 16.08 ± 0.2°, 18.05 ± 0.2°, 18.63 ± 0.2°, 20.49 ± 0.2°, 20.64 ± 0.2°, 21.52 ± 0.2°, 21.72 ± 0.2°, 21.93±0.2°, 23.68±0.2°, 25.19±0.2°, 26.25±0.2°, 26.57±0.2°, 29.91±0.2°, 32.56±0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the hydrochloride crystal form K of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 0 angles: 6.79±0.2°, 7.83±0.2°, 8.04±0.2°, 10.00±0.2°, 10.74 ± 0.2°, 11.61 ± 0.2°, 12.25 ± 0.2 °, 12.64 ± 0.2°, 13.57 ± 0.2°, 14.93 ± 0.2°, 16.08 ± 0.2°, 18.05±0.2°, 18.63±0.2°,  19.43±0.2°,  20.15±0.2°,  20.49±0.2°,  20.64±0.2°,  21.52±0.2°,  21.72±0.2°, 21.93±0.2°,  23.27±0.2°,  23.68±0.2°,  24.73±0.2°,  25.19±0.2°,  26.25±0.2°,  26.57±0.2°, 27.42±0.2°, 28.02±0.2°, 28.67±0.2°, 29.13±0.2°, 29.91±0.2°, 32.56±0.2°. In some embodiments of the present invention, the X-ray powder diffraction (XRPD) pattern of the hydrochloride crystal form K of the compound of Formula I-1 is shown in Figure 62. Table 28 XRPD analysis data for the hydrochloride crystal form K of compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 6.794806 12.9984 691.3811 875.0555 0.192033 0.100 Peak # 2 7.83426 11.27594 288.9213 486.3343 0.08024868 0.120 Peak # 3 8.038795 10.9895 203.2409 403.895 0.05645072 0.120 Peak # 4 9.997069 8.840785 117.7202 330.8371 0.03269712 0.100 Peak # 5 10.74072 8.230294 107.3294 320.8759 0.02981103 0.100 Peak # 6 11.60559 7.618825 687.957 909.0914 0.191082 0.100 Peak # 7 12.25333 7.217494 245.9523 473.5915 0.06831394 0.100 Peak # 8 12.63822 6.998539 204.09 432.644 0.05668657 0.100 Peak # 9 13.57036 6.519837 198.4962 429.6321 0.05513286 0.100 Peak # 10 14.92862 5.929554 3600.324 3866.778 1 0.100 Peak # 11 16.0831 5.506421 1376.485 1669.815 0.3823225 0.100 Peak # 12 18.04593 4.911676 1009.741 1363.736 0.2804584 0.100 Peak # 13 18.63182 4.758526 671.5975 1046.877 0.1865381 0.100 Peak # 14 19.42977 4.564864 496.6809 892.7581 0.1379545 0.100 Peak #15 20.14869 4.403579 441.9977 848.7093 0.1227661 0.100 Peak# 16 20.48797 4.331416 1028.155 1437.222 0.2855728 0.128 Peak # 17 20.64182 4.299478 583.2937 992.8682 0.1620114 0.128 Peak #18 21.52175 4.125638 978.1533 1383.857 0.2716848 0.100 Peak #19 21.72215 4.088027 1036.466 1439.683 0.2878813 0.308 Peak # 20 21.92503 4.050655 739.6849 1139.781 0.2054495 0.308 Peak#21 23.27148 3.819247 248.8957 653.3616 0.06913146 0.102 Peak # 22 23.67982 3.754304 1547.461 1952.999 0.4298115 0.100 Peak # 23 24.72815 3.597466 280.2606 677.2075 0.07784315 0.158 Peak # 24 25.18878 3.532713 791.9027 1179.913 0.2199532 0.104 Peak # 25 26.25322 3.391844 441.882 818.9271 0.122734 0.100 Peak # 26 26.57399 3.351624 425.2781 809.8372 0.1181222 0.210 Peak # 27 27.41809 3.250327 260.4725 657.5086 0.07234696 0.100 Peak # 28 28.02496 3.181306 278.7974 678.9731 0.07743675 0.112 Peak #29 28.66725 3.111473 222.631 620.5598 0.06183639 0.100 Peak # 30 29.12559 3.063542 364.7587 757.3303 0.1013127 0.100 Peak # 31 29.90952 2.985008 394.9463 771.1329 0.1096974 0.179 Peak # 32 32.55656 2.748099 310.4091 669.1288 0.08621699 0.227 In some embodiments of the present invention, the hydrochloride crystal form K of the compound of Formula I-1 has the onsets of the endothermic peaks at 80.73°C ± 2°C and 171.74°C ± 2°C in its differential scanning calorimetry (DSC) curve, and decomposition of the sample begins at 211.42°C ± 2°C. In some embodiments of the present invention, the DSC pattern of the hydrochloride crystal form K of the compound of Formula I-1 is shown in Figure 63. In some embodiments of the present invention, the hydrochloride crystal form K of the compound of Formula I-1 has three weight loss steps at 33.39°C ± 2°C, 125.00°C ± 2°C, and 155.00°C ± 2°C in its thermogravimetric analysis (TGA) curve. In some embodiments of the present invention, the TGA pattern of the hydrochloride crystal form K of the compound of Formula I-1 is shown in Figure 64. The present invention also provides a method for preparing the hydrochloride crystal form K of the compound of Formula I-1, comprising adding the compound of Formula I-1 and hydrochloric acid to methyl tert-butyl ether, and then performing suspension recrystallization at 50°C or under heating-cooling cycles or slurrying to obtain it, the ratio of the compound of Formula I-1 to hydrochloric acid is selected from 0.8 to 1.2, and the hydrochloride crystal form K of the compound of Formula I-1 is a solvate of methyl tert-butyl ether and water, with a methyl tert-butyl ether content of 0.5 equivalents and a water content of 0.93 equivalents. The present invention also provides the hydrochloride crystal form L of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 9 angles: 8.15±0.2°, 12.72±0.2°, 13.59±0.2°, 15.07±0.2°, 15.56 ± 0.2°, 16.60 ± 0.2°, 16.89 ± 0.2°, 17.56 ± 0.2°, 19.74 ± 0.2°, 20.52 ± 0.2°, 21.69±0.2°, 22.60±0.2°, 25.57±0.2°, 27.48±0.2°, 29.54±0.2°, 29.80±0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the hydrochloride crystal form L of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 9 angles: 7.70±0.2°, 8.15±0.2°, 8.82±0.2°, 9.85±0.2°, 11.25±0.2°, 12.72±0.2°,  13.59±0.2°,  14.68±0.2°,  15.07±0.2°,  15.56±0.2°,  16.60±0.2°,  16.89±0.2°, 17.56±0.2°,  18.53±0.2°,  18.98±0.2°,  19.74±0.2°,  20.29±0.2°,  20.52±0.2°,  21.30±0.2°, 21.69±0.2°,  22.60±0.2°,  22.79±0.2°,  24.38±0.2°,  25.57±0.2°,  26.21±0.2°,  26.50±0.2°, 5   26.97±0.2°, 27.48±0.2°,  28.17±0.2°, 28.60±0.2°,  29.54±0.2°, 29.80±0.2°,  31.17±0.2°, 33.28±0.2°. In some embodiments of the present invention, the hydrochloride crystal form L of the compound of Formula I-1 is shown in Figure 65. Table 29 XRPD analysis data for the hydrochloride crystal form L of the compound of 10                                        Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 7.699858 11.47246 131.7752 336.0659 0.02713539 0.100 Peak # 2 8.145549 10.84571 388.0066 598.1743 0.07989903 0.100 Peak # 3 8.823183 10.0142 89.33794 302.069 0.01839663 0.100 Peak # 4 9.853885 8.968925 197.7117 412.7841 0.04071316 0.100 Peak # 5 11.24898 7.859537 369.8264 581.4573 0.07615533 0.100 Peak # 6 12.71896 6.954291 1487.639 1717.048 0.3063374 0.100 Peak # 7 13.58705 6.511866 1030.956 1271.22 0.2122963 0.100 Peak # 8 14.6791 6.029779 391.6135 655.8375 0.08064177 0.100 Peak # 9 15.07415 5.872634 902.8954 1182.24 0.1859259 0.100 Peak#10 15.55735 5.691307 1063.293 1357.591 0.2189553 0.100 Peak #11 16.60393 5.334851 1276.309 1618.283 0.2628199 0.175 Peak#12 16.89181 5.244576 4856.211 5212.304 1 0.100 Peak# 13 17.55518 5.047862 946.9635 1330.313 0.1950005 0.100 Peak # 14 18.52686 4.785248 321.5662 731.5641 0.0662175 0.147 Peak# 15 18.98341 4.671179 102.7261 519.8016 0.02115355 0.100 Peak# 16 19.74166 4.493443 1663.331 2084.444 0.3425161 0.100 Peak # 17 20.29493 4.372176 825.2653 1243.265 0.1699401 0.169 Peak# 18 20.5165 4.325457 1295.536 1710.853 0.2667791 0.134 Peak# 19 21.29701 4.168664 519.0574 937.0649 0.1068853 0.100 Peak # 20 21.68984 4.094043 2100.771 2521.513 0.4325947 0.100 Peak#21 22.59681 3.93173 1945.966 2363.155 0.400717 0.100 Peak # 22 22.79003 3.898831 552.5369 967.1934 0.1137794 0.100 Peak # 23 24.38056 3.647962 656.4279 1057.281 0.1351728 0.100 Peak # 24 25.56504 3.481566 1270.748 1697.177 0.2616749 0.100 Peak # 25 26.20858 3.397519 857.4071 1291.179 0.1765589 0.189 Peak # 26 26.4961 3.3613 814.4917 1249.304 0.1677216 0.174 Peak # 27 26.9705 3.303243 232.8028 666.3146 0.04793919 0.100 Peak # 28 27.47811 3.243364 1526.117 1954.071 0.3142608 0.100 Peak # 29 28.17182 3.165055 141.1872 554.5795 0.02907353 0.109 Peak # 30 28.59997 3.118639 289.7929 690.1832 0.0596747 0.188 Peak # 31 29.54222 3.02128 500.3598 880.1282 0.103035 0.203 Peak # 32 29.80236 2.995497 633.8278 1010.739 0.130519 0.198 Peak # 33 31.17271 2.866868 252.4929 605.6007 0.0519938 0.160 Peak # 34 33.27863 2.690104 190.787 534.211 0.03928722 0.185 In some embodiments of the present invention, the hydrochloride crystal form L of the compound of Formula I-1 has the onsets of the endothermic peaks at 180.17°C ± 2°C in its differential scanning calorimetry (DSC) curve, and decomposition of the sample begins at 212.43°C ± 2°C. In some embodiments of the present invention, the DSC pattern of the hydrochloride crystal form L of the compound of Formula I-1 is shown in Figure 66. In some embodiments of the present invention, the hydrochloride crystal form L of the compound of Formula I-1 has two weight loss steps at 33.53°C ± 2°C and 140.00°C ± 2°C in its thermogravimetric analysis (TGA) curve. In some embodiments of the present invention, the TGA pattern of the hydrochloride crystal form L of the compound of Formula I-1 is shown in Figure 67. The present invention also provides a method for preparing the hydrochloride crystal form L of the compound of Formula I-1, comprising adding the compound of Formula I-1 and hydrochloric acid to toluene, and then performing suspension recrystallization at 25°C, 50°C, or under heating-cooling cycles or slurrying to obtain it, wherein the ratio of the compound of Formula I-1 to hydrochloric acid is selected from 0.8 to 1.2, and the hydrochloride crystal form L of the compound of Formula I-1 is a solvate of toluene, with a toluene content of 0.46 equivalents. The present invention also provides the hydrochloride crystal form M of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 9 angles: 6.84 ± 0.2°, 7.21 ± 0.2°, 14.17 ± 0.2°, 14.90 ± 0.2°, 18.94 ± 0.2°, 19.46 ± 0.2°, 19.71 ± 0.2°, 19.96 ± 0.2°, 20.82 ± 0.2°, 22.60±0.2°, 24.17±0.2°, 25.17±0.2°, 25.45±0.2°, 27.17±0.2°, 28.09±0.2°, 28.88±0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the hydrochloride crystal form M of the compound of formula I-1 has characteristic diffraction peaks at the following 2 9 angles: 6.84±0.2°, 7.21±0.2°, 8.92±0.2°, 10.07±0.2°, 10.69±0.2°, 10.89±0.2°,  11.24±0.2°,  13.23±0.2°,  14.17±0.2°,  14.90±0.2°,  15.59±0.2°,  16.74±0.2°, 17.67±0.2°,  18.29±0.2°,  18.94±0.2°,  19.46±0.2°,  19.71±0.2°,  19.96±0.2°,  20.82±0.2°  , 21.49±0.2°,  21.83±0.2°,  22.60±0.2°,  23.14±0.2°,  23.54±0.2°,  24.17±0.2°,  25.17±0.2°, 25.45±0.2°,  26.10±0.2°,  27.17±0.2°,  27.61±0.2°,  28.09±0.2°,  28.88±0.2°,  29.42±0.2°, 30.12±0.2°, 32.48±0.2°, 35.22±0.2°. In some embodiments of the present invention, the X-ray powder diffraction (XRPD) pattern of the hydrochloride crystal form M of the compound of Formula I-1 is shown in Figure 68. Table 30 XRPD analysis data for the hydrochloride crystal form M of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 6.84472 12.90373 549.0949 615.6407 0.2778722 0.165 Peak # 2 7.211685 12.24792 391.2005 460.1923 0.1979689 0.100 Peak # 3 8.922095 9.903405 211.9704 281.5079 0.1072687 0.100 Peak # 4 10.07171 8.775435 181.1558 251.1664 0.0916748 0.100 Peak # 5 10.69185 8.267802 310.0935 381.4751 0.1569243 0.101 Peak # 6 10.88628 8.120569 260.1903 332.5287 0.1316706 0.101 Peak # 7 11.24487 7.862399 152.6891 225.697 0.07726907 0.133 Peak # 8 13.22875 6.687422 265.7502 344.6351 0.1344842 0.100 Peak # 9 14.16762 6.246297 July 1976 2066.746 1 0.100 Peak # 10 14.90028 5.940766 745.1891 838.3379 0.3771066 0.100 Peak # 11 15.58676 5.680631 351.6713 441.7771 0.177965 0.100 Peak # 12 16.74027 5.291707 195.157 284.6572 0.09876018 0.100 Peak # 13 17.66522 5.016665 220.666 313.7185 0.1116691 0.126 Peak # 14 18.29257 4.846004 266.1616 359.0701 0.1346924 0.100 Peak # 15 18.94302 4.681048 442.7134 543.266 0.2240373 0.100 Peak # 16 19.46487 4.556712 520.9281 631.4868 0.2636183 0.100 Peak # 17 19.70504 4.501712 909.2918 1023.447 0.4601516 0.217 Peak # 18 19.95502 4.445879 693.7634 810.9916 0.3510824 0.295 Peak # 19 20.81669 4.263753 1294.718 1417.268 0.6551984 0.100 Peak # 20 21.48724 4.132186 414.7583 540.3758 0.2098905 0.179 Peak #21 21.82966 4.068136 385.2101 512.3789 0.1949375 0.100 Peak # 22 22.59636 3.931808 1560.034 1689.713 0.789463 0.100 Peak # 23 23.14369 3.840045 310.0418 438.7188 0.1568982 0.160 Peak # 24 23.5415 3.776049 285.9931 411.8756 0.1447282 0.100 Peak # 25 24.17295 3.678821 614.5384 737.225 0.3109902 0.100 Peak # 26 25.16647 3.535795 517.7031 646.9673 0.2619862 0.174 Peak # 27 25.4543 3.496462 643.7325 778.7833 0.325764 0.188 Peak # 28 26.09795 3.411669 351.5211 496.2128 0.177889 0.100 Peak #29 27.16983 3.279461 944.2617 1104.001 0.4778483 0.101 Peak # 30 27.61049 3.228113 145.7133 309.4552 0.07373893 0.135 Peak# 31 28.09237 3.173826 448.1052 613.7818 0.2267659 0.100 Peak # 32 28.87765 3.089279 616.2469 779.606 0.3118548 0.100 Peak # 33 29.41578 3.033977 180.7685 338.6228 0.09147878 0.107 Peak # 34 30.12402 2.964239 214.1834 359.9441 0.1083886 0.105 Peak # 35 32.4794 2.754451 212.3529 339.9138 0.1074622 0.100 Peak # 36 35.21609 2.546415 164.973 299.9358 0.0834854 0.157 In some embodiments of the present invention, the hydrochloride crystal form M of the compound of Formula I-1 has the onsets of the endothermic peaks at 31.74°C ± 2°C and 150.05°C ± 2°C in its differential scanning calorimetry (DSC) curve, and decomposition of the sample begins at 215.09°C ± 2°C. In some embodiments of the present invention, the DSC pattern of the hydrochloride crystal form M of the compound of Formula I-1 is shown in Figure 69. In some embodiments of the present invention, the hydrochloride crystal form M of the compound of Formula I-1 has two weight loss steps at 32.98°C ± 2°C and 115.00°C ± 2°C in its thermogravimetric analysis (TGA) curve. In some embodiments of the present invention, the TGA pattern of the hydrochloride crystal form M of the compound of Formula I-1 is shown in Figure 70. The present invention also provides a method for preparing the hydrochloride crystal form M of the compound of Formula I-1, comprising adding the compound of Formula I-1 and hydrochloric acid to isopropanol / dimethyl sulfoxide, isopropyl acetate / dimethyl sulfoxide, or a mixed solvent of water / dimethyl sulfoxide, and then performing suspension recrystallization at 25°C, 50°C, or under heating-cooling cycles or slurrying to obtain it, the ratio of the compound of Formula I-1 to hydrochloric acid is selected from 0.8 to 1.2, the hydrochloride crystal form M of the compound of Formula I-1 is a solvate of dimethyl sulfoxide and water, with a dimethyl sulfoxide content of 3.4 equivalents and a water content of 13.7 equivalents. The present invention also provides the hydrochloride crystal form N of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 9 angles: 6.61 ± 0.2°, 7.80 ± 0.2°, 13.17 ± 0.2°, 15.24 ± 0.2°, 16.02 ± 0.2°, 16.19 ± 0.2°, 20.10 ± 0.2°, 21.57 ± 0.2°, 21.95 ± 0.2°, 28.42 ± 0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the hydrochloride crystal form N of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 9 angles: 6.61±0.2°, 7.80±0.2°, 9.75±0.2°, 11.19±0.2°, 12.53 ± 0.2°, 13.17 ± 0.2°, 14.61 ± 0.2°, 15.24 ± 0.2°, 16.02 ± 0.2°, 16.19 ± 0.2°, 18.51±0.2°, 19.36±0.2°, 20.10±0.2°,  21.57±0.2°,  21.95±0.2°,  23.47±0.2°,  25.60±0.2°,  27.32±0.2°,  28.42±0.2°, 29.12±0.2°. In some embodiments of the present invention, the XRPD pattern of the hydrochloride crystal form N of the compound of Formula I-1 is shown in Figure 71. Table 31 XRPD analysis data for the hydrochloride crystal form N of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 6.609798 13.36181 794.7955 980.8873 0.3862052 0.100 Peak # 2 7.795767 11.33153 487.4999 690.8655 0.2368848 0.100 Peak # 3 9.745835 9.068117 34.00436 256.8145 0.01652332 0.133 Peak # 4 11.18676 7.903115 155.3221 382.2601 0.07547374 0.141 Peak # 5 12.52697 7.060439 86.51295 323.2003 0.04203818 0.159 Peak # 6 13.16559 6.719363 421.9255 664.773 0.2050211 0.190 Peak # 7 14.60967 6.058279 86.97061 345.4379 0.04226056 0.133 Peak # 8 15.23705 5.810213 304.1442 589.247 0.147789 0.271 Peak # 9 16.0249 5.52629 820.8987 1132.93 0.3988892 0.225 Peak # 10 16.18629 5.471551 893.4421 1210.095 0.4341393 0.225 Peak # 11 18.5144 4.788438 351.1131 770.6374 0.1706121 0.174 Peak # 12 19.35669 4.581933 455.0124 908.4713 0.2210986 0.105 Peak# 13 20.09929 4.414289 2057.962 2534.464 1 0.100 Peak #14 21.57023 4.116475 320.2355 823.3632 0.1556081 0.100 Peak#15 21.95477 4.045236 557.7156 1063.636 0.2710039 0.291 Peak#16 23.47203 3.787067 201.8493 701.9348 0.09808215 0.109 Peak #17 25.59957 3.476949 170.8813 642.3811 0.08303423 0.126 Peak # 18 27.31775 3.262038 172.0372 641.0505 0.08359591 0.164 Peak # 19 28.42086 3.137885 858.4133 1341.339 0.4171182 0.100 Peak # 20 29.12304 3.063805 213.3153 697.6971 0.1036537 0.238 In some embodiments of the present invention, the hydrochloride crystal form N of the compound of Formula I-1 has the onsets of the endothermic peaks at 47.38°C ± 2°C and 167.91°C ± 2°C in its differential scanning calorimetry (DSC) curve, and decomposition of the sample begins at 212.57°C ± 2°C. In some embodiments of the present invention, the DSC pattern of the hydrochloride crystal form N of the compound of Formula I-1 is shown in Figure 72. In some embodiments of the present invention, the hydrochloride crystal form N of the compound of Formula I-1 has three weight loss steps at 33.22°C ± 2°C, 75.00°C ± 2°C, and 150.00°C ± 2°C in its thermogravimetric analysis (TGA) curve. In some embodiments of the present invention, the TGA pattern of the hydrochloride crystal form N of the compound of Formula I-1 is shown in Figure 73. The present invention also provides a method for preparing the hydrochloride crystal form N of the compound of Formula I-1, comprising adding the compound of Formula I-1 and hydrochloric acid to methanol, and then performing suspension recrystallization at 25°C or slurrying to obtain it, the ratio of the compound of Formula I-1 to hydrochloric acid is selected from 0.8 to 1.2, and the hydrochloride crystal form N of the compound of Formula I-1 is a hydrate crystal form, with a water content of 3.0 equivalents. The present invention also provides the hydrochloride crystal form O of the compound of Formula I-1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 9 angles: 6.14±0.2°, 9.90±0.2°, 13.54 ± 0.2°, 14.40 ± 0.2°, 15.33 ± 0.2°, 15.51 ± 0.2°, 15.87 ± 0.2°, 16.79 ± 0.2°, 18.36±0.2°, 20.17±0.2°, 21.14±0.2°, 22.51±0.2°, 22.84±0.2°, 24.59±0.2°, 25.28±0.2°, 26.82±0.2°, 27.07±0.2°, 27.93±0.2°. In some embodiments of the present invention, the X-ray powder diffraction pattern of the hydrochloride crystal form O of the compound of Formula I-1 has characteristic diffraction peaks at the following 2 9 angles: 6.14±0.2°, 8.39±0.2°, 9.90±0.2°, 11.28±0.2°, 13.19 ± 0.2°, 13.54 ± 0.2°, 14.40 ± 0.2°, 15.33 ± 0.2°, 15.51 ± 0.2°, 15.87 ± 0.2°, 16.79 ± 0.2°, 17.32±0.2°, 18.36±0.2°,  19.03±0.2°,  19.38±0.2°,  19.84±0.2°,  20.17±0.2°,  20.39±0.2°,  21.14±0.2°, 21.82±0.2°,  22.51±0.2°,  22.84±0.2°,  23.77±0.2°,  24.59±0.2°,  25.28±0.2°,  26.21±0.2°, 26.82±0.2°,  27.07±0.2°,  27.93±0.2°,  28.45±0.2°,  29.24±0.2°,  29.70±0.2°,  30.12±0.2°, 30.91±0.2°, 31.32±0.2°, 32.02±0.2°, 32.81±0.2°, 33.99±0.2°, 35.51±0.2°, 37.27±0.2°. In some embodiments of the present invention, the XRPD pattern of the hydrochloride crystal form O of the compound of Formula I-1 is shown in Figure 74. Table 32 XRPD analysis data for the hydrochloride crystal form O of the compound of Formula I-1 Name Angle d Value Net Intensity Gross Intensity Rel. Intensity FWHM Peak #1 6.140894 14.38099 1107.957 1293.828 0.3147685 0.100 Peak # 2 8.388501 10.53213 408.1169 632.1091 0.1159452 0.100 Peak # 3 9.903625 8.923991 940.8444 1184.968 0.2672921 0.100 Peak # 4 11.27951 7.838338 283.761 536.4181 0.08061594 0.100 Peak # 5 13.19286 6.705534 181.3849 438.5068 0.0515311 0.100 Peak # 6 13.54282 6.533034 1454.357 1725.367 0.4131799 0.100 Peak # 7 14.39867 6.146578 1165.407 1462.794 0.3310898 0.100 Peak # 8 15.33 5.775193 1091.177 1411.573 0.3100013 0.209 Peak # 9 15.50935 5.708809 1968.812 2294.23 0.5593358 0.209 Peak # 10 15.87208 5.579152 1217.473 1551.602 0.3458818 0.100 Peak # 11 16.79091 5.275862 1137.58 1502.341 0.3231842 0.100 Peak# 12 17.31762 5.116568 762.1778 1150.802 0.2165332 0.100 Peak # 13 18.35663 4.829239 3,033.994 3474.369 0.8619518 0.100 Peak # 14 19.03416 4.658839 835.817 1306.477 0.237454 0.169 Peak# 15 19.38 4.576475 502.326 985.8411 0.1427098 0.108 Peak# 16 19.84427 4.470439 1056.817 1554.823 0.3002395 0.100 Peak # 17 20.17144 4.398664 3519.912 4026.221 1 0.100 Peak# 18 20.38873 4.352273 1279.111 1790.063 0.363393 0.100 Peak# 19 21.14244 4.198789 1425.925 1947.604 0.4051024 0.105 Peak # 20 21.8204 4.069841 566.3649 1090.542 0.1609031 0.125 Peak#21 22.50812 3.947022 756.1846 1275.989 0.2148305 0.191 Peak # 22 22.83675 3.89096 979.7973 1495.056 0.2783585 0.178 Peak # 23 23.77264 3.739855 546.3175 1050.328 0.1552077 0.105 Peak # 24 24.58534 3.618039 980.3226 1470.129 0.2785077 0.122 Peak # 25 25.27836 3.520397 896.8149 1367.909 0.2547834 0.136 Peak # 26 26.21456 3.396758 248.3358 716.5672 0.0705517 0.100 Peak # 27 26.82125 3.321285 737.2324 1215.387 0.2094463 0.100 Peak # 28 27.06781 3.291589 750.5667 1231.206 0.2132345 0.191 Peak # 29 27.92502 3.192464 1087.508 1569.829 0.3089589 0.100 Peak # 30 28.45316 3.134396 279.407 757.3731 0.07937898 0.101 Peak # 31 29.24147 3.051666 309.071 791.8425 0.08780645 0.161 Peak # 32 29.70277 3.005313 501.2726 988.7209 0.1424106 0.121 Peak # 33 30.11823 2.964796 490.5232 979.5004 0.1393567 0.105 Peak # 34 30.91374 2.890291 465.6483 950.4669 0.1322898 0.100 Peak # 35 31.32369 2.853393 169.9911 649.0291 0.04829413 0.129 Peak # 36 32.01775 2.793105 265.0306 734.7343 0.07529467 0.163 Peak # 37 32.81191 2.727294 268.0586 727.3953 0.07615492 0.130 Peak# 38 33.98699 2.635639 302.6802 746.7783 0.08599085 0.131 Peak # 39 35.51149 2.525907 319.0914 750.0336 0.09065324 0.193 Peak # 40 37.27088 2.410611 289.6581 733.1247 0.08229129 0.248 In some embodiments of the present invention, the hydrochloride crystal form O of the compound of Formula I-1 has the onsets of the endothermic peaks starting at 12.36°C ± 2°C and 174.87°C ± 2°C in its differential scanning calorimetry (DSC) curve, with decomposition of the sample begins at 212.00°C ± 2°C. In some embodiments of the present invention, the DSC pattern of the hydrochloride crystal form O of the compound of Formula I-1 is shown in Figure 75. In some embodiments of the present invention, the hydrochloride crystal form O of the compound of Formula I-1 has three weight loss steps at 27.70°C ± 2°C, 115.00°C ± 2°C, and 160.00°C ± 2°C in its thermogravimetric analysis (TGA) curve. In some embodiments of the present invention, the TGA pattern of the hydrochloride crystal form O of the compound of Formula I-1 is shown in Figure 76. The present invention also provides a method for preparing the hydrochloride crystal form O of the compound of Formula I-1, comprising adding the compound of Formula I-1 and hydrochloric acid to dichloromethane, and then performing suspension recrystallization at 25°C or slurrying to obtain it, the ratio of the compound of Formula I-1 to hydrochloric acid is selected from 0.8 to 1.2, and the hydrochloride crystal form O of the compound of Formula I-1 is a hydrate crystal form, with a water content of 0.9 equivalents. In another aspect, the present invention provides a method for preparing a crystal form of a pharmaceutically acceptable salt of the compound of formula (I), characterized by comprising the following steps: a. dissolving or dispersing the compound of formula (I) and an acid in a molar ratio of 1: (0.8-3) in 1-20 times of solvent A; b. performing suspension, recrystallization, or slurrying treatment; wherein the acid is not selected from hydrochloric acid (preferably, the acid is selected from the group consisting of: maleic acid, fumaric acid, glycolic acid, L-malic acid, succinic acid, sulfuric acid, L-tartaric acid, hippuric acid, glutaric acid, p-toluenesulfonic acid, or methanesulfonic acid); wherein the solvent A is selected from the group consisting of: acetonitrile, dichloromethane, tetrahydrofuran, or a combination thereof; or the acid is hydrochloric acid or hydrogen chloride in dioxane; and the solvent A is selected from the group consisting of: ethyl acetate, 2-methyl-tetrahydrofuran, butanone, ethanol, acetone, ethyl acetate, acetonitrile, tetrahydrofuran, methyl isobutyl ketone, trifluoroethanol, water, methanol, tert-butyl methyl ether, toluene, isopropanol, dimethyl sulfoxide, isopropyl acetate, dichloromethane, or a combination thereof. In another preferred embodiment, the solvent A is selected from the group consisting of: methyl isobutyl ketone / trifluoroethanol, methanol / water, methanol / tert-butyl methyl ether, isopropanol / dimethyl sulfoxide, isopropyl acetate / dimethyl sulfoxide, water / dimethyl sulfoxide. In another preferred embodiment, the suspension comprises the following steps: a. suspending the compound of formula (I), acid, and solvent at 45-65°C for 1-3 h; b. allowing the mixture to cool naturally to 20-30°C and continuing performing the suspension for at least 48 h; c. centrifuging the resulting suspension through a 0.4-0.5 gm filter membrane at a speed of 12,000-16,000 rpm; d. vacuum-drying the resulting solid at 45 — 65°C. In another aspect, the present invention provides a method for preparing a crystal form of a pharmaceutically acceptable salt of the compound of formula (I), characterized in that the method is a crystal form transformation by converting one crystal form of a pharmaceutically acceptable salt of the compound of formula (I) into another crystal form thereof; wherein the method of the crystal form transformation comprises the following steps: a. dissolving or dispersing a crystal form of a pharmaceutically acceptable salt of the compound of formula (I) in 1 to 20 times of solvent A; b. performing suspension treatment; c. centrifuging the resulting suspension through a 0.4 to 0.5 pm filter membrane at a speed of 12,000 to 16,000 rpm; wherein the solvent A is selected from the group consisting of: ethanol, acetone, ethyl acetate, acetonitrile, tetrahydrofuran, methyl isobutyl ketone, trifluoroethanol, methanol, 2-methyl-tetrahydrofuran, methyl tert-butyl ether, toluene, isopropanol, dimethyl sulfoxide, isopropyl acetate, dimethyl sulfoxide, methanol, dichloromethane, water, or combinations thereof. In another preferred embodiment, the solvent A is selected from the group consisting of: methyl isobutyl ketone / trifluoroethanol, methanol / water, isopropanol / dimethyl sulfoxide, isopropyl acetate / dimethyl sulfoxide, dimethyl sulfoxide / water. In another preferred embodiment, the suspension treatment comprises the step of stirring at a rate of 300-400 rpm at 20 — 30°C. In another preferred embodiment, the suspension treatment comprises the step of stirring at a rate of 300-400 rpm at 40-60°C. In another preferred embodiment, the suspension treatment comprises the step of performing 8 to 12 heating-cooling cycles at a rate of 0.05 to 0.2°C / min between 5 and 50°C while stirring at a rate of 300 to 400 rpm, with the final temperature of the suspension being 10 to 15°C. In another preferred embodiment, the suspension treatment comprises the step of filtering through a 0.4 — 0.5 pm filter membrane to obtain a clear solution, followed by performing suspension treatment after adding methyl tert-butyl ether at a ratio of 1: (8 — 12). In another aspect, the present invention also provides a pharmaceutical composition comprising the compound of formula (I), the crystal form A, or a crystal form of the compound of formula (I); and one or more pharmaceutically acceptable carriers, excipients, adjuvants, ingredients, and / or diluents. In another preferred embodiment, the pharmaceutical composition further comprises other therapeutic agents. In another preferred embodiment, the other therapeutic agents are selected from the group consisting of: chemotherapeutic agents, kinase inhibitors, targeted epigenetic modulators, antibody drugs, immune checkpoint inhibitors, or combinations thereof. In another preferred embodiment, the chemotherapeutic agent is selected from the group consisting of: cisplatin, doxorubicin, paclitaxel, etoposide, irinotecan, cyclophosphamide, gemcitabine, ifosfamide, tamoxifen, toremifene, fulvestrant, anastrozole, exemestane, goserelin, leprorelin, melphalan, chlorambucil, busulfan, floxuridine, cytarabine, oxaliplatin, leucovorin, pentostatin, and diethylstilbestrol. In another preferred embodiment, the kinase inhibitor is selected from the group consisting of: Akt, TGF-pR, Pim, PKA, PKG, PKC, CaM kinase, CDK2, CDK4, CDK4 / 6, MEK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, PDGFaR, PDGFpR, CSFIR, KIT, c-Met, TRKA, TRKB, TRKC, FLT3, VEGFR, BTK, FAK, SYK, FRK, JAK, HPK1, AXL, ALK, and B-Raf inhibitors. In another preferred embodiment, the targeted epigenetic modulator is selected from the group consisting of: bromodomain inhibitors, histone lysine methyltransferases, histone arginine methyltransferases, histone demethylases, histone deacetylases, histone acetylases, and DNA methyltransferases. In another preferred embodiment, the antibody drug is selected from the group consisting of: anti-HER2 antibodies, anti-VEGFR antibodies, anti-EGFR antibodies, anti-c-MET antibodies, and anti-CD20 antibodies. In another preferred embodiment, the immune checkpoint inhibitor is selected from the group consisting of: CD27, CD28, CD40, CD122, CD96, CD73, CD47, OX40, GITR, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, PD-1, PD-L1, and PD-L2. In another aspect, the present invention also provides a use of the compound of the formula (I), the crystal form A, the crystal form of the compound of formula (I), and the pharmaceutical composition in preparing a medicament for the prevention and / or treatment of diseases associated with increased activity or expression of FGFR2. In another preferred embodiment, the increased activity or expression of FGFR2 is selected from the group consisting of: FGFR2 amplification, FGFR2 gene mutation, FGFR2 gene fusion / rearrangement, FGFR2 gene translocation, and FGFR2 gene activation. In another preferred embodiment, the diseases associated with increased activity or expression of FGFR2 are selected from the group consisting of: cholangiocarcinoma, liver cancer, breast cancer, prostate cancer, lung cancer, thyroid cancer, gastric cancer, ovarian cancer, esophageal cancer, pancreatic cancer, cervical cancer, colorectal cancer, salivary gland cancer, endometrial cancer, and urothelial cancer, and the like. In another preferred embodiment, the cholangiocarcinoma is intrahepatic cholangiocarcinoma. In another preferred embodiment, the liver cancer is hepatocellular carcinoma. In another preferred embodiment, the lung cancer is lung squamous cell carcinoma or non-small cell lung cancer. Description of the Drawings Figure 1 shows the XRPD pattern of crystal form A of the compound of Formula I-1. Figure 2 shows the DSC pattern of crystal form A of the compound of Formula I-1. Figure 3 shows the TGA pattern of crystal form A of the compound of Formula I-1. Figure 4 shows the XRPD pattern of maleate crystal form A of the compound of Formula I-1. Figure 5 shows the XRPD pattern of monomaleate crystal form B of the compound of Formula I-1. Figure 6 shows the DSC pattern of monomaleate crystal form B of the compound of Formula I-1. Figure 7 shows the TGA spectrum of monomaleate crystal form B of the compound of Formula I-1. Figure 8 shows the XRPD pattern of fumarate crystal form A of the compound of Formula I-1. Figure 9 shows the XRPD pattern of hemifumarate crystal form B of the compound of Formula I-1. Figure 10 shows the DSC pattern of hemifumarate crystal form B of the compound of Formula I-1. Figure 11 shows the TGA pattern of hemifumarate crystal form B of the compound of Formula I-1. Figure 12 shows the XRPD pattern of monoglycolate crystal form A of the compound of Formula I-1. Figure 13 shows the DSC pattern of monoglycolate crystal form A of the compound of Formula I-1. Figure 14 shows the TGA pattern of monoglycolate, crystal form A of the compound of Formula I-1. Figure 15 shows the XRPD pattern of glycolate crystal form B of the compound of Formula I-1, . Figure 16 shows the XRPD pattern of the mono-L-malate crystal form A of the compound of Formula I-1. Figure 17 shows the DSC pattern of mono-L-malate crystal form A of the compound of Formula I-1. Figure 18 shows the TGA spectrum of mono-L-malate crystal form A of the compound of Formula I-1. Figure 19 shows the XRPD pattern of monosuccinate crystal form A of the compound of Formula I-1. Figure 20 shows the DSC pattern of monosuccinate crystal form A of the compound of Formula I-1. Figure 21 shows the TGA pattern of monosuccinate crystal form A of the compound of Formula I-1. Figure 22 shows the XRPD pattern of sulfate crystal form A of the compound of Formula I-1. Figure 23 shows the XRPD pattern of L-tartrate crystal form A of the compound of Formula I-1. Figure 24 shows the XRPD pattern of hippurate crystal form A of the compound of Formula I-1. Figure 25 shows the XRPD pattern of glutarate crystal form A of the compound of Formula I-1. Figure 26 shows the XRPD pattern of p-toluenesulfonate crystal form A of the compound of Formula I-1. Figure 27 shows the XRPD pattern of p-toluenesulfonate crystal form B of the compound of Formula I-1. Figure 28 shows the XRPD pattern of methanesulfonate crystal form A of the compound of Formula I-1. Figure 29 shows the XRPD pattern of hydrochloride crystal form C1 of the compound of Formula I-1. Figure 30 shows the DSC pattern of hydrochloride crystal form C1 of the compound of Formula I-1. Figure 31 shows the TGA pattern of hydrochloride crystal form C1 of the compound of Formula I-1. Figure 32 shows the XRPD pattern of hydrochloride crystal form C2 of the compound of Formula I-1. Figure 33 shows the DSC pattern of hydrochloride crystal form C2 of the compound of Formula I-1. Figure 34 shows the TGA pattern of hydrochloride crystal form C2 of the compound of Formula I-1. Figure 35 shows the XRPD pattern of hydrochloride crystal form D of the compound of Formula I-1. Figure 36 shows the DSC pattern of hydrochloride crystal form D of the compound of Formula I-1. Figure 37 shows the TGA pattern of hydrochloride crystal form D of the compound of Formula I-1. Figure 38 shows the XRPD pattern of hydrochloride crystal form E1 of the compound of Formula I-1. Figure 39 shows the DSC pattern of hydrochloride crystal form E1 of the compound of Formula I-1. Figure 40 shows the TGA pattern of hydrochloride crystal form E1 of the compound of Formula I-1. Figure 41 shows the XRPD pattern of hydrochloride crystal form E2 of the compound of Formula I-1. Figure 42 shows the DSC pattern of hydrochloride crystal form E2 of the compound of Formula I-1. Figure 43 shows the TGA pattern of hydrochloride crystal form E2 of the compound of Formula I-1. Figure 44 shows the XRPD pattern of hydrochloride crystal form F of the compound of Formula I-1. Figure 45 shows the DSC pattern of hydrochloride crystal form F of the compound of Formula I-1. Figure 46 shows the TGA pattern of hydrochloride crystal form F of the compound of Formula I-1. Figure 47 shows the XRPD pattern of hydrochloride, crystal form G of the compound of Formula I-1. Figure 48 shows the DSC pattern of hydrochloride crystal form G of the compound of Formula I-1. Figure 49 shows the TGA pattern of hydrochloride crystal form G of the compound of Formula I-1. Figure 50 shows the XRPD pattern of hydrochloride crystal form H of the compound of Formula I-1. Figure 51 shows the DSC pattern of hydrochloride crystal form H of the compound of Formula I-1. Figure 52 shows the TGA pattern of hydrochloride crystal form H of the compound of Formula I-1. Figure 53 shows the XRPD pattern of hydrochloride crystal form I of the compound of Formula I-1. Figure 54 shows the DSC pattern of hydrochloride crystal form I of the compound of Formula I-1. Figure 55 shows the TGA pattern of hydrochloride crystal form I of the compound of Formula I-1. Figure 56 shows the XRPD pattern of hydrochloride crystal form J1 of the compound of Formula I-1. Figure 57 shows the DSC pattern of hydrochloride crystal form J1 of the compound of Formula I-1. Figure 58 shows the TGA pattern of hydrochloride crystal form J1 of the compound of Formula I-1. Figure 59 shows the XRPD pattern of hydrochloride crystal form J2 of the compound of Formula I-1. Figure 60 shows the DSC pattern of hydrochloride crystal form J2 of the compound of Formula I-1. Figure 61 shows the TGA pattern of hydrochloride crystal form J2 of the compound of Formula I-1. Figure 62 shows the XRPD pattern of hydrochloride crystal form K of the compound of Formula I-1. Figure 63 shows the DSC pattern of hydrochloride crystal form K of the compound of Formula I-1. Figure 64 shows the TGA pattern of hydrochloride crystal form K of the compound of Formula I-1. Figure 65 shows the XRPD pattern of hydrochloride crystal form L of the compound of Formula I-1. Figure 66 shows the DSC pattern of hydrochloride crystal form L of the compound of Formula I-1. Figure 67 shows the TGA pattern of hydrochloride crystal form L of the compound of Formula I-1. Figure 68 shows the XRPD pattern of hydrochloride crystal form M of the compound of Formula I-1. Figure 69 shows the DSC pattern of hydrochloride crystal form M of the compound of Formula I-1. Figure 70 shows the TGA pattern of hydrochloride crystal form M of the compound of Formula I-1. Figure 71 shows the XRPD pattern of hydrochloride crystal form N of the compound of Formula I-1. Figure 72 shows the DSC pattern of hydrochloride crystal form N of the compound of Formula I-1. Figure 73 shows the TGA pattern of hydrochloride crystal form N of the compound of Formula I-1. Figure 74 shows the XRPD pattern of hydrochloride crystal form O of the compound of Formula I-1. Figure 75 shows the DSC pattern of hydrochloride crystal form O of the compound of Formula I-1. Figure 76 shows the TGA pattern of hydrochloride crystal form O of the compound of Formula I-1. Detailed Description of the Invention To address the issues in the prior art, the inventors conducted in-depth research on the various forms of the compound of formula I and developed multiple crystal forms and acid salt forms of the compound of formula I, particularly the hydrochloride, which significantly improved the physicochemical properties of the compound of formula I, such as solubility, hygroscopicity, and chemical stability. The crystalline acid salt compound raw materials comply with industrial production standards and meet the requirements for pharmaceutical formulation development. With important clinical application potential, these compounds are expected to accelerate the development of a new generation of FGFR2 inhibitors. Based on this, the present invention was completed. Definitions Unless otherwise specified, the following terms and phrases used herein are intended to have the meanings set forth below. A particular phrase or term should not be considered ambiguous or unclear in the absence of a specific definition, but should be understood in its ordinary sense. When trade names appear herein, they are intended to refer to the corresponding products or their active ingredients. As used herein, the term “ n or more 20 values selected from the group consisting of” refers to any positive integer greater than or equal to n (e.g., n, n+1, •••), where the upper limit Nup is the total number of 2 0 peaks in that set. For example, “ 1 or more” includes not only 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,  • positive integers up to the upper limit Nup, but also includes ranges such as “ 2 or more ” ,  “ 3 or more”,  “ 4 or more ”,  “ 5 or more”,  “ 6 or more”,  “ 7 or more”,  “ 8 or more ”,  “ 9 or more” and “ 10 or more” . For example, “ 3 or more” includes not only 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, • up to the upper limit Nup, but also includes ranges such as “ 4 or more” ,  “ 5 or more” ,  “ 6 or more” ,  “ 7 or more” ,  “ 8 or more” , “ 9 or more” and “ 10 or more” . As used herein, “ dissolving or dispersing the compound of formula (I) in 1 to 5 times of solvent” means dissolving or dispersing 1 gram of the compound of formula (I) in 1 to 5 milliliters of solvent, wherein the solvent includes, but is not limited to, acetonitrile, alcoholic solvents, ester solvents, ether solvents, or mixtures of alcoholic solvents and water. The intermediate compounds of the present invention may be prepared by various synthetic methods known to those skilled in the art, including the specific embodiments listed 5 below, embodiments formed by combining them with other chemical synthesis methods, and equivalent substitutions known to those skilled in the art; preferred embodiments include, but are not limited to, the examples of the present invention. The chemical reactions of the specific embodiments of the present invention are carried out in suitable solvents, which must be appropriate for the chemical transformations of the 10 present invention and the reagents and materials required therein. To obtain the compounds of the present invention, it may sometimes be necessary for those skilled in the art to modify or select synthetic steps or reaction procedures based on existing embodiments. The present invention will be described in detail below through examples, these examples do not intended to exert any limitation on the scope of the invention. 15        All solvents used in the present invention are commercially available and can be used without further purification. The following abbreviations are used in the present invention: Abbreviation Full Name EtOH Ethanol MeOH Methanol IPA Isopropyl alcohol MTBE Methyl tert-butyl ether MIBK Methyl isobutyl ketone EA Ethyl acetate IPAc Isopropyl acetate ACN Acetonitrile THF Tetrahydrofuran 2-MeTHF 2-Methyl- 1,4-dihydrofuran DCM Dichloromethane DMSO Dimethyl sulfoxide FaSSGF Fasted-state simulated gastric fluid FaSSIF-v1 Fasted-state simulated intestinal fluid - Version 1 FeSSIF-v1 Fed-State simulated intestinal fluid - Version 1 XRPD X-ray powder diffraction DSC Differential Scanning Calorimetry TGA Thermogravimetric Analysis DVS Dynamic Vapor Sorption PLM Polarizing Microscope 1H-NMR Hydrogen Nuclear Magnetic Resonance Spectroscopy KF Karl Fischer (titrator) HPLC High-Performance Liquid Chromatography IC Ion Chromatography LOQ Limit of quantification The test items and methods used in this invention are as follows: X-ray Powder Diffractometer (XRPD) Instrument Bruker D8 Advance Method 1 X-ray Path Reflection Mode Detector LYNXEYE_XE_T (1D mode) Opening Angle 2.9°(max) Radioactive Source Cu / K-Alphal (1=1.5406 A) X-ray source power 40 kV, 40 mA Primary beam slit Dual motorized slits: 20.0 mm; Primary Soller slit: 2.5° Secondary beam slit Secondary Soller slit: 2.5° Scanning mode Continuous scan Scan type Dual-beam mode Step size 0.02° Time per step 0.4 s / step Scan range 2°to 40° Sample rotation speed 15 rpm Sample plate Monocrystalline silicon wafer, flat wafer Method 2 X-ray path Reflection mode Detector LYNXEYE_XE_T (1D mode) Opening Angle 2.9°(max) Radioactive Source Cu / K-Alphal (1=1.5406 A) X-ray source power 40 kV, 40 mA Primary beam slit Dual main motorized slits: 10.0 mm; Primary Soller slit: 2.5° Secondary beam slit Secondary Soller slit: 2.5° Scanning mode Continuous scan Scan type Dual-beam mode Step size 0.02° Time per step 0.12 s / step Scan Range 3°to 40° Sample rotation speed 15 rpm Sample plate Monocrystalline silicon wafer, flat plate Differential Scanning Calorimeter (DSC) Instrument TA Instruments Discovery 2500 Sample tray Tzero tray and Tzero hermetic lid with apertures of approximately 0.7 mm in diameter Temperature Range ~30 to 250°C Heating rate 10°C / min Nitrogen flow rate 50 mL / min Sample mass ~0.5-5 mg Thermogravimetric Analyzer (TGA) Instrument TA Instruments Discovery 5500 Sample tray Aluminum dish, open-top Starting Temperature Ambient temperature (below 35 °C) Final temperature 300°C Heating rate 10°C / min Nitrogen flow rate Equilibrium: 10 mL / min; Sample chamber: 25 mL / min Sample volume ~1-10 mg High-Performance Liquid Chromatography (HPLC) Instrument Agilent 1260 Infinity II Binary Pump Method 1 For purity and solubility determination HPLC Method Wavelength: 220 nm Column: Waters Sunfire C18 150 x 460 5pm Detector: DAD Column temperature: 40°C Flow rate: 1.2 mL / min Mobile phase A: 0.1% trifluoroacetic acid Mobile phase B: Acetonitrile Diluent: Acetonitrile Injection volume: 5 pL Gradient: Time      Mobile Phase A  Mobile Phase B (min)      (%)                (%) 0.00        95                   5 9.00        5                    95 13.00       5                    95 13.10       95                   5 17.00       95                   5 Method 2 For HPLC-IC hyphenated analysis HPLC Method Wavelength: 220 nm Column: Waters Sunfire C18 150 x 460 gm, 5 gm Detector: DAD Column temperature: 40°C Flow rate: 1.2 mL / min Mobile phase A: 0.1% trifluoroacetic acid Mobile phase B: Acetonitrile Diluent: Acetonitrile / water (1:1, v / v) Injection volume: 8 gL Gradient: Time      Mobile Phase A  Mobile Phase B (min)      (%)                (%) 0.00        95                   5 9.00        5                    95 13.00       5                    95 13.10       95                   5 17.00       95                   5 To better understand the content of the present invention, further explanation is provided below with reference to specific examples; however, the specific examples are not intended to limit the scope of the present invention. 5 Example 1: Preparation of Compound (I-1) Step 1: Compound a (5.0 g, 26.3 mmol) and triethylamine (8.0 g, 11 ml) were dissolved in DCM (50 ml). At 0 °C, 2-methacryloyl chloride (3.03 g, 2.8 ml) was added dropwise to the reaction solution and stirred for 1 h. The reaction solution was diluted with water (100 mL) and extracted three times with DCM (100 mL). The organic phase was washed with saturated saline solution, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The obtained crude product was purified by silica gel column chromatography (EA / PE = 1 / 4) to obtain compound b (4.9 g, 72%), as a pale yellowish-white solid. MS (ESI) m / z 258, 260 [M + H]+. Step 2: Compound b (2.0 g, 7.75 mmol), bis(pinacolato)diboron (3.94 g, 15.5 mmol), Pd(dppf)Cl2(567 mg, 0.77 mmol), AcOK (2.28 g, 23.25 mmol), and 1,4-dioxane (20 mL) were placed in a sealed tube, which was purged with argon three times. The mixture was reacted at 90°C for 5 h. The reaction was quenched with water and extracted with DCM. The organic phase was washed with saturated saline, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The obtained crude product was purified by silica gel column chromatography (EA / PE = 1 / 8 to 1 / 4) to obtain compound c (1.52 g, 64%), as a yellow solid. MS (ESI) m / z 306 [M + H]+ . !H NMR (500 MHz, CDCk) 6 7.70-7.65 (m, 2H), 7.53 (dd, J = 11.5, 1.9 Hz, 1H), 7.20 (dd, J = 8.2, 1.9 Hz, 1H), 5.78 (s, 1H), 5.48 (d, J = 1.7 Hz, 1H), 2.04 (s, 3H), 1.34 (s, 12H). Step 3: Compound d (2.00 g, 19.6 mmol) and ammonium carbamate (2.29 g, 29.4 mmol) were added sequentially to a flask, followed by the addition of MeOH (40 mL) and iodobenzene diacetate (13.24 g, 41.1 mmol). The reaction solution was stirred uncovered at room temperature for 30 min, then concentrated under reduced pressure to remove the solvent to obtain the crude product. The crude product was purified by column chromatography (MeOH / DCM = 1 / 80) to obtain compound e (1.62 g), as a white solid. MS (ESI) m / z 120 [M + H]+ . Step 4: Compound e (282 mg, 2.35 mmol), cesium carbonate (892 mg, 2.74 mmol), 1-bromo-4-iodobenzene (552 mg, 1.96 mmol), Pd2(dba)3(40 mg, 0.05 mmol), and Xantphos (77 mg, 0.13 mmol) were added to 1,4-dioxane (10 mL), and the reaction solution was heated to 105°C and reacted for 13 h. The reaction solution was filtered through diatomaceous earth; the filtrate was washed with ethyl acetate (50 mL) and saturated saline solution (50 mL), and the organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (PE / EtOAc = 4 / 1 to 1 / 1) to obtain compound f (410 mg), as a yellow oily liquid. MS (ESI) m / z 274 [M + H]+ . Step 5: To a 100 mL round-bottom flask were added sequentially compound f (1.02 g, 3.10 mmol), bis(pinacolato)diboron (0.973 g, 3.83 mmol), Pd(dppf)Cl2(0.461 mg, 0.63 mmol), potassium acetate (0.943 g, 9.61 mmol), and 1,4-dioxane (20 mL). The mixture was heated to 100°C and reacted for 4 h. After monitoring the reaction to completion, the mixture was cooled to room temperature, filtered through diatomaceous earth, and extracted with ethyl acetate (50 mL x 3), and the organic phases was combined, washed with saturated saline solution (50 mL), and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (PE / EtOAc = 1 / 1) to obtain compound g (0.80 g), as a yellow solid. !H NMR (400 MHz, CDCL) 5 7.62 (d, J = 8.3 Hz, 2H), 6.98 (d, J = 8.3 Hz, 2H), 3.373.30 (m, 1H), 3.15-3.08 (m, 1H), 2.20 (dd, J = 29.3, 6.9 Hz, 2H), 1.26 (s, 6H). Step 6: Compound h (10.6 g, 0.0466 mol) was dissolved in dichloromethane (100 mL) and trifluoroacetic acid (26.7 g, 0.2334 mol), and stirred at 10°C. N-iodobutyric imide (10.5 g, 0.0466 mol) was added portionwise, and the mixture was reacted for 4 h. Upon completion of the reaction, 150 mL of saturated sodium bicarbonate solution was slowly added dropwise at 10°C, resulting in the precipitation of solids, which was filtrated and dried to obtain compound i (13.4 g), as a purple solid. !H NMR (400 MHz, CDCl3) 5 8.22 (s, 1H), 5.61 (s, 2H), 3.80 (s, 3H). Step 7: Compound i (2 g, 6.5 mmol), compound c (2.3 g, 6.5 mmol), tetrakis(triphenylphosphine)palladium (0.65 g, 0.56 mmol), and potassium phosphate (3.6 g, 0.017 mmol) were added to a reaction flask, which was purged with nitrogen three times. Then DMF (35 mL) and water (5 mL) were added, and stirred at 50°C for 16 h. Upon completion of the reaction, water (150 mL) and dichloromethane (200 mL) were added for extraction and liquid-liquid separation. The organic phase was washed with saturated saline solution and concentrated to obtain the crude product. The crude product was purified by column chromatography to obtain compound j (1.1 g), as a pale yellow solid. ESI-MS m / z 404.2 [M+H]+ !H NMR (400 MHz, CDCl3) 5 8.35 (s, 1H), 7.82 (dd, J = 11.7, 2.1 Hz, 1H), 7.69 (s, 1H), 7.44-7.33 (m, 2H), 5.87 (s, 1H), 5.66 (s, 2H), 5.58 (q, J = 1.5 Hz, 1H), 3.66 (d, J = 1.1 Hz, 3H), 2.12 (dd, J = 1.6, 0.9 Hz, 3H). Step 8: To a 25 mL round-bottom flask were added sequentially compound g (45 mg, 0.14 mmol), compound j (50 mg, 0.12 mmol), Pd(dppf)Cl2(20 mg, 0.03 mmol), potassium phosphate (80 mg, 0.38 mmol), 1,4-dioxane (5 mL), and water (1 mL). The reaction was heated to 80°C and reacted for 0.5 h. After monitoring the reaction to completion, the reaction was cooled to room temperature, filtered through diatomaceous earth, and extracted with ethyl acetate (20 mL x 3), and the organic layers were combined, washed with saturated saline solution (20 mL), and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (DCM / MeOH = 6 / 1) to obtain the compound of Formula I-1 (22 mg), as a white solid. MS (ESI) m / z 519.4 [M + H]+ !H NMR (400 MHz, CDCl3) 5 8.28 (s, 1H), 7.65-7.61 (m, 1H), 7.48 (s, 1H), 7.05 (d, J = 7.7 Hz, 2H), 7.00 (t, J = 4.1 Hz, 2H), 6.91 (d, J = 8.5 Hz, 2H), 5.73 (s, 1H), 5.45 (d, J = 1.3 Hz, 1H), 4.98 (s, 2H), 3.59 (d, J = 0.9 Hz, 3H), 3.36 (dd, J = 12.6, 6.0 Hz, 2H), 3.13 (dd, J = 12.8, 6.6 Hz, 2H), 2.29-2.19 (m, 3H), 1.99 (d, J = 10.1 Hz, 3H). Example 2: Preparation of crystal form A of the compound of Formula I-1 The compound of formula I-1 (61 g) was added to 100 mL of ethyl acetate, stirred at room temperature overnight, filtered, and dried to obtain a sample of crystal form A of the compound of formula I-1 (58.2 g), as a white solid. Example 3: Preparation of the maleate crystal form A of the compound of Formula I-1 3.1: Approximately 20 mg of the compound of Formula I-1 and 1.0 equivalent of maleic acid were weighed into a 2-mL glass vial, and 0.15 mL of acetonitrile was added to perform a screening experiment using the suspension method. The resulting sample was suspened at 50°C for 2 h, then allowed to cool naturally to 25°C, and suspened at 25°C for at least 48 h. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 um nylon filter membrane, and the resulting solid was vacuum-dried at 50°C for 2 h to yield a sample of the maleate crystal form A of the compound of Formula I-1. 3.2: Approximately 20 mg of the compound of Formula I-1 and 1.0 equivalent of counterion were weighed into a 2-mL glass vial, and 0.15 mL of dichloromethane was added to perform a screening experiment using the suspension method. The resulting sample was suspended at 50°C for 2 hours, then allowed to cool naturally to 25°C, and suspended at 25°C for at least 48 hours. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 um nylon filter membrane, and the resulting solid was vacuum-dried at 50°C for 2 hours to yield a sample of the maleate crystal form A of the compound of Formula I-1. Example 4: Preparation of the monomaleate crystal form B of the compound of Formula I-1 Approximately 20 mg of compound of Formula I-1 and 1.0 equivalent of maleic acid were weighed into a 2-mL glass vial, 0.15 mL of tetrahydrofuran was added to perform a screening experiment using the suspension method. The resulting sample was suspended at 50°C for 2 h, then allowed to cool naturally to 25°C, and suspended at 25°C for at least 48 h. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 um nylon filter membrane, and the resulting solid was vacuum-dried at 50°C for 2 h to obtain a sample of the monomaleate form B of the compound of Formula I-1. Example 5: Preparation of the fumarate crystal form A of the Compound of Formula I-1 5.1: Approximately 20 mg of the compound of Formula I-1 and 1.0 equivalent of fumaric acid were weighed into a 2 mL glass vial, and 0.15 mL of acetonitrile was added to perform a screening experiment using the suspension method. The resulting sample was suspended at 50°C for 2 h, then allowed to cool naturally to 25°C, and suspended at 25°C for at least 48 h. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 um nylon filter membrane, and the resulting solid was vacuum-dried at 50°C for 2 h to yield a sample of the fumarate crystal form A of the compound of Formula I-1. 5.2: Approximately 20 mg of the compound of Formula I-1 and 1.0 equivalent of fumaric acid were weighed into a 2-mL glass vial, and 0.15 mL of dichloromethanewas added to perform a screening experiment using the suspension method. The resulting sample was suspended at 50°C for 2 hours, then allowed to cool naturally to 25°C, and suspended at 25°C for at least 48 hours. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 um nylon filter membrane, and the resulting solid was vacuum-dried at 50°C for 2 hours to obtain a sample of the fumarate crystal form A of the compound of Formula I-1. Example 6: Preparation of the hemifumarate crystal form B of the compound of Formula I-1 Approximately 20 mg of the compound of Formula I-1 and 1.0 equivalent of fumaric acid were weighed into a 2-mL glass vial, and 0.15 mL of tetrahydrofuran was added to perform a screening experiment using the suspension method. The resulting sample was suspended at 50°C for 2 h, then allowed to cool naturally to 25°C, and suspended at 25°C for at least 48 h. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 um nylon filter membrane, and the resulting solid was vacuum-dried at 50°C for 2 h to yield a sample of the hemifumarate crystal form B of the compound of Formula I-1. Example 7: Preparation of the monoglycolate crystal form A of the compound of Formula I-1 Approximately 20 mg of the compound of Formula I-1 and 1.0 equivalent of glycolic acid were weighed into a 2 mL glass vial, and 0.15 mL of acetonitrile was added to perform a screening experiment using the suspension method. The resulting sample was suspended at 50°C for 2 h, then allowed to cool naturally to 25°C, and suspended at 25°C for at least 48 h. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 pm nylon filter membrane, and the resulting solid was vacuum-dried at 50°C for 2 h to yield a sample of the monoglycolate crystal form A of the compound of Formula I-1. Example 8: Preparation of the glycolate crystal form B of the Compound of Formula I-1 8.1: Approximately 20 mg of the compound of Formula I-1 and 1.0 equivalent of glycolic acid were weighed into a 2 mL glass vial, and 0.15 mL of tetrahydrofuran was added to perform a screening experiment using the suspension method. The resulting mixture was suspended at 50°C for 2 h, then allowed to cool naturally to 25°C, and suspended at 25°C for at least 48 h. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 pm nylon filter membrane, and the resulting solid was vacuum-dried at 50°C for 2 h to yield a sample of the glycolate crystal form B of the compound of Formula I-1. 8.2: Approximately 20 mg of the compound of Formula I-1 and 1.0 equivalent of glycolic acid were weighed into a 2-mL glass vial, and 0.15 mL of dichloromethane was added to perform a screening experiment using the suspension method. The resulting sample was suspended at 50°C for 2 h, then allowed to cool naturally to 25°C, and suspended at 25°C for at least 48 h. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 pm nylon filter membrane, and the resulting solid was vacuum-dried at 50°C for 2 h to obtain a sample of the glycolate form B of the compound of Formula I-1. Example 9: Preparation of the mono L-malate crystal form A of the compound of Formula I-1 9.1: Approximately 20 mg of the compound of Formula I-1 and 1.0 equivalent of L-malic acid were weighed into a 2-mL glass vial, and 0.15 mL of tetrahydrofuran was added to perform a screening experiment using the suspension method. The resulting mixture was suspended at 50°C for 2 h, then allowed to cool naturally to 25°C, and suspended at 25°C for at least 48 h. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 pm nylon filter membrane. The resulting solid was vacuum-dried at 50°C for 2 h to yield a sample of the mono L-malate crystal form A of the compound of Formula I-1. 9.2: Approximately 20 mg of the compound of Formula I-1 and 1.0 equivalent of glycolic acid were weighed into a 2-mL glass vial, and 0.15 mL of dichloromethane was added to perform a screening experiment using the suspension method. The resulting sample was suspended at 50°C for 2 h, then allowed to cool naturally to 25°C, and suspended at 25°C for at least 48 h. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 pm nylon filter membrane. The resulting solid was vacuum-dried at 50°C for 2 h to yield a sample of the mono L-malate crystal form A of the compound of Formula I-1. 9.3: Approximately 20 mg of the compound of Formula I-1 and 1.0 equivalent of glycolic acid were weighed into a 2-mL glass vial, and 0.15 mL of acetonitrile was added to perform a screening experiment using the suspension method. The resulting sample was suspended at 50°C for 2 hours, then allowed to cool naturally to 25°C, and suspended at 25°C for at least 48 hours. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 pm nylon filter membrane. The resulting solid was vacuum-dried at 50°C for 2 hours to yield a sample of the mono L-malate crystal form A of compound of Formula I-1. Example 10: Preparation of the monosuccinate crystal form A of the compound of Formula I-1 10.1: Approximately 20 mg of the compound of Formula I-1 and 1.0 equivalent of succinic acid were weighed into a 2 mL glass vial, and 0.15 mL of acetonitrile was added to perform a screening experiment using the suspension method. The resulting mixture was suspended at 50°C for 2 h, then allowed to cool naturally to 25°C, and suspended at 25°C for at least 48 h. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 gm nylon filter membrane. The resulting solid was vacuum-dried at 50°C for 2 h to obtain a sample of the monosuccinate crystal form A of compound of Formula I-1. 10.2: Approximately 20 mg of the compound of Formula I-1 and 1.0 equivalent of succinic acid were weighed into a 2-mL glass vial, and 0.15 mL of dichloromethane was added to perform a screening experiment using the suspension method. The resulting sample was suspended at 50°C for 2 h, then allowed to cool naturally to 25°C, and suspended at 25°C for at least 48 h. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 gm nylon filter membrane. The resulting solid was vacuum-dried at 50°C for 2 h to obtain a sample of the monosuccinate crystal form A of the compound of Formula I-1. Example 11: Preparation of the sulfate crystal form A of the compound of Formula I-1 Approximately 20 mg of the compound of Formula I-1 and 1.0 equivalent of sulfuric acid were weighed into a 2 mL glass vial, and 0.15 mL of acetonitrile was added to perform a screening experiment using the suspension method. The resulting sample was suspended at 50°C for 2 h, then allowed to cool naturally to 25°C, and suspended at 25°C for at least 48 h. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 gm nylon filter membrane. The resulting solid was vacuum-dried at 50°C for 2 h to yield a sample of the sulfate crystal form A of the compound of Formula I-1. Example 12: Preparation of the L-tartrate crystal form A of the compound of Formula I-1 Approximately 20 mg of the compound of Formula I-1 and 1.0 equivalent of L-tartaric acid were weighed into a 2-mL glass vial, and 0.15 mL of acetonitrile was added to perform a screening experiment using the suspension method. The resulting sample was suspended at 50°C for 2 h, then allowed to cool naturally to 25°C, and suspended at 25°C for at least 48 h. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 gm nylon filter membrane. The resulting solid was vacuum-dried at 50°C for 2 h to obtain a sample of the L-tartarate crystal form A of the compound of Formula I-1. Example 13: Preparation of the hippurate crystal form A of the compound of Formula I-1 Approximately 20 mg of the compound of Formula I-1 and 1.0 equivalent of hippuric acid were weighed into a 2 mL glass vial, and 0.15 mL of tetrahydrofuran was added to perform a screening experiment using the suspension method. The resulting sample was suspended at 50°C for 2 h, then allowed to cool naturally to 25°C, and suspended at 25°C for at least 48 h. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 gm nylon filter membrane. The resulting solid was vacuum-dried at 50°C for 2 h to yield a sample of the hippurate crystal form A of the compound of Formula I-1. Example 14: Preparation of the glutarate crystal form A of the compound of Formula I-1 14.1: Approximately 20 mg of the compound of Formula I-1 and 1.0 equivalent of glutaric acid were weighed into a 2-mL glass vial, and 0.15 mL of acetonitrile was added to perform a screening experiment using the suspension method. The resulting mixture was suspended at 50°C for 2 h, then allowed to cool naturally to 25°C, and suspended at 25°C for at least 48 h. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 gm nylon filter membrane. The resulting solid was vacuum-dried at 50°C for 2 h to yield a sample of the glutarate crystal form A of the compound of Formula I-1. 14.2: Approximately 20 mg of the compound of Formula I-1 and 1.0 equivalent of glutaric acid were weighed into a 2-mL glass vial, and 0.15 mL of dichloromethane was added to perform a screening experiment using the suspension method. The resulting sample was suspended at 50°C for 2 h, then allowed to cool naturally to 25°C, and suspended at 25°C for at least 48 h. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 gm nylon filter membrane. The resulting solid was vacuum-dried at 50°C for 2 h to yield a sample of the glutarate crystal form A of the compound of Formula I-1. Example 15: Preparation of the p-toluenesulfonate crystal form A of the compound of Formula I-1 Approximately 20 mg of the compound of Formula I-1 and 1.0 equivalent of p-toluenesulfonic acid were weighed into a 2 mL glass vial, and 0.15 mL of acetonitrile was added to perform a screening experiment using the suspension method. The resulting mixture was suspended at 50°C for 2 h, then allowed to cool naturally to 25°C, and suspended at 25°C for at least 48 h. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 gm nylon filter membrane. The resulting solid was vacuum-dried at 50°C for 2 h to obtain a sample of the p-toluenesulfonate crystal form A of the compound of Formula I-1. Example 16: Preparation of the p-toluenesulfonate crystal form B of the compound of Formula I-1 Approximately 20 mg of the compound of Formula I-1 and 1.0 equivalent of p-toluenesulfonic acid were weighed into a 2 mL glass vial, and 0.15 mL of tetrahydrofuran was added to perform a screening experiment using the suspension method. The resulting sample was suspended at 50°C for 2 h, then allowed to cool naturally to 25°C, and suspended at 25°C for at least 48 h. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 gm nylon filter membrane. The resulting solid was vacuum-dried at 50°C for 2 h to obtain a sample of the p-toluenesulfonate crystal form B of the compound of Formula I-1. Example 17: Preparation of the methanesulfonate crystal form A of the compound of Formula I-1 Approximately 20 mg of the compound of Formula I-1 and 1.0 equivalent of methanesulfonic acid were weighed into a 2 mL glass vial, and 0.15 mL of tetrahydrofuran was added to perform a screening experiment using the suspension method. The resulting mixture was suspended at 50°C for 2 h, then allowed to cool naturally to 25°C, and suspended at 25°C for at least 48 h. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 gm nylon filter membrane. The resulting solid was vacuum-dried at 50°C for 2 h to obtain a sample of the methanesulfonate crystal form A of the compound of Formula I-1. Example 18: Preparation of the hydrochloride crystal form C1 of the compound of Formula I-1 Compound of Formula I-1 (16.5 g) was added to ethyl acetate (165 mL), cooled to approximately 0°C, and 1.0 equivalent of a 4 M solution of hydrochloric acid in dioxane was added dropwise. After the addition was complete, the mixture was allowed to warm to room temperature and stirred overnight, then filtered and dried to obatin a sample of the hydrochloride crystal form C1 of the compound of Formula I-1 (18.3 g), as a white solid. Example 19: Preparation of the hydrochloride crystal form C2 of the compound of Formula I-1 Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, 0.2-0.5 mL of 2-methyl-tetrahydrofuran was added, and the mixture was suspended under magnetic stirring at 25°C at a speed of 300-400 rpm. The resulting suspension was subjected to centrifugal filtration at 14,000rpm using a 0.45 am nylon-membrane centrifuge tube. The resulting solid was the sample of the hydrochloride crystal form C2 of the compound of Formula I-1. Example 20: Preparation of the hydrochloride crystal form D of the compound of Formula I-1 Approximately 40 mg of the compound of Formula I-1 and 1.05 equivalents of hydrochloric acid (dilute hydrochloric acid diluted 10-fold with acetone) were weighed into a 2 mL glass vial, and the screening solvent was added to perform the screening experiment using the suspension method. The resulting sample was suspended at 50°C (35°C, dichloromethane) for 2 h, then allowed to cool naturally to 25°C, and suspended at 25°C for at least 48 h. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 gm nylon filter membrane. The resulting solid was vacuum-dried at 50°C for 2 h to yield a sample of the hydrochloride crystal form D of the compound of Formula I-1. Example 21: Preparation of the hydrochloride crystal form E1 of the compound of Formula I-1 3.0 g of the compound of Formula I-1 was weighed to a 40 mL glass bottle. 4.6 mL of ethanol and approximately 1.2 equivalents of HCl (a 12 N HCl aqueous solution was diluted with ethanol to 1.2 N) were added, and stirred for 10 minutes at 50°C. Approximately 5 mg of the seed crystal of hydrochloride crystal form E2 of the compound of Formula I-1 was added to the system, and stirred at 50°C for 2 h, then the solution was cooled naturally to 25°C and stirred at 25°C for 3 days. ~0.1 equivalents of HCl (12N HCl aqueous solution was diluted with ethanol to 1.2N) was added to the system and stirred at 25°C for another 1 day. The solid fraction was collected by vacuum filtration, and the resulting solid was dried under vacuum at 25°C for approximately 17 hours. The obtained solid was then dried further under vacuum at 50°C for 2 hours to yield a sample of the hydrochloride crystal form E1 of the compound of Formula I-1 (2.8 g), as a nearly white solid. Example 22: Preparation of the hydrochloride crystal form E2 of the compound of Formula I-1 Approximately 40 mg of the compound of Formula I-1 and 1.05 equivalents of hydrochloric acid (dilute hydrochloric acid diluted 10-fold with ethanol) were weighed into a 2 mL glass vial, and the screening solvent was added to perform the screening experiment using the suspension method. The resulting sample was suspended at 50°C (35°C, dichloromethane) for 2 h, then allowed to cool naturally to 25°C, and suspended at 25°C for at least 48 h. The resulting suspension was centrifuged at 14,000 rpm through a 0.45 gm nylon filter membrane. The resulting solid was a sample of hydrochloride crystal form F of the compound of Formula I-1, and it was vacuum-dried at 50°C for 2 h to obtain a sample of the hydrochloride crystal form E2 of the compound of Formula I-1. Example 23: Preparation of the hydrochloride crystal form F of the compound of Formula I-1 23.1: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.2-0.5 mL of ethanol was added, and the mixture was suspended under magnetic stirring at 25°C at a speed of 300-400 rpm. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was a sample of the hydrochloride crystal form F of the compound of Formula I-1. 23.2: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.2-0.5 mL of acetone was added, and the mixture was suspended under magnetic stirring at 25°C at a speed of 300-400 rpm. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was a sample of the hydrochloride crystal form F of the compound of Formula I-1. 23.3: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of formula I-1 were weighed, and 0.2-0.5 mL of acetonitrile was added, and the mixture was suspended under magnetic stirring at 25°C at a speed of 300-400 rpm. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was a sample of the hydrochloride crystal form F of the compound of Formula I-1. 23.4: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of formula I-1 were weighed, and 0.2-0.5 mL of tetrahydrofuran was added, and the mixture was suspended under magnetic stirring at 25°C at a speed of 300-400 rpm. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was a sample of the hydrochloride crystal form F of the compound of Formula I-1. 23.5: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.2-0.5 mL of methyl isobutyl ketone / trifluoroethanol (9:1, v / v) was added, and the mixture was suspended under magnetic stirring at 25°C at a speed of 300-400 rpm. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form F of compound of Formula I-1. 23.6: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of ethanol was added, and the mixture was suspended under magnetic stirring at a speed of 300 — 400 rpm at 50°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form F of compound of Formula I-1. 23.7: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of acetone was added, and the mixture was suspended under magnetic stirring at a speed of 300 — 400 rpm at 50°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form F of the compound of Formula I-1. 23.8: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of ethyl acetate was added, and the mixture was suspended under magnetic stirring at a speed of 300 — 400 rpm at 50°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form F of the compound of Formula I-1. 23.9: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of acetonitrile was added, and the mixture was suspended under magnetic stirring at a speed of 300 — 400 rpm at 50°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form F of the compound of Formula I-1. 23.10: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of tetrahydrofuran was added, and the mixture was suspended under magnetic stirring at 50°C at a speed of 300-400 rpm. The resulting suspension was subjected to centrifugal filtration at 14,000rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form F of the compound of Formula I-1. 23.11: Approximately 40 mg of the hydrochloride crystal form E1 of the compound ofFormula I-1 was weighed, and 0.1-0.5 mL of methyl isobutyl ketone / trifluoroethanol (9 / 1, v / v) was added, and the mixture was suspended under magnetic stirring at a speed of 300 — 400 rpm at 50°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form F of the compound of Formula I-1. 23.12: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of ethanol was added. The mixture was subjected to 10 heatingcooling cycles between 5°C and 50°C at a rate of 0.1°C / min, while suspended under magnetic stirring at a speed of 300-400 rpm, and the temperature at sampling was 10°C. The resulting suspension was subjected to centrifugal filtration at 14,000rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form F of the compound of Formula I-1. 23.13: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of acetone was added. The mixture was subjected to 10 heatingcooling cycles between 5°C and 50°C at a rate of 0.1°C / min, while suspended under magnetic stirring at a speed of 300-400 rpm, and the temperature at sampling was 10°C. The resulting suspension was subjected to centrifugal filtration at 14,000rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form F of the compound of Formula I-1. 23.14: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of ethyl acetate was added. The mixture was subjected to 10 heating-cooling cycles between 5°C and 50°C at a rate of 0.1°C / min, while suspended under magnetic stirring at a speed of 300-400 rpm, and the temperature at sampling was 10°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form F of the compound of Formula I-1. 23.15: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of acetonitrile was added. The mixture was subjected to 10 heating-cooling cycles between 5°C and 50°C at a rate of 0.1°C / min, while suspended under magnetic stirring at a speed of 300-400 rpm, and the temperature at sampling was 10°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form F of the compound of Formula I-1. 23.16: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of tetrahydrofuran was added. The mixture was subjected to 10 heating-cooling cycles between 5°C and 50°C at a rate of 0.1°C / min, while suspended under magnetic stirring at a speed of 300-400 rpm, and the temperature at sampling was 10°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form F of the compound of Formula I-1. 23.17: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of methyl isobutyl ketone / trifluoroethanol (9:1, v / v) was added. The mixture was subjected to 10 heating-cooling cycles between 5°C and 50°C at a rate of 0.1°C / min, while suspended under magnetic stirring at a speed of 300-400 rpm, and the temperature at sampling was 10°C. The resulting suspension was subjected to centrifugal filtration at 14,000rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form F of the compound of Formula I-1. Example 24: Preparation of the hydrochloride crystal form G of the compound of Formula I-1 24.1: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.2-0.5 mL of water was added, and the mixture was suspended under magnetic stirring at 25°C at a speed of 300-400 rpm. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form G of the compound of Formula I-1. 24.2: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of methanol was added, and the mixture was suspended under magnetic stirring at a speed of 300-400 rpm at 50°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form G of the compound of Formula I-1. 24.3: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of methyl isobutyl ketone / trifluoroethanol (9:1, v / v) was added. The mixture was subjected to 10 heating-cooling cycles between 5°C and 50°C at a rate of 0.1°C / min, while suspended under magnetic stirring at a speed of 300-400 rpm, and the temperature at sampling was 10°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form G of the compound of Formula I-1. Example 25: Preparation of the hydrochloride crystal form H of the compound of Formula I-1 25.1: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.2-0.5 mL of methanol / water (1:1, v / v) was added, and the mixture was suspended under magnetic stirring at a speed of 300-400 rpm at 25°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form H of the compound of Formula I-1. 25.2: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of methanol / water (1:1, v / v) was added, and the mixture was suspended under magnetic stirring at a speed of 300-400 rpm at 50°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form H of the compound of Formula I-1. Example 26: Preparation of the hydrochloride crystal form I of the compound of Formula I-1 26.1: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of methanol was added, and the mixture was suspended under magnetic stirring at a speed of 300-400 rpm at 50°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form I of the compound of Formula I-1. 26.2: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and the minimum volume of methanol was added to dissolve it thoroughly at 25°C. The resulting dilute suspension was filtered through a 0.45 pm nylon filter cartridge to obtain a clear solution. 0.8 mL of each clear solution was taken, and 8 mL of methyl tert-butyl ether was added slowly to each. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form I of the compound of Formula I-1. Example 27: Preparation of the hydrochloride crystal form J1 of the compound of Formula I-1 27.1: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of 2-methyl-tetrahydrofuran was added, and the mixture was suspended under magnetic stirring at a speed of 300-400 rpm at 50°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 gm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form J1 of the compound of Formula I-1. 27.2: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of 2-methyl tetrahydrofuran was added. The mixture was subjected to 10 heating-cooling cycles between 5°C and 50°C at a rate of 0.1°C / min, while suspended under magnetic stirring at a speed of 300-400 rpm, and the temperature at sampling was 10°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45gm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form J1 of the compound of Formula I-1. Example 28: Preparation of the hydrochloride crystal form J2 of the compound of Formula I-1 The sample of the hydrochloride crystal form J1 of the compound of Formula I-1 was heated to 110°C to obtain a solid sample of the hydrochloride crystal form J2 of the compound of Formula I-1. Example 29: Preparation of the hydrochloride crystal form K of the compound of Formula I-1 29.1: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of methyl tert-butyl ether was added, and the mixture was suspended under magnetic stirring at 50°C at a speed of 300-400 rpm. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 gm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form K of the compound of Formula I-1. 29.2: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of methyl tert-butyl ether was added. The mixture was subjected to 10 heating-cooling cycles between 5°C and 50°C at a rate of 0.1°C / min, while suspended under magnetic stirring at a speed of 300-400 rpm, and the temperature at sampling was 10°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 gm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form K of the compound of Formula I-1. 29.3: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of toluene was added. The mixture was subjected to 10 heating-cooling cycles between 5°C and 50°C at a rate of 0.1°C / min, while suspended under magnetic stirring at a speed of 300-400 rpm, and the temperature at sampling was 10°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 gm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form K of the compound of Formula I-1. Example 30: Preparation of the hydrochloride crystal form L of the compound of Formula I-1 30.1: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of toluene was added. The mixture was suspended under magnetic stirring at 25°C at a speed of 300-400 rpm. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 gm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form L of the compound of Formula I-1. 30.2: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of toluene was added. The mixture was suspended under magnetic stirring at 50°C at a speed of 300-400 rpm. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 gm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form L of the compound of Formula I-1. Example 31: Preparation of the hydrochloride crystal form M of the compound of Formula I-1 31.1: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of isopropanol / dimethyl sulfoxide (9:1, v / v) was added. The mixture was suspended under magnetic stirring at a speed of 300-400 rpm at 25°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 gm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form M of the compound of Formula I-1. 31.2: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of isopropyl acetate / dimethyl sulfoxide (9:1, v / v) was added. The mixture was suspended under magnetic stirring at a speed of 300-400 rpm at 25°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 gm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form M of the compound of Formula I-1. 31.3: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of dimethyl sulfoxide / water (1 / 1, v / v) was added. The mixture was suspended under magnetic stirring at a speed of 300-400 rpm at 25°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 gm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form M of the compound of Formula I-1. 31.4: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of isopropanol / dimethyl sulfoxide (9:1, v / v) was added. The mixture was suspended under magnetic stirring at a speed of 300-400 rpm at 50°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 gm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form M of the compound of Formula I-1. 31.5: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of isopropyl acetate / dimethyl sulfoxide (9:1, v / v) was added. The mixture was suspended under magnetic stirring at a speed of 300-400 rpm at 50°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 gm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form M of the compound of Formula I-1. 31.6: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of dimethyl sulfoxide / water (1 / 1, v / v) was added. The mixture was suspended under magnetic stirring at a speed of 300-400 rpm at 50°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 gm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form M of the compound of Formula I-1. 31.7: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of isopropanol / dimethyl sulfoxide (9:1, v / v) was added. The mixture was subjected to 10 heating-cooling cycles between 5°C and 50°C at a rate of 0.1°C / min, while suspended under magnetic stirring at a speed of 300-400 rpm, and the temperature at sampling was 10°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 gm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form M of the compound of Formula I-1. 31.8: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of isopropyl acetate / dimethyl sulfoxide (9:1, v / v) was added. The mixture was subjected to 10 heating-cooling cycles between 5°C and 50°C at a rate of 0.1°C / min, while suspended under magnetic stirring at a speed of 300-400 rpm, and the temperature at sampling was 10°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form M of the compound of Formula I-1. 31.9: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of dimethyl sulfoxide / water (1:1, v / v) was added. The mixture was subjected to 10 heating-cooling cycles between 5°C and 50°C at a rate of 0.1°C / min, while suspended under magnetic stirring at a speed of 300-400 rpm, and the temperature at sampling was 10°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form M of the compound of Formula I-1. Example 32: Preparation of the hydrochloride crystal form N of the compound of Formula I-1 32.1: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.2-0.5 mL of methanol was added. The mixture was suspended under magnetic stirring at a speed of 300-400 rpm at 25°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form N of the compound of Formula I-1. 32.2: Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.1-0.5 mL of methanol was added. The mixture was subjected to 10 heating-cooling cycles between 5°C and 50°C at a rate of 0.1°C / min, while suspended under magnetic stirring at a speed of 300-400 rpm, and the temperature at sampling was 10°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form N of the compound of Formula I-1. Example 33: Preparation of the hydrochloride crystal form O of the compound of Formula I-1 Approximately 40 mg of the hydrochloride crystal form E1 of the compound of Formula I-1 was weighed, and 0.2-0.5 mL of dichloromethane was added. The mixture was suspended under magnetic stirring at a speed of 300-400 rpm at 25°C. The resulting suspension was subjected to centrifugal filtration at 14,000 rpm using a 0.45 pm nylon-membrane centrifuge tube. The resulting solid was the hydrochloride crystal form O of the compound of Formula I-1. Experimental Example 1: Solid Stability and Solubility of the Hydrochloride Crystal Form I of the Compound of Formula I-1 1.1 Solid Stability of the Hydrochloride Crystal Form I of the Compound of Formula I-1 An open container containing the hydrochloride crystal form I of the compound of formula I-1 was placed at 25°C / 60% RH for one week. A sealed container containing the hydrochloride crystal form I of the compound of formula I-1 was placed at 60°C for one week. Stability samples under these conditions were subjected to XRPD, HPLC, and stoichiometric ratio testing, and visual observation was performed for color changes of the samples. Table 33 Solid Stability of Hydrochloride Crystal Form I of the Compound of Formula I-1 Experiment No. Initial Purity 99.6% Initial stoichiometric ratio (IC-HPLC) Compound of formula (I): HCl = 1:0.97 Purity Color 1 Solid, 25°C / 60% RH, open container, 1 week Solid (HPLC) 99.5% No color change Stoichiometric ratio (IC-HPLC) Compound of formula (I): HCl = 1:0.99 Solid (XRPD) Hydrochloride crystal form I (no change) 2 Solid, 60°C, sealed container, 1 week Solid (HPLC) 99.6% No color change Stoichiometric ratio (IC-HPLC) Compound of formula (I): HCl = 1:0.98 Solid (XRPD) Hydrochloride crystal form I (no change) 1.2 Solubility of the Free-base Crystal Form A of the Compound of Formula I-1 10 mg of the free-base crystal form A of the compound of formula I-1 or 10.8 mg (equivalent to 10 mg of the free-base anhydrous form) of the hydrochloride crystal form I of 5 the compound of formula I-1 was weighed and placed in an 8 mL glass vial. 5 mL of dissolution medium was added. The resulting suspension / clear solution was stirred at 37°C and 400 rpm for 2 h, 8 h, and 24 h, then the resulting suspension / clear solution was centrifuged at 37°C and 14,000 rpm for 5 min. The solubility of the supernatant was determined by HPLC, and the pH of the supernatant was measured by a pH meter, and the residual solid was detected 10 by XRPD. Table 34 Solubility testing of the free-base crystal form A of compound of formula I-1 Method Solubility at 37°C, target concentration of 2 mg / mL (calculated as free-base form), equilibrated for 24 h, LOQ: 0.0003 mg / mL Experiment No. Dissolution Medium Solubility (mg / mL) Residual solid XRPD 2 h 24 h (pH) 1 Water 0.0012 0.0013 (7.72) Free-base form A 2 FaSSGF, pH 1.6 0.38 0.42 (1.55) Free-base form A 3 FaSSIF-v1, pH 6.5 0.0004 0.0011 (6.50) Free-base form A 4 FeSSIF-v1, pH 5.0 0.0045 0.0066 (4.97) Free-base form A Table 35 Solubility testing of the hydrochloride crystal form I of the compound of Formula I-1 Method Solubility at 37°C, target concentration of 2 mg / mL (calculated as free-base form), equilibrated for 24 h, LOQ: 0.0002 mg / mL Experiment No. Dissolution Medium Solubility (mg / mL) Residual solid XRPD 2 h 8h 24 h (pH) 1 Water 0.12 0.10 0.10 (2.55) Free-base form A 2 FaSSGF, pH 1.6 ^2.0 ^2.0 1.7 (1.56) - 3 FaSSIF-vl, pH 6.5 0.001 0.001 0.002 (6.18) Free-base form A 4 FeSSIF-vl, pH 5.0 0.015 0.015 0.015 (4.90) Free-base form A Conclusion: The hydrochloride crystal form I of the compound of Formula I-1 exhibited no change in total impurities or crystal form, showing favorable physical stability. Moreover, compared with the free-base crystal form of the compound of formula I-1, hydrochloride crystal form I of the compound of Formula I-1 displayed significantly improved solubility in all four media tested. Experiment Example 2: FGFR2 receptor activity inhibition assay for the hydrochloride crystal form I 2.3 Assessment of the activity of hydrochloride crystal form I of the compound of Formula I-1 on FGFR2 background cells This experiment investigates the compound ’ s ability to inhibit cell proliferation by assessing its effect on in vitro cell viability in seven tumor cell lines (KATO III, NCI-H716, SNU-16, AN3CA, MFE-296, SUM52PE, MFM223). The cell lines were cultured in an incubator at 37°C and 5% CO2 under standard conditions, passaged periodically, and cells in the logarithmic growth phase were used for plating. The test compounds were prepared as 10 mM solutions using DMSO. Preparation of the compound storage plate (tube): A 4-fold serial dilution with DMSO was set up from the highest to the lowest concentration to generate a total of 9 concentrations, and the internal reference compound was likewise subjected to 4-fold serial dilution to generate another 9 concentrations. Next, the compound working solutions were prepared as follows: 98 pL of cell culture medium was added to each well of a flat-bottomed 96-well transparent plate, and 2 pL of compound was pipetted from the compound storage plate to the cell culture medium in the 96-well plate. 2 pL of DMSO was added to the solvent control well. After the compound or DMSO was added, it was mixed thoroughly by pipetting. Cell seeding and drug administration: 1) Cells were stained with trypan blue and live cells were counted, cell viability must be ^90%; 2) The cell concentration was adjusted to an appropriate level; 3) 95 pL of cell suspension was added to each well of the compound assay plate (6,000-10,000 cells / well), and cell-free medium (containing 0.1% DMSO) was added to the Min control wells; 4) Compound administration in the compound assay plate: 5 pL of a 20x compound stock solution was added to the cell culture plate as shown in Table 1. 5 pL of a DMSO-cell culture medium mixture was added to the Max control well. The final DMSO concentration was 0.1%; 5) The culture plate was incubated in a 37°C, 5% CO2 incubator for 72 — 96 hours. The assay was performed according to the instructions for the Promega CellTiter-Glo Luminescent Cell Viability Assay Kit (Promega-G7573): 1) CellTiter-Glo buffer was thawed and equilibrated to room temperature; 2) CellTiter-Glo substrate was equilibrated to room temperature; 3) CellTiter-Glo buffer was added to one bottle of CellTiter-Glo substrate to dissolve the substrate, thereby the CellTiter-Glo working solution was prepared; 4) Slow vortex was performed to ensure complete dissolution; 5) The cell culture plate was taken and placed for 10 minutes to be equilibrated to room temperature; 6) 50 pL of CellTiter-Glo working solution (equivalent to half the volume of the cell culture medium in each well) was added to each well; 7) The plate was shaken on a shaking incubator for 2 minutes to induce cell lysis; 8) The plate was placed at room temperature for 10 minutes to stabilize the luminescence signal; 9) The luminescence signal was measured using a SpectraMax Paradigm reader. The cell proliferation inhibition rate data is calculated using the following formula: Inhibition Rate (Inh%) = 100 - (RLUDrug - RLUMm) / (RLUMax - RLUMin) x 100%. The inhibition rates corresponding to different compound concentrations was calculated in Excel, then GraphPad Prism software was used to plot inhibition rate curves and the relevant parameters were calculated, including the maximum and minimum inhibition rates, 5 IC5o value. Table 36 Results of the inhibitory effects of test compounds on the proliferation of FGFR2 ____________________background cell lines____________________ Cell Line Hydrochloride crystal form I of compound of Formula I-1 KATO III 0.8 NCI-H716 2.4 SNU-16 3.0 AN3CA 9.9 MFE-296 14.9 SUM52PE 6.2 MFM223 1.0 10       As shown in Table 36, the compounds of the present invention exhibit good inhibitory effects on cell proliferation of FGFR2 background cells. All documents mentioned in the present invention are cited herein as references, as if each document were individually cited as a reference. Furthermore, it should be understood 15 that, after reading the description of the present invention, those skilled in the art may make various changes or modifications to the present invention, and such equivalent forms also fall within the scope defined by the appended claims.

Claims

1. A compound of formula (I),(X)n(I)in an amorphous form or a crystal form or a solvate thereof; wherein m is 1, 2, 3, 4, 5, 6, 7, 8, or 9;n is 0, 0.5, 1, 1.5, 2, 2.5, or 3; and X is selected from the group consisting of: hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, or phosphoric acid, formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid, hippuric acid, glycolic acid, or glutaric acid.

2. A crystal form A of the compound of formula (I) according to claim 1, wherein, the compound of formula (I) is I-1, n = 0, and the X-ray powder diffraction pattern of the crystal form A has 20 angles selected from the group consisting of: 14.16 ± 0.2°, 16.74 ± 0.2°, and 23.01 ± 0.2°.In another preferred embodiment, the crystal form A further comprises one or more of the following characteristics:a. the X-ray powder diffraction pattern of the crystal form A further has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 8.44±0.2°, 11.59±0.2°, 12.00±0.2°, 12.34 ± 0.2°, 15.50 ± 0.2°, 16.50 ± 0.2°, 18.38 ± 0.2°, 18.81 ± 0.2°, 19.79 ± 0.2 °, 20.44 ± 0.2°, 21.32±0.2°, 21.53±0.2°, 21.80±0.2°, 22.24±0.2°, 24.37±0.2°, 25.43±0.2°,  26.50±0.2°,  27.13±0.2°,  27.74±0.2°,  28.90±0.2°,  29.72±0.2°,  29.93±0.2°,30.83±0.2°, 31.56 ± 0.2 °, 32.47 ± 0.2°, 33.64 ± 0.2°, 34.12 ± 0.2 °, 35.03 ± 0.2°, 36.17 ± 0.2°;b. the differential scanning calorimetry curve of the crystal form A has the onsets of the endothermic peaks at 26.10°C ± 2°C and 223.34°C ± 2°C;c. the thermogravimetric analysis curve of the crystal form A has three small weight loss steps at 24.00°C ± 2°C, 110.00°C ± 2°C, and 200.00°C ± 2°C, and decomposition begins above 250.00°C ± 2°C.In another preferred embodiment, the crystal form A has an X-ray powder diffraction pattern substantially as shown in Figure 1.In another preferred embodiment, the crystal form A has a differential scanning calorimetry pattern substantially as shown in Figure 2.In another preferred embodiment, the crystal form A has a thermogravimetric analysis pattern substantially as shown in Figure 3.

3. A method for preparing the crystal form A according to claim 2, wherein, the method comprises the following steps:a. dissolving or dispersing compound I-1 in acetonitrile, an alcoholic solvent, an ester solvent, an ether solvent, or a mixed solvent of the alcoholic solvent and water at a volume ratio of 1-5 times;b. performing recrystallization or slurrying;wherein the alcoholic solvent is selected from the group consisting of: methanol, ethanol, isopropanol, or a combination thereof;the ester solvent is selected from the group consisting of: ethyl acetate, isopropyl acetate, methyl formate, ethyl formate, isopropyl formate, or a combination thereof;the ether solvent is selected from the group consisting of: methyl tert-butyl ether, tetrahydrofuran, ethylene glycol dimethyl ether, or a combination thereof;the mixed solvent of the alcoholic solvent and water is selected from the group consisting of: a mixture of methanol and water, a mixture of ethanol and water, or a mixture of isopropanol and water; wherein the volume ratio of the alcoholic solvent to water is 1: (0.11.5).

4. A crystal form of the compound of formula (I) according to claim 1, wherein, the compound of formula (I) is a salt formed by compound I-1 and an acid; wherein the acid is an inorganic acid or an organic acid;preferably, the inorganic acid is selected from the group consisting of: hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, or phosphoric acid;preferably, the organic acid is selected from the group consisting of: formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid, hippuric acid, glycolic acid, or glutaric acid;preferably, the molar ratio of compound I-1 to the acid is 1: (0.8-3); more preferably, 1: (0.8-2).

5. The crystal form according to claim 4, wherein, the crystal form is the maleate crystal form A of the compound of formula I-1, the X-ray powder diffraction pattern of the maleate crystal form A has 20 angles selected from the group consisting of: 15.17 ± 0.2°, 23.02 ± 0.2 °, 24.42 ± 0.2°.In another preferred embodiment, the X-ray powder diffraction pattern of the maleate crystal form A further comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 5.82±0.2°, 9.86±0.2°, 11.06 ± 0.2 °, 11.29 ± 0.2 °, 11.64 ± 0.2 °, 11.90 ± 0.2 °, 12.72 ± 0.2 °, 13.04 ± 0.2 °, 15.66 ± 0.2°, 16.36±0.2°, 17.70±0.2°, 17.88±0.2°,  18.11±0.2°,  18.35±0.2°,  18.61±0.2°,  19.41±0.2°,  20.16±0.2°,  20.38±0.2°,20.69±0.2°,  21.32±0.2°,  21.62±0.2°,  22.28±0.2°,  22.71±0.2°,  25.00±0.2°,  25.34±0.2°,26.24±0.2°, 26.77±0.2°, 29.85±0.2°, 34.09±0.2°.In another preferred embodiment, the maleate crystal form A has an X-ray powder diffraction pattern substantially as shown in Figure 4.

6. The crystal form according to claim 4, wherein, the crystal form is the monomaleate crystal form B of the compound of Formula I-1, the X-ray powder diffraction pattern of the monomaleate crystal form B has 20 angles selected from the group consisting of: 16.57±0.2°, 17.38 ± 0.2°, and 20.39 ± 0.2°.In another preferred embodiment, the monomaleate crystal form B further comprises one or more of the following characteristics:a. the X-ray powder diffraction pattern of the monomaleate crystal form B further has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 7.98±0.2°, 8.29±0.2°, 10.27±0.2°, 11.61 ± 0.2 °, 13.21 ± 0.2 °, 13.99 ± 0.2 °, 14.52 ± 0.2 °, 15.25 ± 0.2 °, 15.95 ± 0.2 °, 16.89 ± 0.2°, 18.06±0.2°, 20.61±0.2°, 21.25±0.2°, 21.61±0.2°, 22.17±0.2°,  23.31±0.2°,  23.54±0.2°,  23.98±0.2°,  24.70±0.2°,  24.93±0.2°,  25.32±0.2°,25.91±0.2°,  26.55±0.2°,  27.24±0.2°,  28.23±0.2°,  28.54±0.2°,  29.00±0.2°,  29.47±0.2°,29.71±0.2°, 32.64±0.2°, 35.12±0.2°;b. the differential scanning calorimetry curve of the monomaleate crystal form B has the onset of the endothermic peak at 213.92°C ± 2°C;c. the thermogravimetric analysis curve of the monomaleate crystal form B has twoweight loss steps at 24.00°C ± 2°C and 180.00°C ± 2°C, and decomposition begins above 250.00°C ± 2°C.In another preferred embodiment, the maleate crystal form B has an X-ray powder diffraction pattern substantially as shown in Figure 5.In another preferred embodiment, the maleate crystal form B has a differential scanning calorimetry pattern substantially as shown in Figure 6.In another preferred embodiment, the maleate crystal form B has a thermogravimetric analysis pattern substantially as shown in Figure 7.

7. The crystal form according to claim 4, wherein, the crystal form is the fumarate crystal form A of the compound of formula I-1, the X-ray powder diffraction pattern of the fumarate crystal form A has 20 angles selected from the group consisting of: 5.11±0.2°, 14.23±0.2°, 28.85 ± 0.2°.In another preferred embodiment, the X-ray powder diffraction pattern of the fumarate crystal form A further has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 7.26±0.2°, 10.20±0.2°, 10.51 ± 0.2 °, 14.47 ± 0.2 °, 14.93 ± 0.2°, 16.17 ± 0.2°, 17.03 ± 0.2°, 17.90 ± 0.2°, 18.79 ± 0.2°, 19.44±0.2°, 20.19±0.2°, 20.80±0.2°, 22.48±0.2°,  23.07±0.2°,  23.74±0.2°,  24.07±0.2°,  27.06±0.2°,  27.85±0.2°,  28.30±0.2°,29.46±0.2°, 38.24±0.2°.In another preferred embodiment, the fumarate crystal form A has an X-ray powder diffraction pattern substantially as shown in Figure 8.

8. The crystal form according to claim 4, wherein, the crystal form is the hemifumarate crystal form B of the compound of formula I-1, the X-ray powder diffraction pattern of the hemifumarate crystal form B has 20 angles selected from the group consisting of: 5.12±0.2°, 14.24±0.2°, 10.20±0.2°.In another preferred embodiment, the hemifumarate crystal form B further comprises one or more of the following characteristics:a. the X-ray powder diffraction pattern of the hemifumarate crystal form B further comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 7.27±0.2°, 7.48±0.2°, 8.77 ± 0.2°, 9.18 ± 0.2°, 9.74 ± 0.2°, 10.53 ± 0.2°, 14.96 ± 0.2°, 16.09 ± 0.2°, 16.99 ± 0.2°, 17.61±0.2°, 17.95±0.2°, 18.81±0.2°, 19.45±0.2°, 20.22±0.2°, 20.43±0.2°,  20.84±0.2°,  22.51±0.2°,  23.11±0.2°,  23.76±0.2°,  24.19±0.2°,  25.24±0.2°,27.04±0.2°,  27.90±0.2°,  28.25±0.2°,  28.75±0.2°,  29.73±0.2°,  30.14±0.2°,  30.77±0.2°,31.28±0.2°, 33.95±0.2°, 34.52±0.2°, 37.07±0.2°, 38.26±0.2°;b. the differential scanning calorimetry curve of the hemifumarate crystal form B has the onsets of the endothermic peaks at 21.34°C ± 2°C, 172.21°C ± 2°C, and 234.34°C ± 2°C;c. the thermogravimetric analysis curve of the hemifumarate crystal form B has three weight loss steps at 31.90°C ± 2°C, 90.00°C ± 2°C, and 190.00°C ± 2°C, and decomposition begins above 270.00°C ± 2°C.In another preferred embodiment, the hemifumarate crystal form B has an X-ray powder diffraction pattern substantially as shown in Figure 9.In another preferred embodiment, the hemifumarate crystal form B has a differential scanning calorimetry pattern substantially as shown in Figure 10.In another preferred embodiment, the hemifumarate crystal form B has a thermogravimetric analysis pattern substantially as shown in Figure 11.

9. The crystal form according to claim 4, wherein, the crystal form is the monoglycolate crystal form A of the compound of formula I-1, the X-ray powder diffraction pattern of the monoglycolate crystal form A has 20 angles selected from the group consisting of: 18.22±0.2°, 22.83±0.2°, 26.41±0.2°.In another preferred embodiment, the monoglycolate crystal form A further comprises one or more of the following characteristics:a. the X-ray powder diffraction pattern of the monoglycolate crystal form A also has oneor more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 6.37±0.2°, 10.37±0.2°, 11.09 ± 0.2°, 11.70 ± 0.2°, 12.69 ± 0.2°, 13.55 ± 0.2°, 14.06 ± 0.2°, 15.97 ± 0.2°, 17.34 ± 0.2°, 18.47±0.2°, 19.09±0.2°, 20.41±0.2°, 20.71±0.2°, 21.25±0.2°, 22.06±0.2°,  22.43±0.2°,  23.49±0.2°,  24.09±0.2°,  24.79±0.2°,  25.21±0.2°,  27.23±0.2°,28.00±0.2°, 29.59±0.2°, 30.44±0.2°, 30.96±0.2°, 38.67±0.2°;b. the differential scanning calorimetry curve of the monoglycolate crystal form A has the onsets of the endothermic peaks at 109.66°C ± 2°C and 198.83°C ± 2°C;c. the thermogravimetric analysis curve of the monoglycolate crystal form A has three weight loss steps at 33.00°C ±  2°C, 100.00°C  ±  2°C, and 165.00°C ± 2°C, anddecomposition begins above 200.00°C ± 2°C.In another preferred embodiment, the monoglycolate crystal form A has an X-ray powder diffraction pattern substantially as shown in Figure 12.In another preferred embodiment, the monoglycolate crystal form A has a differential scanning calorimetry pattern substantially as shown in Figure 13.In another preferred embodiment, the monoglycolate crystal form A has a thermogravimetric analysis pattern substantially as shown in Figure 14.

10. The crystal form according to claim 4, wherein, the crystal form is the glycolate crystal form B of the compound of formula I-1, the X-ray powder diffraction pattern of the glycolate crystal form B has 20 angles selected from the group consisting of: 13.87±0.2°, 17.30±0.2°, 19.49±0.2°, 23.50±0.2°.In another preferred embodiment, the X-ray powder diffraction pattern of the glycolate crystal form B further has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 5.95±0.2°, 11.06±0.2°, 12.20 ± 0.2°, 15.01 ± 0.2°, 15.79 ± 0.2°, 15.97 ± 0.2°, 16.44 ± 0.2°, 16.63 ± 0.2°, 16.79±0.2°, 17.90±0.2°, 18.33±0.2°, 18.91±0.2°, 21.59±0.2°,  22.18±0.2°,  22.80±0.2°,  23.16±0.2°,  23.93±0.2°,  24.49±0.2°,  25.13±0.2°,26.68±0.2°, 27.95±0.2°, 30.49±0.2°, 31.62±0.2°, 32.27±0.2°.In another preferred embodiment, the glycolate crystal form B has an X-ray powder diffraction pattern substantially as shown in Figure 15.

11. The crystal form according to claim 4, wherein, the crystal form is of the compound of formula I-1, the X-ray powder diffraction pattern of the mono-L-malate crystal form A has 20 angles selected from the group consisting of: 17.99±0.2°, 22.58±0.2°, and 24.00±0.2°.In another preferred embodiment, the mono-L-malate crystal form A further comprises one or more of the following characteristics:a. the X-ray powder diffraction pattern of the mono-L-malate crystal form A also has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 6.01±0.2°, 10.06±0.2°, 11.04 ± 0.2°, 11.98 ± 0.2°, 12.66 ± 0.2°, 12.86 ± 0.2°, 13.39 ± 0.2°, 15.15 ± 0.2°, 15.62 ± 0.2°, 16.46±0.2°, 17.27±0.2°, 18.58±0.2°, 19.53±0.2°, 19.77±0.2°, 20.25±0.2°,  21.01±0.2°,  21.57±0.2°,  22.04±0.2°,  23.67±0.2°,  24.50±0.2°,  25.00±0.2°,27.34±0.2°, 28.54±0.2°, 28.91 ± 0.2 ° , 29.40 ± 0.2 °, 29.89 ± 0.2 °, 30.53 ± 0.2°, 31.33 ± 0.2°, 33.67 ± 0.2°, 36.16 ± 0.2°;b. the differential scanning calorimetry curve of the mono-L-malate crystal form A has the onset of the endothermic peak at 204.74°C ± 2°C;c. the thermogravimetric analysis curve of the mono-L-malate crystal form A has two weight loss steps at 33.00°C ± 2°C and 185.00°C ± 2°C, and decomposition begins at 250.00°C ± 2°C.In another preferred embodiment, the mono-L-malate crystal form A has an X-ray powder diffraction pattern substantially as shown in Figure 16.In another preferred embodiment, the mono-L-malate crystal form A has a differential scanning calorimetry pattern substantially as shown in Figure 17.In another preferred embodiment, the mono-L-malate crystal form A has a thermogravimetric analysis pattern substantially as shown in Figure 18.

12. The crystal form according to claim 4, wherein, the crystal form is the monosuccinate crystal form A of the compound of formula I-1, the X-ray powder diffraction pattern of the monosuccinate crystal form A has 20 angles selected from the group consisting of: 18.40±0.2°, 24.09 ± 0.2°, and 24.62 ± 0.2°.In another preferred embodiment, the monosuccinate crystal form A further comprises one or more of the following characteristics:a. the X-ray powder diffraction pattern of the monosuccinate crystal form A also has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 6.15±0.2°, 9.64±0.2°, 9.95 ± 0.2°, 11.19 ± 0.2°, 12.26 ± 0.2°, 12.70 ± 0.2°, 13.30 ± 0.2°, 14.95 ± 0.2°, 15.25 ± 0.2°, 16.18±0.2°, 17.59±0.2°, 18.89±0.2°, 19.11±0.2°, 19.73±0.2°, 20.28±0.2°, 20.90±0.2°,  21.27±0.2°,  21.64±0.2°,  22.12±0.2°,  23.12±0.2°,  23.83±0.2°,  24.35±0.2°,24.93±0.2°,  25.17±0.2°,  26.05±0.2°,  27.00±0.2°,  28.27±0.2°,  28.72±0.2°,  30.12±0.2°,31.20±0.2°, 33.57±0.2°, 34.13±0.2°, 34.58±0.2°, 35.60±0.2°, 38.23±0.2°;b. the differential scanning calorimetry curve of the monosuccinate crystal form A has the onsets of the endothermic peaks at 72.75°C ± 2°C, 146.41°C ± 2°C, and 175.72°C ± 2°C;c. the thermogravimetric analysis curve of the monosuccinate crystal form A has three weight loss steps at 33.00°C  ±  2°C, 90.00°C  ±  2°C, and 160.00°C ± 2°C, anddecomposition begins above 260.00°C ± 2°C.In another preferred embodiment, the monosuccinate crystal form A has an X-ray powder diffraction pattern substantially as shown in Figure 19.In another preferred embodiment, the monosuccinate crystal form A has a differential scanning calorimetry pattern substantially as shown in Figure 20.In another preferred embodiment, the monosuccinate crystal form A has a thermogravimetric analysis pattern substantially as shown in Figure 21.

13. The crystal form according to claim 4, wherein, the crystal form is sulfate crystal form A of the compound of formula I-1, the X-ray powder diffraction pattern of sulfate crystal form A has 20 angles selected from the group consisting of: 14.97±0.2°, 20.21±0.2°, 22.58 ± 0.2°.In another preferred embodiment, the X-ray powder diffraction pattern of the sulfate crystal form A further comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 6.74±0.2°, 9.56±0.2°, 12.89 ± 0.2°, 13.78 ± 0.2°, 14.68 ± 0.2°, 15.49 ± 0.2°, 15.70 ± 0.2°, 16.41 ± 0.2°, 16.90 ± 0.2°, 18.47±0.2°, 18.68±0.2°, 18.86±0.2°, 19.33±0.2°,  19.87±0.2°,  20.70±0.2°,  21.54±0.2°,  21.76±0.2°,  22.25±0.2°,  23.75±0.2°,24.11±0.2°,  24.50±0.2°,  25.25±0.2°,  25.86±0.2°,  26.10±0.2°,  26.71±0.2°,  26.96±0.2°,27.73±0.2°, 28.41±0.2°, 28.90±0.2°, 29.70±0.2°, 30.21±0.2°, 30.99±0.2°.In another preferred embodiment, the sulfate crystal form A has an X-ray powder diffraction pattern substantially as shown in Figure 22.

14. The crystal form according to claim 4, wherein, the crystal form is the L-tartrate crystal form A of the compound of Formula I-1, the X-ray powder diffraction pattern of the L-tartrate crystal form A has 20 angles selected from the group consisting of: 5.53±0.2°, 16.95±0.2°, 20.79±0.2°.In another preferred embodiment, the X-ray powder diffraction pattern of L-tartarate crystal form A further has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 8.90±0.2°, 9.35±0.2°, 11.05±0.2°, 12.54±0.2°, 12.90±0.2°,14.35±0.2°,  14.64±0.2°,  18.70±0.2°,  19.45±0.2°,  19.74±0.2°,  20.38±0.2°,  21.45±0.2°,21.94±0.2°,  22.88±0.2°,  23.80±0.2°,  25.01±0.2°,  25.77±0.2°,  27.33±0.2°,  27.80±0.2°,28.65±0.2°, 29.41±0.2°, 30.00±0.2°, 31.09±0.2°.In another preferred embodiment, the L-tartarate crystal form A has an X-ray powder diffraction pattern substantially as shown in Figure 23.

15. The crystal form according to claim 4, wherein, the crystal form is the hippuratecrystal form A of the compound of Formula I-1, the X-ray powder diffraction pattern of the hippurate crystal form A has 29 angles selected from the group consisting of: 6.17±0.2°, 12.30 ± 0.2°, and 18.78 ± 0.2°.In another preferred embodiment, the X-ray powder diffraction pattern of the hippurate crystal form A further has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 29 angles selected from the group consisting of: 6.52±0.2°, 8.77±0.2°, 10.74±0.2°, 11.16±0.2°, 14.18±0.2°, 14.70±0.2°,  15.62±0.2°,  16.06±0.2°,  16.78±0.2°,  17.64±0.2°,  20.42±0.2°,  21.15±0.2°,21.29±0.2°,  21.79±0.2°,  23.03±0.2°,  24.05±0.2°,  24.42±0.2°,  25.32±0.2°,  26.45±0.2°,26.87±0.2°, 28.85±0.2°.In another preferred embodiment, the hippurate crystal form A has an X-ray powder diffraction pattern substantially as shown in Figure 24.

16. The crystal form according to claim 4, wherein, the crystal form is the glutarate crystal form A of the compound of Formula I-1, the X-ray powder diffraction pattern of the glutarate crystal form A has 29 angles selected from the group consisting of: 17.82±0.2°, 23.20 ± 0.2°, and 24.47 ± 0.2°.In another preferred embodiment, the X-ray powder diffraction pattern of the glutarate crystal form A further has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 29 angles selected from the group consisting of: 9.86±0.2°, 10.97±0.2°, 11.82 ± 0.2°, 12.29 ± 0.2°, 12.75 ± 0.2°, 13.19 ± 0.2°, 14.87 ± 0.2°, 15.10 ± 0.2°, 15.37 ± 0.2°, 16.33±0.2°, 17.10±0.2°, 18.35±0.2°, 19.17±0.2°, 19.75±0.2°, 20.14±0.2°, 20.70±0.2°, 21.14±0.2°, 22.23±0.2°, 24.26±0.2°, 24.86±0.2°, 25.28±0.2°, 29.92±0.2°.In another preferred embodiment, the glutarate crystal form A has an X-ray powder diffraction pattern substantially as shown in Figure 25.

17. The crystal form according to claim 4, wherein, the crystal form is the p-toluenesulfonate crystal form A of the compound of Formula I-1, the X-ray powder diffraction pattern of the p-toluenesulfonate crystal form A has 29 angles selected from the group consisting of: 19.12±0.2°, 20.11 ± 0.2°, and 20.53 ± 0.2°.In another preferred embodiment, the X-ray powder diffraction pattern of the p-toluenesulfonate crystal form A further has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 29 angles selected from the group consisting of: 7.08±0.2°, 8.00±0.2°, 9.39 ± 0.2°, 10.23 ± 0.2°, 13.36 ± 0.2 °, 14.16 ± 0.2°, 14.81 ± 0.2°, 15.77 ± 0.2°, 16.21±0.2°, 17.77±0.2°, 18.10±0.2°, 18.90±0.2°,  20.91±0.2°,  21.29±0.2°,  22.49±0.2°,  23.11±0.2°,  24.41±0.2°,  25.51±0.2°,26.77±0.2°, 28.28±0.2°, 28.81±0.2°, 29.22±0.2°, 29.95±0.2°, 30.98±0.2°, 35.22±0.2°.In another preferred embodiment, the p-toluenesulfonate crystal form A has an X-ray powder diffraction pattern substantially as shown in Figure 26.

18. The crystal form according to claim 4, wherein, the crystal form is the p-toluenesulfonate crystal form B of the compound of formula I-1, the X-ray powder diffraction pattern of p-toluenesulfonate crystal form B has 29 angles selected from the group consisting of: 13.95±0.2°, 19.52 ± 0.2°, and 25.40 ± 0.2°.In another preferred embodiment, the X-ray powder diffraction pattern of the p-toluenesulfonate crystal form B further has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 29 angles selected from the group consisting of: 8.27 ± 0.2°, 12.59 ± 0.2°, 13.69 ± 0.2°, 14.63 ± 0.2°, 16.15 ± 0.2°, 17.72 ± 0.2°, 18.68 ± 0.2°, 20.75 ± 0.2°, 21.05±0.2°, 21.92±0.2°, 22.45±0.2°, 23.23±0.2°, 23.91±0.2°, 27.33±0.2°, 29.25±0.2°.In another preferred embodiment, the p-toluenesulfonate crystal form B has an X-ray powder diffraction pattern substantially as shown in Figure 27.

19. The crystal form according to claim 4, wherein, the crystal form is the methanesulfonate crystal form A of the compound of formula I-1, the X-ray powder diffraction pattern of the methanesulfonate crystal form A has 29 angles selected from the group consisting of: 19.57±0.2°, 14.27±0.2°, 24.99±0.2°.In another preferred embodiment, the X-ray powder diffraction pattern of themethanesulfonate crystal form A further comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 29 angles selected from the group consisting of: 6.70±0.2°, 9.10±0.2°, 9.81 ± 0.2°, 10.16 ± 0.2°, 13.34 ± 0.2°, 13.87 ± 0.2°, 15.37 ± 0.2°, 15.79 ± 0.2°, 17.21 ± 0.2°, 18.75±0.2°, 21.16±0.2°,  22.09±0.2°,  23.31±0.2°,  23.86±0.2°,  24.30±0.2°,  27.18±0.2°,  28.04±0.2°,28.83±0.2°.In another preferred embodiment, the methanesulfonate crystal form A has an X-ray powder diffraction pattern substantially as shown in Figure 28.

20. The crystal form according to claim 4, wherein, the crystal form is the hydrochloride crystal form C1 of the compound of Formula I-1, the X-ray powder diffraction pattern of the hydrochloride crystal form C1 has 29 angles selected from the group consisting of: 7.73±0.2°, 19.57±0.2°, 19.78 ± 0.2°.In another preferred embodiment, the hydrochloride crystal form C1 further comprises one or more of the following characteristics:a. the X-ray powder diffraction pattern of the hydrochloride crystal form C1 also has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 29 angles selected from the group consisting of: 7.47±0.2°, 9.63±0.2°, 11.46±0.2°, 12.25 ± 0.2°, 13.18 ± 0.2°, 13.51 ± 0.2°, 14.96 ± 0.2°, 15.46 ± 0.2°, 16.79 ± 0.2°, 17.04 ± 0.2°, 17.31±0.2°, 17.72±0.2°, 18.56±0.2°, 19.34±0.2°, 20.01±0.2°, 20.41±0.2°, 20.76±0.2°, 22.60±0.2°, 23.09±0.2°, 23.80±0.2°, 24.36±0.2°, 25.63±0.2°, 26.47 ± 0.2°, 27.51 ± 0.2°, 29.09 ± 0.2°, 30.76 ± 0.2°, 31.99 ± 0.2°, 36.24 ± 0.2°;b. the differential scanning calorimetry curve of the hydrochloride crystal form C1 has the onsets of the endothermic peaks at 39.76°C ± 2°C and 153.80°C ± 2°C;c. the thermogravimetric analysis curve of the hydrochloride crystal form C1 has three weight loss steps at 26.03°C ±  2°C, 100.00°C  ±  2°C, and 150.00°C ± 2°C, anddecomposition begins at 214.75°C ± 2°C.In another preferred embodiment, the hydrochloride crystal form C1 has an X-ray powder diffraction pattern substantially as shown in Figure 29.In another preferred embodiment, the hydrochloride crystal form C1 has a differential scanning calorimetry pattern substantially as shown in Figure 30.In another preferred embodiment, the hydrochloride crystal form C1 has a thermogravimetric analysis pattern substantially as shown in Figure 31.In another preferred embodiment, the hydrochloride crystal form C1 is an ethyl acetate solvate and hydrate crystal form, wherein the ethyl acetate content is 0.1 to 1 equivalent and the water content is 1 to 5 equivalents.

21. The crystal form according to claim 4, wherein, the crystal form is the hydrochloride crystal form C2 of the compound of formula I-1, the X-ray powder diffraction pattern of the hydrochloride crystal form C2 has 29 angles selected from the group consisting of: 7.79±0.2°, 19.66±0.2°, 19.82 ± 0.2°.In another preferred embodiment, the hydrochloride crystal form C2 further comprises one or more of the following characteristics:a. the X-ray powder diffraction pattern of the hydrochloride crystal form C2 further has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 29 angles selected from the group consisting of: 7.56±0.2°, 9.65±0.2°, 11.48±0.2°, 12.32 ± 0.2°, 13.21 ± 0.2°, 13.63 ± 0.2°, 15.10 ± 0.2°, 15.56 ± 0.2°, 16.86 ± 0.2°, 17.16 ± 0.2°, 17.41±0.2°, 17.77±0.2°, 18.58±0.2°, 19.36±0.2°, 20.32±0.2°,  20.91±0.2°,  22.71±0.2°,  23.21±0.2°,  23.80±0.2°,  24.35±0.2°,  25.71±0.2°,26.56±0.2°,  27.53±0.2°,  27.80±0.2°,  28.20±0.2°,  29.15±0.2°,  30.74±0.2°,  32.06±0.2°,36.30±0.2°, 38.22±0.2°;b. the differential scanning calorimetry curve of the hydrochloride crystal form C2 has the onsets of the endothermic peaks at 33.27°C ± 2°C and 155.72°C ± 2°C;c. the thermogravimetric analysis curve of the hydrochloride crystal form C2 has three weight loss steps at 28.19°C ± 2°C, 115.00°C ± 2°C, and 150.00°C ± 2°C, and decomposition begins at 212.45°C ± 2°C.In another preferred embodiment, the hydrochloride crystal form C2 has an X-ray powder diffraction pattern substantially as shown in Figure 32.In another preferred embodiment, the hydrochloride crystal form C2 has a differential scanning calorimetry pattern substantially as shown in Figure 33.In another preferred embodiment, the hydrochloride crystal form C2 has a thermogravimetric analysis pattern substantially as shown in Figure 34.In another preferred embodiment, the hydrochloride crystal form C2 is a 2-methyl-tetrahydrofuran solvate and hydrate crystal form, wherein the 2-methyl-tetrahydrofuran content is 0.05 to 0.5 equivalents and the water content is 1 to 5 equivalents.

22. The crystal form according to claim 4, wherein, the crystal form is the hydrochloride crystal form D of the compound of formula I-1, the X-ray powder diffraction pattern of the hydrochloride crystal form D has 20 angles selected from the group consisting of: 15.93±0.2°, 20.09±0.2°, 20.41 ± 0.2°.In another preferred embodiment, the hydrochloride crystal form D further comprises one or more of the following characteristics:a. the X-ray powder diffraction pattern of the hydrochloride crystal form D also has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 6.60±0.2°, 7.26 ± 0.2 °, 7.79 ± 0.2 °, 8.48 ± 0.2 °, 9.84 ± 0.2 °, 11.18 ± 0.2 °, 13.31 ± 0.2°, 13.89±0.2°,  14.64±0.2°,  14.98±0.2°,  15.23±0.2°,  16.27±0.2°,  17.04±0.2°,  18.21±0.2°,19.33±0.2°, 21.23±0.2°, 21.80±0.2°, 23.49±0.2°, 24.79±0.2°, 28.43±0.2°;b. the differential scanning calorimetry curve of the hydrochloride crystal form D has the onsets of the endothermic peaks at 55.20°C ± 2°C and 164.37°C ± 2°C,c. the thermogravimetric analysis curve of the hydrochloride crystal form D has two weight loss steps at 36.24°C ±  2°C and 110.00°C ± 2°C, and decomposition begins at211.35°C ± 2°C.In another preferred embodiment, the hydrochloride crystal form D has an X-ray powder diffraction pattern substantially as shown in Figure 35.In another preferred embodiment, the hydrochloride crystal form D has a differential scanning calorimetry pattern substantially as shown in Figure 36.In another preferred embodiment, the hydrochloride crystal form D has a thermogravimetric analysis pattern substantially as shown in Figure 37.

23. The crystal form according to claim 4, wherein, the crystal form is the hydrochloride crystal form E1 of the compound of formula I-1, the X-ray powder diffraction pattern of the hydrochloride crystal form E1 has 20 angles selected from the group consisting of: 7.90±0.2°, 14.06 ± 0.2 °, 20.19 ± 0.2 °.In another preferred embodiment, the hydrochloride crystal form E1 further comprises one or more of the following characteristics:a. the X-ray powder diffraction pattern of the hydrochloride crystal form E1 further has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 6.15±0.2°, 7.66±0.2°, 8.41 ± 0.2°, 9.49 ± 0.2°, 9.91 ± 0.2°, 10.88 ± 0.2°, 11.42 ± 0.2°, 13.06 ± 0.2°, 13.66 ± 0.2°, 14.69 ± 0.2 °, 15.32 ± 0.2 °, 15.52 ± 0.2 °, 15.88 ± 0.2 °, 16.25 ± 0.2 °, 16.81 ± 0.2 °, 17.35 ± 0.2°, 18.37±0.2°, 19.01±0.2°, 19.75±0.2°, 21.15±0.2°, 21.51±0.2°, 21.81±0.2°,  22.50±0.2°,  22.87±0.2°,  23.56±0.2°,  24.95±0.2°,  25.18±0.2°,  25.63±0.2°,26.71±0.2°,  27.10±0.2°,  27.91±0.2°,  28.47±0.2°,  29.30±0.2°,  29.81±0.2°,  30.12±0.2°,32.93±0.2°, 34.96±0.2°;b. the differential scanning calorimetry curve of the hydrochloride crystal form E1 has the onsets of the endothermic peaks at 13.36°C ± 2°C and 174.06°C ± 2°C;c. The thermogravimetric analysis curve of the hydrochloride crystal form E1 has three weight loss steps at 25.81°C ±  2°C, 120.00°C  ±  2°C, and 160.00°C  ±  2°C, anddecomposition begins at 211.29°C ± 2°C.In another preferred embodiment, the hydrochloride crystal form E1 has an X-ray powderdiffraction pattern substantially as shown in Figure 38.In another preferred embodiment, the hydrochloride crystal form E1 has a differential scanning calorimetry pattern substantially as shown in Figure 39.In another preferred embodiment, the hydrochloride crystal form E1 has a thermogravimetric analysis pattern substantially as shown in Figure 40.In another preferred embodiment, the hydrochloride crystal form E1 of the compound of formula (I) is a hydrate crystal form, wherein the water content is 0.5 to 4 equivalents.

24. The crystal form according to claim 4, wherein, the crystal form is the hydrochloride crystal form E2 of the compound of formula I-1, the X-ray powder diffraction pattern of the hydrochloride crystal form E2 has 20 angles selected from the group consisting of: 7.88±0.2°, 14.14±0.2°, 19.75 ± 0.2°.In another preferred embodiment, the hydrochloride crystal form E2 further comprisesone or more of the following characteristics:a. the X-ray powder diffraction pattern of the hydrochloride crystal form E2 also has oneor more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 9.51±0.2°, 10.90±0.2°, 11.49±0.2°, 13.10±0.2°, 13.64±0.2°, 14.76±0.2°, 15.39±0.2°, 15.75±0.2°, 16.30±0.2°,  16.93±0.2°,  19.01±0.2°,  20.69±0.2°,  21.54±0.2°,  21.84±0.2°,  22.19±0.2°,22.57±0.2°,  23.01±0.2°,  23.63±0.2°,  24.96±0.2°,  25.90±0.2°,  26.32±0.2°,  26.78±0.2°,27.19±0.2°,  27.48±0.2°,  27.94±0.2°,  28.68±0.2°,  29.07±0.2°,  29.50±0.2°,  29.91±0.2°,31.74±0.2°, 32.96±0.2°, 33.66±0.2°;b. the differential scanning calorimetry curve of the hydrochloride crystal form E2 has the onsets of the endothermic peaks at 14.99°C ± 2°C and 174.19°C ± 2°C;c. the thermogravimetric analysis curve of the hydrochloride crystal form E2 has three weight loss steps at 33.18°C ± 2°C, 90.00°C ± 2°C, and 140.00°C ± 2°C, and decomposition begins at 213.17°C ± 2°C.In another preferred embodiment, the hydrochloride crystal form E2 has an X-ray powder diffraction pattern substantially as shown in Figure 41.In another preferred embodiment, the hydrochloride crystal form E2 has a differential scanning calorimetry pattern substantially as shown in Figure 42.In another preferred embodiment, the hydrochloride crystal form E2 has a thermogravimetric analysis pattern substantially as shown in Figure 43.In another preferred embodiment, the hydrochloride crystal form E2 of the compound of formula (I) is prepared by subjecting the hydrochloride crystal form F of the compound of formula (I) to vacuum at 10°C to 70°C.In another preferred embodiment, the hydrochloride crystal form E2 of the compound of formula (I) is prepared by drying the hydrochloride crystal form F of the compound of formula (I) at 80°C to 120°C.In another preferred embodiment, the hydrochloride crystal form E2 of the compound of formula (I) is a hydrate crystal form, wherein the water content is 0.5 to 4 equivalents.

25. The crystal form according to claim 4, wherein, the crystal form is the hydrochloride crystal form F of the compound of Formula I-1, wherein the X-ray powder diffraction pattern of the hydrochloride crystal form F has 20 angles selected from the group consisting of: 7.65±0.2°, 11.47 ± 0.2°, and 13.93 ± 0.2°.In another preferred embodiment, the hydrochloride crystal form F further comprises one or more of the following characteristics:a. the X-ray powder diffraction pattern of the hydrochloride crystal form F also has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 6.85±0.2°, 10.21±0.2°, 10.70±0.2°, 14.80 ± 0.2°, 15.25 ± 0.2°, 16.60 ± 0.2°, 16.88 ± 0.2 °, 17.84 ± 0.2 °, 19.00 ± 0.2 °, 19.16 ± 0.2 °, 19.84 ± 0.2° , 20.09 ± 0.2°, 20.34 ± 0.2°, 21.51±0.2°, 22.35±0.2°, 23.22±0.2°, 23.86±0.2°, 25.06±0.2°, 25.31±0.2°, 25.63±0.2°, 26.68 ± 0.2 °, 28.10 ± 0.2 °, 28.87 ± 0.2 °, 30.53 ± 0.2 °, 32.45 ± 0.2 °, 33.59 ± 0.2°;b. the differential scanning calorimetry curve of the hydrochloride crystal form F has the onsets of the endothermic peaks at 36.03°C ± 2°C and 172.45°C ± 2°C;c. the thermogravimetric analysis curve of the hydrochloride crystal form F has three weight loss steps at 33.35°C  ±  2°C, 100.00°C  ±  2°C, and 150.00°C ± 2°C, anddecomposition begins at 212.66°C ± 2°C.In another preferred embodiment, the hydrochloride crystal form F has an X-ray powder diffraction pattern substantially as shown in Figure 44.In another preferred embodiment, the hydrochloride crystal form F has a differential scanning calorimetry pattern substantially as shown in Figure 45.In another preferred embodiment, the hydrochloride crystal form F has a thermogravimetric analysis pattern substantially as shown in Figure 46.In another preferred embodiment, the hydrochloride crystal form F of the compound of formula (I) is a hydrate crystal form, wherein the water content is 1 to 4 equivalents.

26. The crystal form according to claim 4, wherein, the crystal form is the hydrochloride crystal form G of the compound of formula I-1, the X-ray powder diffraction pattern of the hydrochloride crystal form G has 20 angles selected from the group consisting of: 15.52±0.2°, 16.77 ± 0.2°, and 23.04 ± 0.2°.In another preferred embodiment, the hydrochloride crystal form G further comprises one or more of the following characteristics:a. the X-ray powder diffraction pattern of the hydrochloride crystal form G also has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 5.83±0.2°, 7.18±0.2°, 9.97±0.2°, 11.63 ± 0.2°, 12.00 ± 0.2°, 12.35 ± 0.2°, 13.26 ± 0.2°, 13.58 ± 0.2°, 14.17 ± 0.2° , 14.60 ± 0.2°, 17.64±0.2°, 18.37±0.2°, 18.81±0.2°, 19.14±0.2°, 19.80±0.2°, 20.27±0.2°,  20.48±0.2°,  21.35±0.2°,  21.82±0.2°,  22.65±0.2°,  23.35±0.2°,  24.43±0.2°,25.47±0.2°,  26.24±0.2°,  26.54±0.2°,  26.84±0.2°,  27.92±0.2°,  28.94±0.2°,  29.31±0.2°,30.18±0.2°;b. the differential scanning calorimetry curve of the hydrochloride crystal form G has the onsets of the endothermic peaks at 59.42°C ± 2°C, 151.02°C ± 2°C, and 166.01°C ± 2°C;c. the thermogravimetric analysis curve of the hydrochloride crystal form G has three weight loss steps at 26.28°C ± 2°C, 120.00°C ± 2°C, and 150.00°C ± 2°C.In another preferred embodiment, the hydrochloride crystal form G has an X-ray powder diffraction pattern substantially as shown in Figure 47.In another preferred embodiment, the hydrochloride crystal form G has a differential scanning calorimetry pattern substantially as shown in Figure 48.In another preferred embodiment, the hydrochloride crystal form G has a thermogravimetric analysis pattern substantially as shown in Figure 49.In another preferred embodiment, the hydrochloride crystal form G of the compound of formula (I) is a hydrate crystal form, wherein the water content is 1.0 to 6 equivalents.

27. The crystal form according to claim 4, wherein, the crystal form is the hydrochloride crystal form H of the compound of formula I-1, the X-ray powder diffraction pattern of the hydrochloride crystal form H has 20 angles selected from the group consisting of: 5.83±0.2°, 16.67±0.2°, 18.40 ± 0.2°.In another preferred embodiment, the hydrochloride crystal form H further comprises one or more of the following characteristics:a. the X-ray powder diffraction pattern of the hydrochloride crystal form H further has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 7.16±0.2°, 10.02±0.2°, 11.64±0.2°, 12.35 ± 0.2 °, 13.23 ± 0.2 °, 13.59 ± 0.2 °, 14.58 ± 0.2 °, 15.51 ± 0.2 °, 15.97 ± 0.2 °, 17.63 ± 0.2°, 18.62±0.2°, 19.11±0.2°, 20.23±0.2°, 20.54±0.2°, 21.40±0.2°,  22.07±0.2°,  22.62±0.2°,  22.78±0.2°,  23.36±0.2°,  24.73±0.2°,  24.98±0.2°,26.23±0.2°,  26.57±0.2°,  26.91±0.2°,  27.88±0.2°,  29.01±0.2°,  29.30±0.2°,  29.61±0.2°,30.21±0.2°, 31.21±0.2°, 32.12±0.2°, 34.66±0.2°;b. the differential scanning calorimetry curve of the hydrochloride crystal form H has the onsets of the endothermic peaks at 51.49°C ± 2°C and 153.61°C ± 2°C;c. the thermogravimetric analysis curve of the hydrochloride crystal form H has three weight loss steps at 26.12°C ± 2°C, 110.00°C ± 2°C, and 150.00°C ± 2°C, and decomposition begins at 211.73°C ± 2°C.In another preferred embodiment, the hydrochloride crystal form H has an X-ray powder diffraction pattern substantially as shown in Figure 50.In another preferred embodiment, the hydrochloride crystal form H has a differential scanning calorimetry pattern substantially as shown in Figure 51.In another preferred embodiment, the hydrochloride crystal form H has a thermogravimetric analysis pattern substantially as shown in Figure 52.In another preferred embodiment, the hydrochloride crystal form H of the compound of formula (I) is a hydrate crystal form, wherein the water content is 2 to 8 equivalents.

28. The crystal form according to claim 4, wherein, the crystal form is hydrochloride crystal form I, the X-ray powder diffraction pattern of the hydrochloride crystal form I has 20 angles selected from the group consisting of: 6.68 ± 0.2°, 13.34 ± 0.2°, and 21.42 ± 0.2°.In another preferred embodiment, the hydrochloride crystal form I further comprises one or more of the following characteristics:a. the X-ray powder diffraction pattern of the hydrochloride crystal form I also has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 9.50±0.2°, 12.31±0.2°, 12.54 ± 0.2°, 14.05 ± 0.2°, 14.96 ± 0.2°, 15.38 ± 0.2° , 17.18 ± 0.2°, 17.92 ± 0.2°, 19.03 ± 0.2°, 19.74±0.2°, 19.99±0.2°, 20.96±0.2°, 21.62±0.2°, 21.99±0.2°,22.98±0.2°,  23.52±0.2°,  23.80±0.2°,  24.38±0.2°,  25.92±0.2°,  26.81±0.2°,  27.21±0.2°,27.60±0.2°,  27.78±0.2°,  28.26±0.2°,  28.74±0.2°,  30.07±0.2°,  31.00±0.2°,  32.69±0.2°,34.02±0.2°, 34.83±0.2°;b. the differential scanning calorimetry curve of the hydrochloride crystal form I has the onsets of the endothermic peaks at 18.15°C ± 2°C and 194.49°C ± 2°C;c. the thermogravimetric analysis curve of the hydrochloride crystal form I has three weight loss steps at 28.31°C ± 2°C, 70.00°C ± 2°C, and 173.00°C ± 2°C, and decomposition begins at 215.51°C ± 2°C.In another preferred embodiment, the hydrochloride crystal form I has an X-ray powder diffraction pattern substantially as shown in Figure 53.In another preferred embodiment, the hydrochloride crystal form I has a differential scanning calorimetry pattern substantially as shown in Figure 54.In another preferred embodiment, the hydrochloride crystal form I has a thermogravimetric analysis pattern substantially as shown in Figure 55.In another preferred embodiment, the hydrochloride crystal form I of the compound of formula (I) is an anhydrous crystal form.

29. The crystal form according to claim 4, wherein, the crystal form is hydrochloride crystal form J1 , the X-ray powder diffraction pattern of hydrochloride crystal form J1 comprises 20 angles selected from the group consisting of: 6.80±0.2°, 14.87±0.2°, and 20.41±0.2°.In another preferred embodiment, the hydrochloride crystal form J1 further comprises one or more of the following characteristics:a. the X-ray powder diffraction pattern of the hydrochloride crystal form J1 also has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 7.82±0.2°, 7.95±0.2°, 10.08±0.2°, 11.69 ± 0.2°, 12.30 ± 0.2°, 12.60 ± 0.2°, 13.60 ± 0.2°, 15.98 ± 0.2°, 16.25 ± 0.2°, 18.05 ± 0.2°, 18.60±0.2°, 18.79±0.2°, 19.49±0.2°, 20.82±0.2°, 21.55±0.2°, 21.70±0.2°, 22.06±0.2°, 22.88±0.2°, 23.69±0.2°, 24.92±0.2°, 25.13±0.2°, 26.19±0.2°, 26.57 ± 0.2 °, 29.07 ± 0.2 °, 30.16 ± 0.2 °, 31.85 ± 0.2 °, 32.80 ± 0.2 °;b. the differential scanning calorimetry curve of the hydrochloride crystal form J1 hasthe onsets of the endothermic peaks at 70.82°C ± 2°C and 165.48°C ± 2°C;c. the thermogravimetric analysis curve of the hydrochloride crystal form J1 has two weight loss steps at 33.94°C ±  2°C and 110.00°C ± 2°C, and decomposition begins at212.96°C ± 2°C.In another preferred embodiment, the hydrochloride crystal form J1 has an X-ray powder diffraction pattern substantially as shown in Figure 56.In another preferred embodiment, the hydrochloride crystal form J1 has a differential scanning calorimetry pattern substantially as shown in Figure 57.In another preferred embodiment, the hydrochloride crystal form J1 has a thermogravimetric analysis pattern substantially as shown in Figure 58.In another preferred embodiment, the hydrochloride crystal form J1 of the compound of formula (I) is a solvate of 2-methyl-tetrahydrofuran and water, wherein the content of 2-methyl-tetrahydrofuran is 0.1 to 2 equivalents and the content of water is 0.1 to 2 equivalents.

30. The crystal form according to claim 4, wherein, the crystal form is hydrochloride crystal form J2, the X-ray powder diffraction pattern of hydrochloride crystal form J2 has 20 angles selected from the group consisting of: 14.69 ± 0.2°, 18.89 ± 0.2°, and 22.23 ± 0.2°.In another preferred embodiment, the hydrochloride crystal form J2 further comprises one or more of the following characteristics:a. the X-ray powder diffraction pattern of the hydrochloride crystal form J2 also has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 6.78±0.2°, 7.96±0.2°, 8.31±0.2°, 11.59 ± 0.2°, 12.24 ± 0.2°, 13.56 ± 0.2°, 16.44 ± 0.2°, 16.63 ± 0.2°, 17.45 ± 0.2° , 18.12 ± 0.2°, 19.51±0.2°, 20.12±0.2°, 20.35±0.2°, 20.49±0.2°, 21.28±0.2°, 21.46±0.2°,  22.75±0.2°,  23.27±0.2°,  24.09±0.2°,  24.86±0.2°,  24.99±0.2°,  25.37±0.2°,25.65±0.2°,  26.54±0.2°,  27.62±0.2°,  28.61±0.2°,  29.00±0.2°,  30.43±0.2°,  32.10±0.2°,33.01±0.2°, 36.96±0.2°;b. the differential scanning calorimetry curve of hydrochloride crystal form J2 has the onsets of the endothermic peaks at 77.60°C ± 2°C and 163.47°C ± 2°C;c. the thermogravimetric analysis curve of the hydrochloride crystal form J2 has two weight loss steps at 28.73°C ± 2°C and 120.00°C ± 2°C, and decomposition begins at 211.78°C ± 2°C.In another preferred embodiment, the hydrochloride crystal form J2 has an X-ray powder diffraction pattern substantially as shown in Figure 59.In another preferred embodiment, the hydrochloride crystal form J2 has a differential scanning calorimetry pattern substantially as shown in Figure 60.In another preferred embodiment, the hydrochloride crystal form J2 has a thermogravimetric analysis pattern substantially as shown in Figure 61.In another preferred embodiment, the hydrochloride crystal form J2 of the compound of formula (I) is prepared by heating the hydrochloride crystal form J1 of the compound of formula (I) to 90°C to 130°C.In another preferred embodiment, the hydrochloride crystal form J2 of the compound of formula (I) is a solvate of 2-methyl-tetrahydrofuran and water, wherein the content of 2-methyl-tetrahydrofuran is 0.2 to 0.8 equivalents and the content of water is 0.5 to 2 equivalents.

31. The crystal form according to claim 4, wherein, the crystal form is hydrochloride crystal form K, the X-ray powder diffraction pattern of the hydrochloride crystal form K has 20 angles selected from the group consisting of: 14.93 ± 0.2°, 16.08 ± 0.2°, and 23.68 ± 0.2°.In another preferred embodiment, the hydrochloride crystal form K further comprises one or more of the following characteristics:a. the X-ray powder diffraction pattern of the hydrochloride crystal form K also has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 6.79±0.2°, 7.83 ± 0.2°, 8.04 ± 0.2 °, 10.00 ± 0.2 °, 10.74 ± 0.2 °, 11.61 ± 0.2 °, 12.25 ± 0.2 °, 12.64 ± 0.2°, 13.57±0.2°, 18.05±0.2°, 18.63±0.2°, 19.43±0.2°, 20.15±0.2°, 20.49±0.2°,20.64±0.2°,  21.52±0.2°,  21.72±0.2°,  21.93±0.2°,  23.27±0.2°,  24.73±0.2°,  25.19±0.2°,26.25±0.2°,  26.57±0.2°,  27.42±0.2°,  28.02±0.2°,  28.67±0.2°,  29.13±0.2°,  29.91±0.2°,32.56±0.2°;b. the differential scanning calorimetry curve of the hydrochloride crystal form K has the onsets of the endothermic peaks at 80.73°C ± 2°C and 171.74°C ± 2°C;c. the thermogravimetric analysis curve of the hydrochloride crystal form K has three weight loss steps at 33.39°C  ±  2°C, 125.00°C ±  2°C, and 155.00°C ± 2°C, anddecomposition begins at 211.42°C ± 2°C.In another preferred embodiment, the hydrochloride crystal form K has an X-ray powder diffraction pattern substantially as shown in Figure 62.In another preferred embodiment, the hydrochloride crystal form K has a differential scanning calorimetry pattern substantially as shown in Figure 63.In another preferred embodiment, the hydrochloride crystal form K has a thermogravimetric analysis pattern substantially as shown in Figure 64.In another preferred embodiment, the hydrochloride crystal form K of the compound of formula (I) is a solvate of methyl tert-butyl ether and water, wherein the content of methyl tert-butyl ether is 0.1 to 1 equivalent and the content of water is 0.5 to 2 equivalents.

32. The crystal form according to claim 4, wherein, the crystal form is hydrochloride crystal form L, the X-ray powder diffraction pattern of hydrochloride crystal form L has 20 angles selected from the group consisting of: 16.89 ± 0.2°, 21.69 ± 0.2°, and 22.60 ± 0.2°.In another preferred embodiment, the hydrochloride crystal form L further comprises one or more of the following characteristics:a. the X-ray powder diffraction pattern of the hydrochloride crystal form L further has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 7.70±0.2°, 8.15±0.2°, 8.82±0.2°, 9.85 ± 0.2 °, 11.25 ± 0.2 °, 12.72 ± 0.2 °, 13.59 ± 0.2 °, 14.68 ± 0.2 °, 15.07 ± 0.2 °, 15.56 ± 0.2°, 16.60±0.2°, 17.56±0.2°, 18.53±0.2°, 18.98±0.2°, 19.74±0.2°,  20.29±0.2°,  20.52±0.2°,  21.30±0.2°,  22.79±0.2°,  24.38±0.2°,  25.57±0.2°,26.21±0.2°,  26.50±0.2°,  26.97±0.2°,  27.48±0.2°,  28.17±0.2°,  28.60±0.2°,  29.54±0.2°,29.80±0.2°, 31.17±0.2°, 33.28±0.2°;b. the differential scanning calorimetry curve of the hydrochloride crystal form L has an onset of an endothermic peak at 180.17°C ± 2°C;c. the thermogravimetric analysis curve of the hydrochloride crystal form L has two weight loss steps at 33.53°C ±  2°C and 140.00°C ± 2°C, and decomposition begins at212.43°C ± 2°C.In another preferred embodiment, the hydrochloride crystal form L has an X-ray powder diffraction pattern substantially as shown in Figure 65.In another preferred embodiment, the hydrochloride crystal form L has a differential scanning calorimetry pattern substantially as shown in Figure 66.In another preferred embodiment, the hydrochloride crystal form L has a thermogravimetric analysis pattern substantially as shown in Figure 67.In another preferred embodiment, the hydrochloride crystal form L of the compound of formula (I) is a toluene solvate, wherein the toluene content is 0.2 to 1 equivalent.

33. The crystal form according to claim 4, wherein, the crystal form is hydrochloride crystal form M, the X-ray powder diffraction pattern of hydrochloride crystal form M has 20 angles selected from the group consisting of: 14.17 ± 0.2°, 20.82 ± 0.2°, and 22.60 ± 0.2°.In another preferred embodiment, the hydrochloride crystal form M further comprises one or more of the following characteristics:a. the X-ray powder diffraction pattern of the hydrochloride crystal form M also has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 6.84±0.2°, 7.21 ± 0.2 °, 8.92 ± 0.2 °, 10.07 ± 0.2 °, 10.69 ± 0.2 °, 10.89 ± 0.2°, 11.24 ± 0.2 °, 13.23 ± 0.2 °, 14.90 ± 0.2 °, 15.59 ± 0.2 °, 16.74 ± 0.2 °, 17.67 ± 0.2 °, 18.29 ± 0.2°, 18.94±0.2°,19.46±0.2°,  19.71±0.2°,  19.96±0.2°,  21.49±0.2°,  21.83±0.2°,  23.14±0.2°,  23.54±0.2°,24.17±0.2°,  25.17±0.2°,  25.45±0.2°,  26.10±0.2°,  27.17±0.2°,  27.61±0.2°,  28.09±0.2°,28.88±0.2°, 29.42±0.2°, 30.12±0.2°, 32.48±0.2°, 35.22±0.2°;b. the differential scanning calorimetry curve of the hydrochloride crystal form M has the onsets of the endothermic peaks at 31.74°C ± 2°C and 150.05°C ± 2°C;c. the thermogravimetric analysis curve of the hydrochloride crystal form M has two weight loss steps at 32.98°C ±  2°C and 115.00°C ± 2°C, and decomposition begins at215.09°C ± 2°C.In another preferred embodiment, the hydrochloride crystal form M has an X-ray powder diffraction pattern substantially as shown in Figure 68.In another preferred embodiment, the hydrochloride crystal form M has a differential scanning calorimetry pattern substantially as shown in Figure 69.In another preferred embodiment, the hydrochloride crystal form M has a thermogravimetric analysis pattern substantially as shown in Figure 70.In another preferred embodiment, the hydrochloride crystal form M of the compound of formula (I) is a solvate of dimethyl sulfoxide and water, wherein the content of dimethyl sulfoxide is 1 to 7 equivalents and the content of water is 5 to 25 equivalents.

34. The crystal form according to claim 4, wherein, the crystal form is hydrochloride crystal form N, the X-ray powder diffraction pattern of hydrochloride crystal form N has 20 angles selected from the group consisting of: 16.19 ± 0.2°, 20.10 ± 0.2°, and 28.42 ± 0.2°.In another preferred embodiment, the hydrochloride crystal form N further comprises one or more of the following characteristics:a. the X-ray powder diffraction pattern of the hydrochloride crystal form N also has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 6.61±0.2°, 7.80±0.2°, 9.75±0.2°, 11.19 ± 0.2°, 12.53 ± 0.2°, 13.17 ± 0.2°, 14.61 ± 0.2°, 15.24 ± 0.2°, 16.02 ± 0.2°, 18.51 ± 0.2°, 19.36 ± 0.2°, 21.57 ± 0.2°, 21.95 ± 0.2°, 23.47 ± 0.2°, 25.60 ± 0.2°, 27.32 ± 0.2°, 29.12 ± 0.2°;b. the differential scanning calorimetry curve of the hydrochloride crystal form N has the onsets of the endothermic peaks at 47.38°C ± 2°C and 167.91°C ± 2°C;c. the thermogravimetric analysis curve of the hydrochloride crystal form N has three weight loss steps at 33.22°C ± 2°C, 75.00°C ± 2°C, and 150.00°C ± 2°C, and decomposition begins at 212.57°C ± 2°C.In another preferred embodiment, the hydrochloride crystal form N has an X-ray powder diffraction pattern substantially as shown in Figure 71.In another preferred embodiment, the hydrochloride crystal form N has a differential scanning calorimetry pattern substantially as shown in Figure 72.In another preferred embodiment, the hydrochloride crystal form N has a thermogravimetric analysis pattern substantially as shown in Figure 73.In another preferred embodiment, the hydrochloride crystal form N of the compound of formula (I) is a hydrate crystal form, wherein the water content is 1 to 6 equivalents.

35. The crystal form according to claim 4, wherein, the crystal form is hydrochloride crystal form O, the X-ray powder diffraction pattern of hydrochloride crystal form O has 20 angles selected from the group consisting of: 15.51 ± 0.2°, 18.36 ± 0.2°, and 20.17 ± 0.2°.In another preferred embodiment, the hydrochloride crystal form O further comprises one or more of the following characteristics:a. the X-ray powder diffraction pattern of the hydrochloride crystal form O also has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) 20 angles selected from the group consisting of: 6.14±0.2°, 8.39±0.2°, 9.90±0.2°, 11.28 ± 0.2 °, 13.19 ± 0.2 °, 13.54 ± 0.2 °, 14.40 ± 0.2 °, 15.33 ± 0.2 °, 15.87 ± 0.2 °, 16.79 ± 0.2°, 17.32±0.2°, 19.03±0.2°, 19.38±0.2°, 19.84±0.2°, 20.39±0.2°, 21.14±0.2°,  21.82±0.2°,  22.51±0.2°,  22.84±0.2°,  23.77±0.2°,  24.59±0.2°,  25.28±0.2°,26.21±0.2°,  26.82±0.2°,  27.07±0.2°,  27.93±0.2°,  28.45±0.2°,  29.24±0.2°,  29.70±0.2°,30.12±0.2°,  30.91±0.2°,  31.32±0.2°,  32.02±0.2°,  32.81±0.2°,  33.99±0.2°,  35.51±0.2°,37.27±0.2°;b. the differential scanning calorimetry curve of the hydrochloride crystal form O has the onsets of the endothermic peaks at 12.36°C ± 2°C and 174.87°C ± 2°C;c. the thermogravimetric analysis curve of the hydrochloride crystal form O has three weight loss steps at 27.70°C ± 2°C, 115.00°C ± 2°C, and 160.00°C ± 2°C, and decomposition begins at 212.00°C ± 2°C.In another preferred embodiment, the hydrochloride crystal form O has an X-ray powder diffraction pattern substantially as shown in Figure 74.In another preferred embodiment, the hydrochloride crystal form O has a differential scanning calorimetry pattern substantially as shown in Figure 75.In another preferred embodiment, the hydrochloride crystal form O has a thermogravimetric analysis pattern substantially as shown in Figure 76.In another preferred embodiment, the hydrochloride crystal form O of the compound of formula (I) is a hydrate crystal form, wherein the water content is 0.4 to 2 equivalents.

36. A method for preparing a crystal form of a pharmaceutically acceptable salt of the compound of formula (I) according to any one of claims 5-35, wherein, the method comprises the following steps:a. dissolving or dispersing the compound of formula (I) and an acid at a molar ratio of 1: (0.8-3) into 1-20 times of solvent A;b. performing suspension, recrystallization, or slurrying treatment;wherein the acid is not selected from hydrochloric acid (preferably, the acid is selected from the group consisting of: maleic acid, fumaric acid, glycolic acid, L-malic acid, succinic acid, sulfuric acid, L-tartaric acid, hippuric acid, glutaric acid, p-toluenesulfonic acid, or methanesulfonic acid);wherein solvent A is selected from the group consisting of: acetonitrile, dichloromethane, tetrahydrofuran, or a combination thereof;or the acid is hydrochloric acid or hydrogen chloride in dioxane; and the solvent A is selected from the group consisting of: ethyl acetate, 2-methyl-4-hydroxyfuran, butanone, ethanol, acetone, ethyl acetate, acetonitrile, tetrahydrofuran, methyl isobutyl ketone, trifluoroethanol, water, methanol, tert-butyl methyl ether, toluene, isopropanol, dimethyl sulfoxide, isopropyl acetate, dichloromethane, or combinations thereof.In another preferred embodiment, the solvent A is selected from the group consisting of: methyl isobutyl ketone / trifluoroethanol, methanol / water, methanol / tert-butyl methyl ether, isopropanol / dimethyl sulfoxide, isopropyl acetate / dimethyl sulfoxide, and water / dimethyl sulfoxide.In another preferred embodiment, the suspension treatment comprises the following steps: a. suspending the compound of formula (I), acid, and solvent at 45-65°C for 1-3 h;b. allowing the mixture to cool naturally to 20-30°C and continuing performing the suspension for at least 48 h;c. centrifuging the resulting suspension through a 0.4-0.5 gm filter membrane at a speed of 12,000-16,000 rpm;d. vacuum-drying the resulting solid at 45 — 65°C.

37. A method for preparing a crystal form of a pharmaceutically acceptable salt of the compound of formula (I) according to any one of claims 5-36, wherein, the method is a crystal form transformation by converting one crystal form of a pharmaceutically acceptable salt of the compound of formula (I) into another crystal form thereof;wherein the method of crystal form transformation comprises the following steps:a. dissolving or dispersing a crystal form of a pharmaceutically acceptable salt of the compound of formula (I) in 1-20 times of solvent A;b. performing suspension treatment;c. centrifuging the resulting suspension through a 0.4 to 0.5 ^m filter membrane at a speed of 12,000 to 16,000 rpm;wherein the solvent A is selected from the group consisting of: ethanol, acetone, ethyl acetate, acetonitrile, tetrahydrofuran, methyl isobutyl ketone, trifluoroethanol, methanol, 2-methyl-tetrahydrofuran, methyl tert-butyl ether, toluene, isopropanol, dimethyl sulfoxide, isopropyl acetate, dimethyl sulfoxide, methanol, dichloromethane, water, or a combination thereof.In another preferred embodiment, the solvent A is selected from the group consisting of: methyl isobutyl ketone / trifluoroethanol, methanol / water, isopropanol / dimethyl sulfoxide, isopropyl acetate / dimethyl sulfoxide, and dimethyl sulfoxide / water.In another preferred embodiment, the suspension treatment comprises the step of stirring at a rate of 300-400 rpm at 20 — 30°C.In another preferred embodiment, the suspension treatment comprises the step of stirring at a rate of 300-400 rpm at 40-60°C.In another preferred embodiment, the suspension treatment comprises the step of performing 8 to 12 heating-cooling cycles at a rate of 0.05 to 0.2°C / min between 5 and 50°C while stirring at a rate of 300 to 400 rpm, with the final temperature of the suspension being 10 to 15°C.In another preferred embodiment, the suspension treatment comprises the step of filtering through a 0.4 — 0.5 pm filter membrane to obtain a clear solution, followed by performing suspension treatment after adding methyl tert-butyl ether at a ratio of 1: (8 — 12).

38. A pharmaceutical composition comprising the compound of formula (I) according to any one of claims 1 — 2, the crystal form A according to any one of claims 3 — 4, or the crystal form of the compound of formula (I) according to any one of claims 5-36;andone or more pharmaceutically acceptable carriers, excipients, adjuvants, ingredients, and / or diluents.In another preferred embodiment, the pharmaceutical composition further comprises other therapeutic agents.In another preferred embodiment, the other therapeutic agents are selected from the group consisting of: chemotherapeutic agents, kinase inhibitors, targeted epigenetic modulators, antibody drugs, immune checkpoint inhibitors, or combinations thereof. In another preferred embodiment, the chemotherapeutic agent is selected from the group consisting of: cisplatin, doxorubicin, paclitaxel, etoposide, irinotecan, cyclophosphamide, gemcitabine, ifosfamide, tamoxifen, toremifene, fulvestrant, anastrozole, exemestane, goserelin, leuprorelin, melphalan, chlorambucil, busulfan, floxuridine, cytarabine, oxaliplatin, leucovorin, pentostatin, and diethylstilbestrol.In another preferred embodiment, the kinase inhibitor is selected from the group consisting of: Akt, TGF-pR, Pim, PKA, PKG, PKC, CaM kinase, CDK2, CDK4, CDK4 / 6, MEK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, PDGFaR, PDGFpR, CSFIR, KIT, c-Met, TRKA, TRKB, TRKC, FLT3, VEGFR, BTK, FAK, SYK, FRK, JAK, HPK1, AXL, ALK, and B-Raf inhibitors. In another preferred embodiment, the targeted epigenetic modulator is selected from the group consisting of: bromodomain inhibitors, histone lysine methyltransferases, histone arginine methyltransferases, histone demethylases, histone deacetylases, histone acetylases, and DNA methyltransferases. In another preferred embodiment, the antibody drug is selected from the group consisting of: anti-HER2 antibodies, anti-VEGFR antibodies, anti-EGFR antibodies, anti-c-MET antibodies, and anti-CD20 antibodies.In another preferred embodiment, the immune checkpoint inhibitor is selected from the group consisting of: CD27, CD28, CD40, CD122, CD96, CD73, CD47, OX40, GITR, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, PD-1, PD-L1, and PD-L2.

39. A use of the compound of formula (I) according to any one of claims 1-2, the crystal form A according to any one of claims 3-4, the crystal forms of the compound of formula (I) according to any one of claims 5-36, and the pharmaceutical composition according to claim 38 in preparing a medicament for the prevention and / or treatment of diseases associated with 5 increased activity or expression of FGFR2.In another preferred embodiment, the increased activity or expression of FGFR2 is selected from the group consisting of: FGFR2 amplification, FGFR2 gene mutation, FGFR2 gene fusion / rearrangement, FGFR2 gene translocation, and FGFR2 gene activation.In another preferred embodiment, the diseases associated with increased FGFR2 activity 10 or expression are selected from the group consisting of: cholangiocarcinoma, liver cancer, breast cancer, prostate cancer, lung cancer, thyroid cancer, gastric cancer, ovarian cancer, esophageal cancer, pancreatic cancer, cervical cancer, colorectal cancer, salivary gland cancer, endometrial cancer, and urothelial cancer, and the like.In another preferred embodiment, the cholangiocarcinoma is intrahepatic 15 cholangiocarcinoma.In another preferred embodiment, the liver cancer is hepatocellular carcinoma.In another preferred embodiment, the lung cancer is lung squamous cell carcinoma or non-small cell lung cancer.

Images